[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 810
1. Schoene-Bake JC, Parpaley Y, Weber B, Panksepp J, Hurwitz TA, Coenen VA: Tractographic analysis of historical lesion surgery for depression. Neuropsychopharmacology; 2010 Dec;35(13):2553-63
MedlinePlus Health Information. consumer health - Depression.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Various surgical brain ablation procedures for the treatment of refractory depression were developed in the twentieth century.
  • It is possible that the observed clinical improvements of these various surgical procedures may reflect shared influences on presently unspecified brain affect-regulating networks.
  • Such possibilities can now be analyzed using modern brain connectivity procedures such as diffusion tensor imaging (DTI) tractography.
  • Accordingly, modestly sized historical lesions, especially of the anatomical overlap areas, were 'implanted' in brain-MRI scans of 53 healthy subjects.
  • [MeSH-major] Brain / anatomy & histology. Depression / surgery. Neural Pathways / anatomy & histology. Neuroanatomical Tract-Tracing Techniques / methods. Psychosurgery / methods

  • Genetic Alliance. consumer health - Depression.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Med Image Anal. 2001 Jun;5(2):143-56 [11516708.001]
  • [Cites] Neurosurg Focus. 2008;25(1):E2 [18590379.001]
  • [Cites] Neurosurgery. 2002 May;50(5):1043-9; discussion 1049-52 [11950407.001]
  • [Cites] Neurol Med Chir (Tokyo). 2002 Sep;42(9):365-71 [12371591.001]
  • [Cites] JAMA. 2003 Jun 18;289(23):3095-105 [12813115.001]
  • [Cites] Nat Neurosci. 2003 Jul;6(7):750-7 [12808459.001]
  • [Cites] Neurosurg Clin N Am. 2003 Apr;14(2):199-212 [12856488.001]
  • [Cites] Neurosurg Clin N Am. 2003 Apr;14(2):225-35 [12856490.001]
  • [Cites] Stereotact Funct Neurosurg. 2002;79(3-4):234-44 [12890982.001]
  • [Cites] Br J Psychiatry. 1969 Mar;115(520):257-66 [4893673.001]
  • [Cites] Exp Neurol. 1973 Sep;40(3):798-805 [4124980.001]
  • [Cites] Br J Psychiatry. 1973 Aug;123(573):141-8 [4582235.001]
  • [Cites] Med J Aust. 1973 Aug 25;2(8):366-71 [4749527.001]
  • [Cites] Postgrad Med J. 1973 Dec;49(578):860-4 [4618905.001]
  • [Cites] Br J Psychiatry. 1976 Mar;128:226-40 [1252686.001]
  • [Cites] Stereotact Funct Neurosurg. 1991;57(4):175-94 [1842976.001]
  • [Cites] J Clin Psychiatry. 1993 Nov;54(11):405-18 [8270583.001]
  • [Cites] Br J Psychiatry. 1994 Nov;165(5):599-611; discussion 612-3 [7866675.001]
  • [Cites] Annu Rev Psychol. 1995;46:209-35 [7872730.001]
  • [Cites] J Neuropsychiatry Clin Neurosci. 1995 Winter;7(1):103-12 [7711480.001]
  • [Cites] J Neuropsychiatry Clin Neurosci. 1995 Spring;7(2):230-4 [7626968.001]
  • [Cites] Arch Gen Psychiatry. 1961 Jun;4:561-71 [13688369.001]
  • [Cites] Cereb Cortex. 2005 Jan;15(1):31-9 [15238447.001]
  • [Cites] Neuron. 2005 Mar 3;45(5):651-60 [15748841.001]
  • [Cites] Gesnerus. 2005;62(1-2):77-101 [16201322.001]
  • [Cites] Neuroimage. 2006 May 15;31(1):440-57 [16466680.001]
  • [Cites] Stereotact Funct Neurosurg. 2006;84(5-6):228-35 [17063044.001]
  • [Cites] Neuroimage. 2007 Jan 1;34(1):144-55 [17070705.001]
  • [Cites] Brain. 2007 Mar;130(Pt 3):630-53 [17293361.001]
  • [Cites] Neuroimage. 2007 May 1;35(4):1531-7 [17391987.001]
  • [Cites] Ann N Y Acad Sci. 2007 May;1104:70-88 [17344522.001]
  • [Cites] Brain Res Rev. 2007 Dec;56(2):283-321 [17905440.001]
  • [Cites] Neuropsychopharmacology. 2008 Jan;33(2):368-77 [17429407.001]
  • [Cites] J Clin Neurosci. 2008 Feb;15(2):138-42 [18068369.001]
  • [Cites] CNS Spectr. 2008 Aug;13(8):663-81 [18704022.001]
  • [Cites] Biol Psychiatry. 2008 Sep 15;64(6):461-7 [18639234.001]
  • [Cites] Psychiatry Res. 2008 Nov 30;164(2):132-42 [18945599.001]
  • [Cites] Nat Neurosci. 2009 Jan;12(1):32-4 [19029888.001]
  • [Cites] Biol Psychiatry. 2009 Feb 15;65(4):276-82 [19013554.001]
  • [Cites] J Clin Invest. 2009 Apr;119(4):717-25 [19339763.001]
  • [Cites] Science. 2009 Apr 17;324(5925):354-9 [19299587.001]
  • [Cites] Neurosurgery. 2009 Jun;64(6):1106-14; discussion 1114-5 [19487890.001]
  • [Cites] J Neurosurg. 2009 Dec;111(6):1209-15 [19480538.001]
  • [Cites] Biol Psychiatry. 2010 Jan 15;67(2):117-24 [19819426.001]
  • [Cites] Neuropsychopharmacology. 2010 Jan;35(1):4-26 [19812543.001]
  • [Cites] CNS Drugs. 2010 Feb;24(2):131-61 [20088620.001]
  • [Cites] Neuron. 2010 Mar 25;65(6):748-51 [20346752.001]
  • [Cites] J Psychiatr Res. 2010 Aug;44(11):683-7 [20096858.001]
  • [Cites] Neuroimage. 2008 Apr 1;40(2):570-82 [18255316.001]
  • [Cites] Biol Psychiatry. 2008 Apr 1;63(7):670-7 [17916331.001]
  • [Cites] Cereb Cortex. 2008 Jun;18(6):1374-83 [17928332.001]
  • [Cites] J Nerv Ment Dis. 2008 May;196(5):405-10 [18477883.001]
  • [Cites] Philos Trans R Soc Lond B Biol Sci. 2001 Aug 29;356(1412):1293-322 [11545704.001]
  • (PMID = 20736994.001).
  • [ISSN] 1740-634X
  • [Journal-full-title] Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology
  • [ISO-abbreviation] Neuropsychopharmacology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC3055575
  •  go-up   go-down


2. McCarthy BJ, Kruchko C, Central Brain Tumor Registry of the United States: Consensus conference on cancer registration of brain and central nervous system tumors. Neuro Oncol; 2005 Apr;7(2):196-201
Genetic Alliance. consumer health - Brain Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Consensus conference on cancer registration of brain and central nervous system tumors.
  • The passage of Public Law 107-260, the Benign Brain Tumor Cancer Registries Amendment Act, in October 2002 has made the collection of all primary brain tumors a reality.
  • However, at the first Consensus Conference on Brain Tumor Definition for Registration in 2002, and during the development of training materials for benign brain tumor collection, several issues were identified that were tabled for future discussion.
  • These and other issues were addressed at the subsequent 2003 Consensus Conference on Cancer Registration of Brain and Central Nervous System Tumors, at which the Central Brain Tumor Registry of the United States facilitated a discussion among epidemiologists, neurosurgeons, and neuropathologists.
  • (1) amend the histology coding scheme for cysts and tumor-like lesions that currently have a code in the third edition of the International Classification of Disease for Oncology (ICDO), (2) collect data on all instances of specific cysts and tumor-like lesions that are located in brain and other CNS sites but currently lack ICDO codes, (3) establish a new ICDO topography site for skull base tumors for the brain and CNS, and (4) collect data on genetic syndromes in patients diagnosed with brain or CNS tumors.
  • Because classification of primary intracranial and other CNS tumors is dynamic, and the registration and coding of these tumors will need to be periodically reviewed.
  • [MeSH-major] Central Nervous System Neoplasms / classification. Central Nervous System Neoplasms / pathology. Registries

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 1998 Jul 15;90(14):1039-71 [9672254.001]
  • [Cites] Neuro Oncol. 2002 Apr;4(2):134-45 [11916506.001]
  • (PMID = 15831238.001).
  • [ISSN] 1522-8517
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] eng
  • [Publication-type] Consensus Development Conference; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 13
  • [Other-IDs] NLM/ PMC1871892
  •  go-up   go-down


3. Liu J, Zheng S, Yu JK, Zhang JM, Chen Z: Serum protein fingerprinting coupled with artificial neural network distinguishes glioma from healthy population or brain benign tumor. J Zhejiang Univ Sci B; 2005 Jan;6(1):4-10
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum protein fingerprinting coupled with artificial neural network distinguishes glioma from healthy population or brain benign tumor.
  • To screen and evaluate protein biomarkers for the detection of gliomas (Astrocytoma grade I-IV) from healthy individuals and gliomas from brain benign tumors by using surface enhanced laser desorption/ionization time of flight mass spectrometry (SELDI-TOF-MS) coupled with an artificial neural network (ANN) algorithm.
  • SELDI-TOF-MS protein fingerprinting of serum from 105 brain tumor patients and healthy individuals, included 28 patients with glioma (Astrocytoma I-IV), 37 patients with brain benign tumor, and 40 age-matched healthy individuals.
  • An accuracy of 95.7%, sensitivity of 88.9%, specificity of 100%, positive predictive value of 90% and negative predictive value of 100% were obtained in a blinded test set comparing gliomas patients with healthy individuals; an accuracy of 86.4%, sensitivity of 88.9%, specificity of 84.6%, positive predictive value of 90% and negative predictive value of 85.7% were obtained when patient's gliomas was compared with benign brain tumor.
  • The high sensitivity and specificity achieved by the use of selected biomarkers showed great potential application for the discrimination of gliomas patients from healthy individuals and gliomas from brain benign tumors.
  • [MeSH-major] Astrocytoma / blood. Astrocytoma / diagnosis. Biomarkers, Tumor / blood. Brain Neoplasms / blood. Brain Neoplasms / diagnosis. Diagnosis, Computer-Assisted / methods. Neoplasm Proteins / blood. Peptide Mapping / methods

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] CA Cancer J Clin. 2003 Jan-Feb;53(1):5-26 [12568441.001]
  • [Cites] Pain. 2003 Apr;102(3):251-6 [12670666.001]
  • [Cites] Curr Med Chem. 2003 May;10(10):831-43 [12678686.001]
  • [Cites] J Clin Oncol. 2003 May 15;21(10 Suppl):200s-205s [12743135.001]
  • [Cites] Lung Cancer. 2003 Jun;40(3):267-79 [12781425.001]
  • [Cites] Curr Pharm Biotechnol. 2004 Feb;5(1):45-67 [14965209.001]
  • [Cites] Curr Opin Biotechnol. 2004 Feb;15(1):24-30 [15102462.001]
  • [Cites] Electrophoresis. 2000 Apr;21(6):1164-77 [10786889.001]
  • [Cites] N Engl J Med. 2001 Jan 11;344(2):114-23 [11150363.001]
  • [Cites] Bioinformatics. 2002 Mar;18(3):395-404 [11934738.001]
  • [Cites] Clin Chem. 2002 Aug;48(8):1160-9 [12142368.001]
  • [Cites] Clin Chem. 2002 Aug;48(8):1296-304 [12142387.001]
  • [Cites] Clin Cancer Res. 2002 Aug;8(8):2541-52 [12171882.001]
  • (PMID = 15593384.001).
  • [ISSN] 1673-1581
  • [Journal-full-title] Journal of Zhejiang University. Science. B
  • [ISO-abbreviation] J Zhejiang Univ Sci B
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Controlled Clinical Trial; Letter; Research Support, Non-U.S. Gov't; Validation Studies
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins
  • [Other-IDs] NLM/ PMC1390751
  •  go-up   go-down


Advertisement
4. Claus EB, Bondy ML, Schildkraut JM, Wiemels JL, Wrensch M, Black PM: Epidemiology of intracranial meningioma. Neurosurgery; 2005 Dec;57(6):1088-95; discussion 1088-95
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Meningiomas are the most frequently reported primary intracranial neoplasms, accounting for approximately 25% of all such lesions diagnosed in the United States.
  • Few studies have examined the risk factors associated with a diagnosis of meningioma with two categories of exposure, hormones (both endogenous and exogenous) and radiation, most strongly associated with meningioma risk.
  • Recent legislation passed in the United States (The Benign Brain Tumor Cancer Registries Amendment Act [H.R.
  • 5204]) mandates registration of benign brain tumors such as meningioma.
  • The increased emphasis on research dedicated to the study of brain tumors coupled with the advent of new tools in genetic and molecular epidemiology make the current era an ideal time to advance knowledge for intracranial meningioma.

  • Genetic Alliance. consumer health - Meningioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16331155.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R25 CA089017; United States / NCI NIH HHS / CA / 5R25-CA089017-03; United States / NCI NIH HHS / CA / P50-CA097257; United States / NCI NIH HHS / CA / R01-CA52689
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 76
  •  go-up   go-down


5. Knisely JP, Linskey ME: Less common indications for stereotactic radiosurgery or fractionated radiotherapy for patients with benign brain tumors. Neurosurg Clin N Am; 2006 Apr;17(2):149-67, vii
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Less common indications for stereotactic radiosurgery or fractionated radiotherapy for patients with benign brain tumors.
  • Microsurgical resection remains the mainstay of treatment for truly benign brain tumors that can be safely resected because of the potential for permanent cure with most histologic findings, including most of the histologic findings discussed in this article.
  • Physicians must keep in mind the indolent nature of many of the benign brain tumors and realize that many patients are likely to live out normal life spans if tumor control is achieved.
  • Therefore, it is not sufficient simply to consider local tumor control rates and short-term toxicity risks when choosing between surgery, stereotactic radiosurgery, and fractionated radiotherapy.
  • For benign brain tumors, these decisions may have consequences that last for decades.
  • [MeSH-major] Brain Neoplasms / radiotherapy. Brain Neoplasms / surgery. Patient Selection
  • [MeSH-minor] Astrocytoma / diagnosis. Astrocytoma / radiotherapy. Astrocytoma / surgery. Chordoma / diagnosis. Chordoma / radiotherapy. Chordoma / surgery. Dose Fractionation. Glomus Tumor / diagnosis. Glomus Tumor / radiotherapy. Glomus Tumor / surgery. Humans. Magnetic Resonance Imaging. Neurocytoma / diagnosis. Neurocytoma / radiotherapy. Neurocytoma / surgery. Paraganglioma / diagnosis. Paraganglioma / radiotherapy. Paraganglioma / surgery. Paraganglioma, Extra-Adrenal / diagnosis. Paraganglioma, Extra-Adrenal / radiotherapy. Paraganglioma, Extra-Adrenal / surgery. Pinealoma / diagnosis. Pinealoma / radiotherapy. Pinealoma / surgery. Radiosurgery / methods. Skull Base Neoplasms / diagnosis. Skull Base Neoplasms / radiotherapy. Skull Base Neoplasms / surgery. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16793507.001).
  • [ISSN] 1042-3680
  • [Journal-full-title] Neurosurgery clinics of North America
  • [ISO-abbreviation] Neurosurg. Clin. N. Am.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 148
  •  go-up   go-down


6. Mascarenhas F, Costa MS, Ortiz M, Almeida A, Carvalho H, Ferreira AG, Cattoni MB: [Stereotactic radiosurgery in the intracranial benign neoplasms and malignant tumors of the brain]. Acta Med Port; 2005 Jan-Feb;18(1):45-60
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Stereotactic radiosurgery in the intracranial benign neoplasms and malignant tumors of the brain].
  • Stereotactic Radiosurgery has proven to be during the last years the therapy of choice in more and more patients with benign and malignant brain tumors.
  • This series presents the experience of treating more than 100 intracranial lesions with linear accelerator-based radiosurgery at Hospital de Santa Maria in Lisbon with special emphasis on the indications and results.
  • It also provides a review of the concepts and procedures of this modality as well as a general overview of the main published results in series of patients with brain tumors treated with stereotactic radiosurgery.
  • [MeSH-major] Brain Neoplasms / surgery. Radiosurgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16202334.001).
  • [ISSN] 1646-0758
  • [Journal-full-title] Acta médica portuguesa
  • [ISO-abbreviation] Acta Med Port
  • [Language] por
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Portugal
  •  go-up   go-down


7. McCarthy BJ, Schellinger KA, Propp JM, Kruchko C, Malmer B: A case for the worldwide collection of primary benign brain tumors. Neuroepidemiology; 2009;33(3):268-75
figshare. supplemental materials - Supporting Data and Materials for the article .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case for the worldwide collection of primary benign brain tumors.
  • BACKGROUND: Incidence data on malignant tumors are reported by the International Agency for Research on Cancer, with 189,485 new malignant brain tumors globally in 2002.
  • However, collection and reporting of benign brain tumors are not universal.
  • The objective here is to encourage the collection of primary benign brain tumors worldwide.
  • METHODS: Worldwide numbers of primary benign brain tumors were estimated through published articles and cancer registry reports presenting directly or indirectly reported benign incidence rates or frequencies for regions or countries.
  • RESULTS: An estimated 186,678 benign brain tumors were diagnosed worldwide in 2002.
  • The estimated numbers of benign brain tumors were higher in females than males (105,918 vs. 80,759).
  • Since many countries do not report primary benign brain tumors, the incidence rate estimates vary significantly by region.
  • CONCLUSIONS: This is the first survey to assess worldwide numbers of benign brain tumors.
  • However, the estimated number of benign brain tumors approximately equals, and could exceed, the number of malignant brain tumors globally.
  • Registration of primary benign brain histologies in different geographical areas and ethnicities could provide clues to the underlying causes of these tumors.
  • [MeSH-major] Brain Neoplasms / epidemiology. Global Health

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - International Health.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 S. Karger AG, Basel.
  • (PMID = 19648771.001).
  • [ISSN] 1423-0208
  • [Journal-full-title] Neuroepidemiology
  • [ISO-abbreviation] Neuroepidemiology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Switzerland
  • [Number-of-references] 57
  •  go-up   go-down


8. Zhou GF, Wang XY, Huang MP: [BOLD-fMRI in sensory area and motor hand functional area with brain tumor in the central area]. Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2008 Jul;33(7):576-81
Hazardous Substances Data Bank. OXYGEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [BOLD-fMRI in sensory area and motor hand functional area with brain tumor in the central area].
  • OBJECTIVE: To explore the geomorphological performance, the characteristics of volume, and the largest signal intension of blood oxygenation level dependent functional magnetic resonance imaging (BOLD-fMRI) in brain tumors located in or closed to the central area.
  • METHODS: We recruited 13 normal volunteers and 31(13 benign tumors and 18 malignant tumors) patients with brain tumor located in or closed to the central area, to examine both side hand motor and tactile function by BOLD-fMRI and obtained the activation map and its superposition image with T1 imaging, the volume, and the largest signal intension of the functional area by SPM software which manipulated the raw data in the off-line work station.
  • There was difference in the activated signal pixel number and the largest signal intension of the functional area between the benign brain tumors, malignant brain tumors, and the normal volunteers (P < 0.05).
  • The shape, anatomic location, the volume, and the largest signal intension of the functional area were changed in the patients with brain tumors.
  • CONCLUSION: BOLD-fMRI is a valid method to assess the pre-surgical risk of patients with brain tumors, which can get the volume, the largest signal intension, the basic shape,and the anatomic location of the functional area.
  • [MeSH-major] Brain Neoplasms / physiopathology. Hand / physiopathology. Magnetic Resonance Imaging / methods. Motor Cortex / physiopathology. Somatosensory Cortex / physiopathology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18667768.001).
  • [ISSN] 1672-7347
  • [Journal-full-title] Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences
  • [ISO-abbreviation] Zhong Nan Da Xue Xue Bao Yi Xue Ban
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] S88TT14065 / Oxygen
  •  go-up   go-down


9. Jagannathan J, Kanter AS, Sheehan JP, Jane JA Jr, Laws ER Jr: Benign brain tumors: sellar/parasellar tumors. Neurol Clin; 2007 Nov;25(4):1231-49, xi
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign brain tumors: sellar/parasellar tumors.
  • Neoplasms of the sellar region include pituitary adenomas, craniopharyngiomas, Rathke's cleft cysts, and, less commonly, meningiomas, germinomas, and hamartomas.
  • The diagnosis of sellar lesions involves a multidisciplinary effort; detailed endocrinologic, ophthalmologic, and neurologic tests are critical.
  • The management of pituitary tumors varies.
  • For most tumors, transsphenoidal resection remains the mainstay of treatment.
  • [MeSH-major] Brain Neoplasms / pathology. Pituitary Neoplasms / pathology. Sella Turcica / pathology
  • [MeSH-minor] Acromegaly / diagnosis. Chemotherapy, Adjuvant. Diagnosis, Differential. Humans. Magnetic Resonance Imaging. Pituitary ACTH Hypersecretion / diagnosis. Pituitary ACTH Hypersecretion / etiology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17964033.001).
  • [ISSN] 0733-8619
  • [Journal-full-title] Neurologic clinics
  • [ISO-abbreviation] Neurol Clin
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 69
  •  go-up   go-down


10. McCall T, Chin SS, Salzman KL, Fults DW: Tuberous sclerosis: a syndrome of incomplete tumor suppression. Neurosurg Focus; 2006;20(1):E3
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tuberous sclerosis: a syndrome of incomplete tumor suppression.
  • The latter is a benign brain tumor of mixed neuronal and glial origin.
  • [MeSH-major] Hamartoma / complications. Tuberous Sclerosis / etiology. Tuberous Sclerosis / genetics. Tumor Suppressor Proteins / metabolism
  • [MeSH-minor] Animals. Brain Neoplasms / complications. Brain Neoplasms / genetics. Humans. Models, Biological

  • Genetic Alliance. consumer health - Tuberous sclerosis.
  • MedlinePlus Health Information. consumer health - Tuberous Sclerosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16459993.001).
  • [ISSN] 1092-0684
  • [Journal-full-title] Neurosurgical focus
  • [ISO-abbreviation] Neurosurg Focus
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Tumor Suppressor Proteins; 0 / tuberous sclerosis complex 1 protein; 4JG2LF96VF / tuberous sclerosis complex 2 protein
  • [Number-of-references] 92
  •  go-up   go-down


11. Cozzi L, Clivio A, Vanetti E, Nicolini G, Fogliata A: Comparative planning study for proton radiotherapy of benign brain tumors. Strahlenther Onkol; 2006 Jul;182(7):376-81
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparative planning study for proton radiotherapy of benign brain tumors.
  • Twelve cases of "benign" brain tumors were considered (meningiomas, neurinomas, and hypophyseal adenomas).
  • Organs at risk included chiasm, brainstem, eyes and optic nerves as well as the not otherwise specified healthy brain tissue in view of long-term toxicity.
  • Plans designed with the spot-scanning technique presented the minimum involvement of healthy tissue (e. g., the lowest maximum significant dose to healthy brain [25.6 Gy] or the lowest conformity index [CI(95) = 1.3], between 38% and 46% lower than for the other techniques).
  • [MeSH-major] Brain Neoplasms / radiotherapy. Protons / therapeutic use. Radiotherapy Planning, Computer-Assisted / methods. Radiotherapy, Computer-Assisted / methods

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16826355.001).
  • [ISSN] 0179-7158
  • [Journal-full-title] Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al]
  • [ISO-abbreviation] Strahlenther Onkol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Protons
  •  go-up   go-down


12. Kubo O, Chernov M, Izawa M, Hayashi M, Muragaki Y, Maruyama T, Hori T, Takakura K: Malignant progression of benign brain tumors after gamma knife radiosurgery: is it really caused by irradiation? Minim Invasive Neurosurg; 2005 Dec;48(6):334-9
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant progression of benign brain tumors after gamma knife radiosurgery: is it really caused by irradiation?
  • Malignant transformation of benign neoplasm after radiosurgery is usually diagnosed based on the initial presence of benign tumor, its exposure to ionizing radiation, elapsed time from radiation exposure to malignant progression, and different histological characteristics or growth rate of the regrowing tumor comparing with those originally treated.
  • Three presented cases fulfilled these diagnostic criteria; however, it seems that progression of the tumors (schwannoma, meningioma, chordoma) resulted from the natural course of the disease, rather than represented side effects of gamma knife radiosurgery.
  • Evaluation of the proliferative potential of the benign neoplasm before radiosurgical treatment either directly, if tumor sampling is available, or indirectly, by calculation of the tumor growth rate and/or analysis of the data of the metabolic imaging (PET, MRS) is important for identification of "aggressive" subtypes, precise prediction of prognosis, and confirmation of the radiation-induced malignant transformation in cases of tumor regrowth.
  • [MeSH-major] Brain Neoplasms / surgery. Cell Transformation, Neoplastic / radiation effects. Chordoma / surgery. Meningeal Neoplasms / surgery. Meningioma / surgery. Neoplasms, Radiation-Induced / physiopathology. Neurilemmoma / surgery. Radiosurgery / adverse effects
  • [MeSH-minor] Adult. Brain Diseases / surgery. Cell Proliferation. Female. Humans. Male. Middle Aged. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16432782.001).
  • [ISSN] 0946-7211
  • [Journal-full-title] Minimally invasive neurosurgery : MIN
  • [ISO-abbreviation] Minim Invasive Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


13. Shrieve DC: Basic principles of radiobiology applied to radiotherapy of benign intracranial tumors. Neurosurg Clin N Am; 2006 Apr;17(2):67-78, v
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basic principles of radiobiology applied to radiotherapy of benign intracranial tumors.
  • The use of ionizing radiation in the treatment of benign intracranial tumors may involve one of several types of ionizing radiation given as single-fraction radiosurgery or fractionated radiotherapy.
  • This article discusses the basic radiobiologic principles applicable to radiotherapy of benign brain tumors.
  • [MeSH-major] Brain / radiation effects. Brain Neoplasms / radiotherapy. Radiobiology / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16793500.001).
  • [ISSN] 1042-3680
  • [Journal-full-title] Neurosurgery clinics of North America
  • [ISO-abbreviation] Neurosurg. Clin. N. Am.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Huang CF, Tu HT, Liu WS, Lin LY: Gamma Knife surgery for trigeminal pain caused by benign brain tumors. J Neurosurg; 2008 Dec;109 Suppl:154-9
MedlinePlus Health Information. consumer health - Trigeminal Neuralgia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gamma Knife surgery for trigeminal pain caused by benign brain tumors.
  • OBJECT: The authors report the effects of Gamma Knife surgery (GKS) on benign tumor-related trigeminal pain in patients who underwent follow-up for a mean 57.8 months.
  • METHODS: From 1999 to 2004, 21 patients with benign tumor-related trigeminal pain (12 meningiomas and 9 schwannomas) underwent GKS as a primary or repeated treatment.
  • These patients harbored tumors within the radiosurgical target area.
  • For meningiomas, the mean radiosurgical treatment volume was 8.2 ml (range 1.1-21 ml), and the mean radiosurgical tumor margin dose was 12.7 Gy (range 12-15 Gy); for schwannomas, the mean volume was 5.6 ml (range 2-9.2 ml), and the mean marginal dose was 13 Gy (range 11.5-16 Gy).
  • For all 21 patients (100%), control of tumor growth was documented at a mean of 46 months after GKS.
  • CONCLUSIONS: Gamma Knife surgery appears to be an effective tool to treat benign tumor-related trigeminal pain and control tumor growth.
  • [MeSH-major] Brain Neoplasms / surgery. Meningeal Neoplasms / surgery. Meningioma / surgery. Neurilemmoma / surgery. Radiosurgery. Trigeminal Neuralgia / prevention & control

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19123903.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Spinner RJ, Amrami KK: What's new in the management of benign peripheral nerve lesions? Neurosurg Clin N Am; 2008 Oct;19(4):517-31, v
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] What's new in the management of benign peripheral nerve lesions?
  • Over the past 2 decades, there has been increasing interest in and experience with benign peripheral nerve lesions.
  • [MeSH-major] Neurosurgery / trends. Peripheral Nervous System Neoplasms / surgery
  • [MeSH-minor] Brain Neoplasms / pathology. Brain Neoplasms / surgery. Humans. Magnetic Resonance Imaging. Nerve Sheath Neoplasms / surgery

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19010278.001).
  • [ISSN] 1558-1349
  • [Journal-full-title] Neurosurgery clinics of North America
  • [ISO-abbreviation] Neurosurg. Clin. N. Am.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 54
  •  go-up   go-down


16. Guan M, Chen Y: Aberrant expression of DeltaNp73 in benign and malignant tumours of the prostate: correlation with Gleason score. J Clin Pathol; 2005 Nov;58(11):1175-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aberrant expression of DeltaNp73 in benign and malignant tumours of the prostate: correlation with Gleason score.
  • N-terminal truncated isoforms of p73 (DeltaNp73) act as dominant-negative inhibitors of wild-type p53 and TAp73 and result in tumour growth in nude mice.
  • AIMS: To detect DeltaNp73 expression in 24 benign prostatic hyperplasia samples, 33 prostate carcinomas, and five normal samples and to evaluate the relation between DeltaNp73, TAp73 concentrations, and the clinicopathological characteristics of patients with prostate cancer.
  • RESULTS: A significant increase of DeltaNp73 was seen in 20 of 33 carcinomas and 17 of 24 benign prostate hyperplasia tissues, but in none of the normal samples.
  • [MeSH-major] Biomarkers, Tumor / metabolism. DNA-Binding Proteins / metabolism. Nuclear Proteins / metabolism. Prostatic Neoplasms / metabolism. Tumor Suppressor Proteins / metabolism
  • [MeSH-minor] Aged. Blotting, Western. Disease Progression. Humans. Male. Middle Aged. Neoplasm Staging. Polymerase Chain Reaction / methods. Prostate / metabolism. Prostatic Hyperplasia / metabolism. Prostatic Hyperplasia / pathology. Reverse Transcriptase Polymerase Chain Reaction / methods. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell Death Differ. 2001 Dec;8(12):1213-23 [11753569.001]
  • [Cites] Cancer Res. 1993 Jul 15;53(14):3369-73 [8324747.001]
  • [Cites] Clin Cancer Res. 2002 Jan;8(1):165-70 [11801554.001]
  • [Cites] Trends Genet. 2002 Feb;18(2):90-5 [11818141.001]
  • [Cites] Cancer Res. 2002 Feb 1;62(3):636-41 [11830511.001]
  • [Cites] Cell Death Differ. 2002 Mar;9(3):343-5 [11859417.001]
  • [Cites] Cancer Res. 2002 Jul 1;62(13):3598-602 [12097259.001]
  • [Cites] Oncogene. 2002 Jul 18;21(31):4715-27 [12101410.001]
  • [Cites] J Exp Med. 2002 Sep 16;196(6):765-80 [12235210.001]
  • [Cites] Acta Oncol. 2002;41(6):550-5 [12546528.001]
  • [Cites] Prostate Cancer Prostatic Dis. 2003;6(2):174-81 [12806379.001]
  • [Cites] Jpn J Clin Oncol. 2003 May;33(5):215-20 [12865464.001]
  • [Cites] Int J Cancer. 2004 Jan 1;108(1):162-6 [14618632.001]
  • [Cites] Oncol Rep. 2004 Jun;11(6):1337-41 [15138575.001]
  • [Cites] Clin Cancer Res. 2004 Oct 15;10(20):6905-11 [15501968.001]
  • [Cites] Cell. 1997 Aug 22;90(4):809-19 [9288759.001]
  • [Cites] Nature. 1997 Sep 11;389(6647):191-4 [9296498.001]
  • [Cites] Cancer Res. 1998 May 15;58(10):2076-7 [9605745.001]
  • [Cites] J Natl Cancer Inst. 1999 Jul 7;91(13):1154-8 [10393724.001]
  • [Cites] Nat Genet. 2000 Dec;26(4):464-9 [11101847.001]
  • [Cites] Clin Cancer Res. 2001 Jan;7(1):81-8 [11205922.001]
  • [Cites] Brain Pathol. 2001 Jul;11(3):296-305 [11414472.001]
  • [Cites] Ann Oncol. 2001 Jul;12(7):981-6 [11521806.001]
  • [Cites] J Natl Cancer Inst. 1992 Jun 3;84(11):883-7 [1350643.001]
  • [Cites] Chin Med J (Engl). 2000 Apr;113(4):299-302 [11775222.001]
  • (PMID = 16254107.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / Nuclear Proteins; 0 / Tumor Suppressor Proteins
  • [Other-IDs] NLM/ PMC1770779
  •  go-up   go-down


17. Demir C, Gultekin SH, Yener B: Learning the topological properties of brain tumors. IEEE/ACM Trans Comput Biol Bioinform; 2005 Jul-Sep;2(3):262-70
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Learning the topological properties of brain tumors.
  • This work presents a graph-based representation (a.k.a., cell-graph) of histopathological images for automated cancer diagnosis by probabilistically assigning a link between a pair of cells (or cell clusters).
  • First, it is shown that without establishing a pairwise spatial relation between the cells (i.e., the edges of a cell-graph), neither the spatial distribution of the cells nor the texture analysis of the images yields accurate results for tissue level diagnosis of brain cancer called malignant glioma.
  • In this work, the results are obtained on the photomicrographs of 646 archival brain biopsy samples of 60 different patients.
  • It is shown that the global metrics of cell-graphs distinguish cancerous tissues from noncancerous ones with high accuracy (at least 99 percent accuracy for healthy tissues with lower cellular density level, and at least 92 percent accuracy for benign tissues with similar high cellular density level such as nonneoplastic reactive/inflammatory conditions).

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17044189.001).
  • [ISSN] 1545-5963
  • [Journal-full-title] IEEE/ACM transactions on computational biology and bioinformatics
  • [ISO-abbreviation] IEEE/ACM Trans Comput Biol Bioinform
  • [Language] ENG
  • [Publication-type] Evaluation Studies; Journal Article; Validation Studies
  • [Publication-country] United States
  •  go-up   go-down


18. Allan R, Chaseling R, Graf N, Dexter M: Aqueduct stenosis-?Benign. J Clin Neurosci; 2005 Feb;12(2):178-82
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aqueduct stenosis-?Benign.
  • 'Benign' aqueduct stenosis is a common cause of hydrocephalus in the paediatric population and is frequently treated by endoscopic third ventriculostomy.
  • The case histories are presented, along with the recommendation for increased radiological screening of patients with this usually 'benign' presentation.
  • [MeSH-major] Brain Neoplasms / complications. Cerebral Aqueduct / pathology. Pineal Gland / pathology. Pinealoma / complications

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15749425.001).
  • [ISSN] 0967-5868
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Scotland
  •  go-up   go-down


19. Trott KR, Kamprad F: Estimation of cancer risks from radiotherapy of benign diseases. Strahlenther Onkol; 2006 Aug;182(8):431-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Estimation of cancer risks from radiotherapy of benign diseases.
  • METHODS: The risk of cancer induction by radiotherapy of benign diseases should be based on epidemiologic data directly derived from follow-up studies of patients who had been given radiotherapy for nonmalignant diseases in the past.
  • [MeSH-minor] Adolescent. Adult. Age Factors. Bone Marrow / radiation effects. Brain Neoplasms / epidemiology. Brain Neoplasms / etiology. Breast Neoplasms / etiology. Carcinoma, Basal Cell / etiology. Child. Cohort Studies. Dose-Response Relationship, Radiation. Female. Follow-Up Studies. Humans. Incidence. Lung Neoplasms / epidemiology. Lung Neoplasms / etiology. Male. Mastitis / radiotherapy. Middle Aged. Neoplasms, Radiation-Induced / etiology. Peptic Ulcer / radiotherapy. Radiodermatitis / etiology. Radiotherapy Dosage. Retinal Neoplasms / radiotherapy. Retinoblastoma / radiotherapy. Risk. Risk Factors. Sarcoma / etiology. Sarcoma / radiotherapy. Skin Neoplasms / epidemiology. Skin Neoplasms / etiology. Spondylitis, Ankylosing / radiotherapy. Thyroid Neoplasms / etiology. Time Factors. Tinea Capitis / radiotherapy

  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16896588.001).
  • [ISSN] 0179-7158
  • [Journal-full-title] Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al]
  • [ISO-abbreviation] Strahlenther Onkol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 27
  •  go-up   go-down


20. Nasseri K, Mills JR: Epidemiology of primary brain tumors in the Middle Eastern population in California, USA 2001-2005. Cancer Detect Prev; 2009;32(5-6):363-71
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epidemiology of primary brain tumors in the Middle Eastern population in California, USA 2001-2005.
  • The purpose of this study was to compare the epidemiology of primary brain tumors in this ethnic population with the non-Hispanic, non-Middle Eastern White (NHNMW) in California.
  • Data for 683 cases of primary brain tumors (429 benign, 238 malignant, 16 uncertain) in the ME and 15,589 cases (8352 benign, 6812 malignant, 425 uncertain) in the NHNMW were available for this study.
  • RESULTS: ME patients were significantly (p < 0.05) younger and their age-adjusted incidence rates per 100,000 for benign tumors of 10.0 in men and 17.6 in women were higher than similar rates of 7.3 and 10.6 in the NHNMW group (p < 0.05).
  • Rates for malignant tumors were similar.
  • Also increased were benign tumors of the pituitary and pineal glands.
  • The overall mortality in patients with benign tumors was significantly lower than malignant tumors.
  • CONCLUSIONS: This study presents a significantly high incidence of benign meningioma in the ME population in California.
  • This may be due to higher susceptibility or exposure of this ethnic group to the risk factor(s) for this neoplasm.
  • Considering the reported causal association of benign meningioma with childhood radiation exposure from Israel, exposure to this risk factor in this ethnic group needs to be evaluated in future studies.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2005 Dec 15;104(12):2798-806 [16288487.001]
  • [Cites] Radiat Res. 2005 Apr;163(4):424-32 [15799699.001]
  • [Cites] Calif Med. 1949 Mar;70(3):189-93 [18112454.001]
  • [Cites] Asian Pac J Cancer Prev. 2007 Jul-Sep;8(3):405-11 [18159978.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2008 Apr;105(4):470-80 [18206397.001]
  • [Cites] Cancer Causes Control. 2008 Dec;19(10):1183-91 [18543070.001]
  • [Cites] Am J Epidemiol. 2000 Feb 1;151(3):266-72 [10670551.001]
  • [Cites] Dermatol Surg. 2001 Jul;27(7):667-9 [11442620.001]
  • [Cites] Neuro Oncol. 1999 Jul;1(3):205-11 [11554389.001]
  • [Cites] Neoplasma. 2001;48(6):442-4 [11949834.001]
  • [Cites] Neuro Oncol. 2002 Oct;4(4):278-99 [12356358.001]
  • [Cites] Cancer Detect Prev. 2003;27(3):203-8 [12787727.001]
  • [Cites] Br J Surg. 1977 Jul;64(7):457-9 [922301.001]
  • [Cites] Neuroepidemiology. 1989;8(6):283-95 [2586698.001]
  • [Cites] Health Inf Manag. 1997 Mar-May;27(1):31-8 [10169442.001]
  • [Cites] Cancer Detect Prev. 2007;31(5):424-9 [18023539.001]
  • (PMID = 19588542.001).
  • [ISSN] 1525-1500
  • [Journal-full-title] Cancer detection and prevention
  • [ISO-abbreviation] Cancer Detect. Prev.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA103457-02; United States / NCI NIH HHS / CA / CA103457; United States / NCI NIH HHS / PC / N01-PC-35139; United States / NCCDPHP CDC HHS / DP / U58 DP000807; United States / NCI NIH HHS / CA / N01PC54404; United States / NCI NIH HHS / CA / R03 CA103457-02; United States / NCI NIH HHS / CA / R03 CA103457; United States / NCI NIH HHS / CA / N01PC35136; United States / NCI NIH HHS / CA / N01PC35139; United States / NCI NIH HHS / PC / N01-PC-54404; United States / NCI NIH HHS / PC / N01-PC-35136; United States / NCCDPHP CDC HHS / DP / 1U58DP00807-01
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Other-IDs] NLM/ NIHMS140088; NLM/ PMC2785228
  •  go-up   go-down


21. Schaller BJ, Cornelius JF, Sandu N, Buchfelder M: Molecular imaging of brain tumors personal experience and review of the literature. Curr Mol Med; 2008 Dec;8(8):711-26
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular imaging of brain tumors personal experience and review of the literature.
  • Non-invasive energy metabolism measurements in brain tumors in vivo are now performed widely as molecular imaging by positron emission tomography.
  • Common clinical indications for molecular imaging of primary brain tumors therefore contain (i) primary brain tumor diagnosis, (ii) identification of the metabolically most active brain tumor reactions (differentiation of viable tumor tissue from necrosis), and (iii) prediction of treatment response by measurement of tumor perfusion, or ischemia.
  • Molecular imaging may identify early disease and differentiate benign from malignant lesions.
  • Moreover, an early identification of treatment effectiveness could influence patient management by providing objective criteria for evaluation of therapeutic strategies for primary brain tumors.
  • The authors present here illustrative data of PET imaging: the thymidine kinase gene expression in experimentally transplanted F98 gliomas in cat brain indicates, that [(18)F]FHBG visualizes cells expressing TK-GFP gene in transduced gliomas as well as quantities and localizes transduced HSV-1-TK expression if the blood brain barrier is disrupted.
  • The higher uptake of [(18)F]FLT in the wild-type compared to the transduced type may demonstrate the different doubling time of both tumor tissues suggesting different cytosolic thymidine kinase activity.
  • [MeSH-major] Brain Neoplasms / radionuclide imaging
  • [MeSH-minor] Animals. Capillary Permeability. Diagnosis, Differential. Drug Discovery. Gene Expression. Genes, Reporter. Genetic Therapy. Humans. Neovascularization, Pathologic. Positron-Emission Tomography / methods. Signal Transduction. Thymidine Kinase / genetics

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19075670.001).
  • [ISSN] 1566-5240
  • [Journal-full-title] Current molecular medicine
  • [ISO-abbreviation] Curr. Mol. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] EC 2.7.1.21 / Thymidine Kinase
  • [Number-of-references] 158
  •  go-up   go-down


22. Aggarwal S, Subberwal M, Kumar S, Sharma M: Brain tumor and role of beta-carotene, a-tocopherol, superoxide dismutase and glutathione peroxidase. J Cancer Res Ther; 2006 Jan-Mar;2(1):24-7
Hazardous Substances Data Bank. BETA-CAROTENE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Brain tumor and role of beta-carotene, a-tocopherol, superoxide dismutase and glutathione peroxidase.
  • The erythrocyte levels of the antioxidant enzymes SOD and GPx, and serum levels of antioxidants vitamins beta-carotene and beta-tocopherol were estimated in various types of brain tumors, and were compared with the levels in controls.
  • Statistically significant (P<.001) diminished levels of beta-carotene, beta-tocopherol, SOD and GPx, were observed in all the brain tumor patients as compared to controls.
  • Malignant tumor also showed a relative decrease in antioxidant levels as compared to benign tumors.
  • Comparison of histopathological sections of brain tumors also suggested a inverse relationship between antioxidant level and grades of malignancy.
  • Marked decrease in antioxidant levels may have a role in genesis of considerable oxidative stress in brain tumors.
  • Furthermore, the degree of decline in antioxidant levels may indicate severity of malignancy in brain tumors.
  • [MeSH-major] Antioxidants / analysis. Brain Neoplasms / blood. Glutathione Peroxidase / blood. Superoxide Dismutase / blood. alpha-Tocopherol / blood. beta Carotene / blood
  • [MeSH-minor] Adolescent. Adult. Aged. Brain Chemistry / physiology. Child. Female. Humans. Male. Middle Aged. Oxidative Stress / physiology

  • MedlinePlus Health Information. consumer health - Antioxidants.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • Hazardous Substances Data Bank. VITAMIN E .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17998669.001).
  • [ISSN] 1998-4138
  • [Journal-full-title] Journal of cancer research and therapeutics
  • [ISO-abbreviation] J Cancer Res Ther
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Antioxidants; 01YAE03M7J / beta Carotene; EC 1.11.1.9 / Glutathione Peroxidase; EC 1.15.1.1 / Superoxide Dismutase; H4N855PNZ1 / alpha-Tocopherol
  •  go-up   go-down


23. Jozwiak J, Grajkowska W, Kotulska K, Jozwiak S, Zalewski W, Zajaczkowska A, Roszkowski M, Slupianek A, Wlodarski P: Brain tumor formation in tuberous sclerosis depends on Erk activation. Neuromolecular Med; 2007;9(2):117-27
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Brain tumor formation in tuberous sclerosis depends on Erk activation.
  • Tuberous sclerosis (TS) is an autosomal dominant disease associated with the formation of usually benign tumors or hamartomas.
  • Here, we show for the first time that in all four brain lesions and one angiomyolipoma from TS patients both extracellular signal-regulated kinase (Erk) and p90 ribosomal S6 kinase 1 activation as well as Erk-dependent phosphorylation of p70 ribosomal S6 kinase 1 are markedly elevated whereas Akt, participating in the classical pathway of mammalian target of rapamycin activation is not always activated.
  • [MeSH-major] Brain Neoplasms / enzymology. Extracellular Signal-Regulated MAP Kinases / metabolism. Tuberous Sclerosis / pathology

  • Genetic Alliance. consumer health - Tuberous sclerosis.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Tuberous Sclerosis.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Cell Biol. 2002 Sep;4(9):658-65 [12172554.001]
  • [Cites] J Biol Chem. 2003 Jul 25;278(30):28130-8 [12740386.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jun 14;102(24):8573-8 [15937108.001]
  • [Cites] Anticancer Res. 2004 Sep-Oct;24(5A):2697-704 [15517874.001]
  • [Cites] Curr Biol. 2005 Apr 26;15(8):702-13 [15854902.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Sep 14;101(37):13489-94 [15342917.001]
  • [Cites] Neurol Med Chir (Tokyo). 2003 Dec;43(12):616-8 [14723270.001]
  • [Cites] Am J Pathol. 1997 Dec;151(6):1639-47 [9403714.001]
  • [Cites] J Biol Chem. 2004 Jan 23;279(4):2737-46 [14576155.001]
  • [Cites] J Biol Chem. 2002 Sep 20;277(38):35364-70 [12167664.001]
  • [Cites] Mol Cell Biol. 1998 Jul;18(7):3708-17 [9632753.001]
  • [Cites] Cancer Res. 2004 Feb 1;64(3):812-6 [14871804.001]
  • [Cites] Acta Neuropathol. 2000 May;99(5):503-10 [10805093.001]
  • [Cites] Cancer Res. 2003 Nov 15;63(22):7652-6 [14633685.001]
  • [Cites] J Biol Chem. 2001 Nov 23;276(47):43871-8 [11571286.001]
  • [Cites] Cell Mol Neurobiol. 2005 Aug;25(5):795-805 [16133934.001]
  • [Cites] Epilepsia. 2004 Dec;45(12 ):1525-30 [15571510.001]
  • [Cites] Nat Cell Biol. 2003 Jun;5(6):578-81 [12771962.001]
  • [Cites] Brain Dev. 2001 Nov;23(7):508-15 [11701246.001]
  • [Cites] J Child Neurol. 2000 Oct;15(10):652-9 [11063078.001]
  • [Cites] Cell. 1996 Oct 18;87(2):159-70 [8861899.001]
  • [Cites] Cancer Res. 2005 Sep 1;65(17):7800-8 [16140948.001]
  • [Cites] Przegl Lek. 2001;58 Suppl 1:12-5 [11355103.001]
  • [Cites] Am J Pathol. 2005 Apr;166(4):1153-62 [15793295.001]
  • [Cites] Clin Cancer Res. 2003 Aug 15;9(9):3469-75 [12960139.001]
  • [Cites] Hum Mol Genet. 2005 Feb 1;14(3):429-35 [15601645.001]
  • [Cites] Mol Cell Biol. 1984 Aug;4(8):1577-82 [6092920.001]
  • [Cites] Cell. 2005 Apr 22;121(2):179-93 [15851026.001]
  • [Cites] Nat Cell Biol. 2002 Sep;4(9):648-57 [12172553.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Aug 5;333(3):818-26 [15963462.001]
  • [Cites] Genes Dev. 2004 Oct 15;18(20):2479-84 [15466161.001]
  • [Cites] Int J Cancer. 2006 Jan 1;118(1):1-5 [16206276.001]
  • [Cites] Neurology. 2004 Oct 12;63(7):1293-5 [15477556.001]
  • [Cites] J Clin Invest. 1999 Sep;104(6):687-95 [10491404.001]
  • (PMID = 17627032.001).
  • [ISSN] 1535-1084
  • [Journal-full-title] Neuromolecular medicine
  • [ISO-abbreviation] Neuromolecular Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Butadienes; 0 / Enzyme Inhibitors; 0 / Nitriles; 0 / U 0126; EC 2.7.- / Protein Kinases; EC 2.7.1.1 / MTOR protein, human; EC 2.7.1.1 / TOR Serine-Threonine Kinases; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 2.7.11.24 / Extracellular Signal-Regulated MAP Kinases
  •  go-up   go-down


24. Jalali R, Budrukkar A, Sarin R, Sharma DS: High precision conformal radiotherapy employing conservative margins in childhood benign and low-grade brain tumours. Radiother Oncol; 2005 Jan;74(1):37-44
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High precision conformal radiotherapy employing conservative margins in childhood benign and low-grade brain tumours.
  • BACKGROUND AND PURPOSE: To report local control and follow up outcome data of high precision conformal radiotherapy in childhood brain tumours.
  • MATERIALS AND METHODS: Between December 1999 and December 2002, 26 children (17 boys and 9 girls, median age 11.5 years) with incompletely excised or recurrent benign and low-grade brain tumours [13 craniopharyngiomas, 11 low-grade gliomas (LGG) and 2 others] were treated with three-dimensional (3D) conformal radiotherapy (CRT) (12 patients) and stereotactic conformal radiotherapy (SCRT) (14 patients).
  • Gross tumour volume (GTV) included neuro-imaging based visible tumour and/or resected tumour bed.
  • CONCLUSION: High-precision conformal techniques delivering irradiation to a computer generated target volume employing 7-10 mm 3D margins beyond the visible tumour and/or resected tumour bed appear to be safe in children with incompletely resected or recurrent benign and low-grade brain tumours, based on these data.
  • [MeSH-major] Brain Neoplasms / radiotherapy. Craniopharyngioma / radiotherapy. Glioma / radiotherapy. Radiotherapy, Conformal
  • [MeSH-minor] Adolescent. Adult. Brain Diseases / etiology. Child. Child, Preschool. Combined Modality Therapy. Cysts / etiology. Dose Fractionation. Female. Humans. Male. Radiation Injuries. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15683667.001).
  • [ISSN] 0167-8140
  • [Journal-full-title] Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  • [ISO-abbreviation] Radiother Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  •  go-up   go-down


25. Simis A, Pires de Aguiar PH, Leite CC, Santana PA Jr, Rosemberg S, Teixeira MJ: Peritumoral brain edema in benign meningiomas: correlation with clinical, radiologic, and surgical factors and possible role on recurrence. Surg Neurol; 2008 Nov;70(5):471-7; discussion 477
Genetic Alliance. consumer health - Edema.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peritumoral brain edema in benign meningiomas: correlation with clinical, radiologic, and surgical factors and possible role on recurrence.
  • METHODS: Sixty-one patients with benign meningiomas were chosen for surgical treatment by the Group of Brain Tumors and Metastasis of the Department of Neurosurgery.
  • Tumors located in the cavernous sinus, tuberculum sellae, foramen magnum, ventricles, and petroclival region were excluded.
  • CONCLUSION: Peritumoral brain edema may be related to the invading potential of meningiomas and may play a role in the recurrence potential of the tumor.
  • [MeSH-major] Brain Edema / complications. Meningeal Neoplasms / pathology. Meningeal Neoplasms / surgery. Meningioma / pathology. Meningioma / surgery. Neoplasm Recurrence, Local / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18586307.001).
  • [ISSN] 0090-3019
  • [Journal-full-title] Surgical neurology
  • [ISO-abbreviation] Surg Neurol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


26. Cozzi L, Clivio A, Bauman G, Cora S, Nicolini G, Pellegrini R, Vanetti E, Yartsev S, Fogliata A: Comparison of advanced irradiation techniques with photons for benign intracranial tumours. Radiother Oncol; 2006 Aug;80(2):268-73
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of advanced irradiation techniques with photons for benign intracranial tumours.
  • BACKGROUND AND PURPOSE: The potential benefits and limitations of different radiation techniques (stereotactic arc therapy (SRS/T), intensity modulated radiotherapy (IMRT), helical tomotherapy (HT), Cyberknife and intensity-modulated multiple arc therapy (AMOA)) have been assessed using comparative treatment planning methods on twelve patients presenting with 'benign' brain tumours.
  • For organs at risk all techniques respected planning objectives with a tendency of Cyberknife and SRS/T to better spare the brain stem and the healthy brain tissue (e.g., V(20Gy) of 2.0% and 2.3%, respectively, compared to 3.1-5.0% for the other techniques).
  • [MeSH-major] Brain Neoplasms / radiotherapy. Photons / therapeutic use

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16890315.001).
  • [ISSN] 0167-8140
  • [Journal-full-title] Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  • [ISO-abbreviation] Radiother Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  •  go-up   go-down


27. Hardell L, Carlberg M, Hansson Mild K: Pooled analysis of two case-control studies on the use of cellular and cordless telephones and the risk of benign brain tumours diagnosed during 1997-2003. Int J Oncol; 2006 Feb;28(2):509-18
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pooled analysis of two case-control studies on the use of cellular and cordless telephones and the risk of benign brain tumours diagnosed during 1997-2003.
  • The use of cellular and cordless telephones and the risk of brain tumours is of concern since the brain is a high exposure area.
  • We present the results of a pooled analysis of two case-control studies on benign brain tumours diagnosed during 1997-2003 including answers from 1,254 (88%) cases and 2,162 (89%) controls aged 20-80 years.
  • [MeSH-major] Brain Neoplasms / etiology. Cell Phones. Meningioma / etiology. Neuroma, Acoustic / etiology

  • MedlinePlus Health Information. consumer health - Acoustic Neuroma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16391807.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  •  go-up   go-down


28. Britz-Cunningham SH, Millstine JW, Gerbaudo VH: Improved discrimination of benign and malignant lesions on FDG PET/CT, using comparative activity ratios to brain, basal ganglia, or cerebellum. Clin Nucl Med; 2008 Oct;33(10):681-7
MedlinePlus Health Information. consumer health - CT Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Improved discrimination of benign and malignant lesions on FDG PET/CT, using comparative activity ratios to brain, basal ganglia, or cerebellum.
  • PURPOSE: This study demonstrates a simple background correction method, which improves the discrimination of benign from malignant lesions on FDG PET-CT imaging, using activity ratios compared with brain, basal ganglia, or cerebellum.
  • METHODS: Standardized uptake values (SUVs) and comparative activity ratios (CARs) were determined for FDG uptake in 92 lesions (39 benign and 53 malignant) in 49 patients.
  • Reference tissues included cerebral cortex, basal ganglia, cerebellum, lung, liver, and aortic blood pool.
  • Discriminant power for each CAR was evaluated as malignant-to-benign ratio of mean uptake and ratio of intermediate-likelihood lesions to total number of lesions.
  • RESULTS: Uncorrected SUV varied widely for malignant and benign lesions, with considerable overlap.
  • Ratio of mean uptake for malignant lesions versus benign lesions was lowest for uncorrected SUVAVG and SUVAVG/liver (1.92), and highest for SUVMAX/cerebral cortex (3.52).
  • CONCLUSIONS: Ability to discriminate malignant from benign lesions was enhanced by using CARs derived from cerebral cortex, basal ganglia, or cerebellum.
  • [MeSH-major] Brain Neoplasms / diagnosis. Fluorodeoxyglucose F18. Image Enhancement / methods. Image Interpretation, Computer-Assisted / methods. Positron-Emission Tomography / methods. Tomography, X-Ray Computed / methods
  • [MeSH-minor] Brain / radiography. Brain / radionuclide imaging. Diagnosis, Differential. Humans. Radiopharmaceuticals. Reproducibility of Results. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18806567.001).
  • [ISSN] 1536-0229
  • [Journal-full-title] Clinical nuclear medicine
  • [ISO-abbreviation] Clin Nucl Med
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


29. Hu H, Yao HT, Zhang WP, Zhang L, Ding W, Zhang SH, Chen Z, Wei EQ: Increased expression of aquaporin-4 in human traumatic brain injury and brain tumors. J Zhejiang Univ Sci B; 2005 Jan;6(1):33-7
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased expression of aquaporin-4 in human traumatic brain injury and brain tumors.
  • OBJECTIVE: To characterize the expression of aquaporin-4 (AQP4), one of the aquaporins (AQPs), in human brain specimens from patients with traumatic brain injury or brain tumors.
  • METHODS: Nineteen human brain specimens were obtained from the patients with traumatic brain injury, brain tumors, benign meningioma or early stage hemorrhagic stroke.
  • MRI or CT imaging was used to assess brain edema.
  • CONCLUSION: AQP4 expression increases in human brains after traumatic brain injury, within brain-derived tumors, and around brain tumors.
  • [MeSH-major] Aquaporins / metabolism. Brain Edema / metabolism. Brain Edema / pathology. Brain Injuries / metabolism. Brain Injuries / pathology. Brain Neoplasms / metabolism. Brain Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Med. 2000 Feb;6(2):159-63 [10655103.001]
  • [Cites] Brain Res Mol Brain Res. 2000 May 31;78(1-2):131-7 [10891592.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2002 Feb;72(2):262-5 [11796780.001]
  • [Cites] Brain Res Brain Res Rev. 2002 Jun;39(1):55-73 [12086708.001]
  • [Cites] J Anat. 2002 Jun;200(6):617-27 [12162729.001]
  • [Cites] J Neurosurg. 2003 Mar;98(3):565-9 [12650429.001]
  • [Cites] Acta Neuropathol. 2003 Aug;106(2):121-4 [12715185.001]
  • [Cites] J Biol Chem. 1988 Oct 25;263(30):15634-42 [3049610.001]
  • [Cites] J Neurosci. 1997 Jan 1;17(1):171-80 [8987746.001]
  • [Cites] J Biol Chem. 1997 Jun 27;272(26):16140-6 [9195910.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Sep 29;95(20):11981-6 [9751776.001]
  • (PMID = 15593389.001).
  • [ISSN] 1673-1581
  • [Journal-full-title] Journal of Zhejiang University. Science. B
  • [ISO-abbreviation] J Zhejiang Univ Sci B
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Controlled Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / AQP4 protein, human; 0 / Aquaporin 4; 0 / Aquaporins; 0 / Biomarkers
  • [Other-IDs] NLM/ PMC1390756
  •  go-up   go-down


30. Juric-Sekhar G, Zarkovic K, Waeg G, Cipak A, Zarkovic N: Distribution of 4-hydroxynonenal-protein conjugates as a marker of lipid peroxidation and parameter of malignancy in astrocytic and ependymal tumors of the brain. Tumori; 2009 Nov-Dec;95(6):762-8
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Distribution of 4-hydroxynonenal-protein conjugates as a marker of lipid peroxidation and parameter of malignancy in astrocytic and ependymal tumors of the brain.
  • It results in the production of 4-hydroxynonenal (HNE), which plays a crucial role in hypoxic brain injury, neuronal degeneration and apoptosis.
  • The aim of this study was to evaluate the expression of HNE in 120 astrocytic and 40 ependymal tumors in relation to tumor type, grade of malignancy, angiogenesis, and presence of necrosis and apoptosis.
  • RESULTS: HNE-protein adducts were found in all tumors.
  • The incidence of HNE-immunopositive tumor cells increased with increasing grades of malignancy.
  • Significantly higher HNE expression was found in tumor cells of glioblastomas multiforme than in cells of pilocytic astrocytomas (P < 0.005), and in anaplastic ependymomas than in benign ependymomas (P < 0.01).
  • HNE-immunopositive tumor cells were distributed more diffusely than in perivascular locations (P < 0.05).
  • HNE was expressed in the endothelium of almost all tumor vessels, but its expression in the walls of the vessels was significantly higher in diffuse and anaplastic astrocytomas than in pilocytic astrocytomas and glioblastomas multiforme (P < 0.05).
  • The number of microvessels containing HNE in their endothelium and walls was significantly associated with the grade of malignancy in both astrocytic (P < 0.001) and ependymal tumors (P < 0.05), although microvessels in pilocytic astrocytomas were significantly more numerous (P < 0.05) than in diffuse astrocytomas.
  • CONCLUSIONS: LPO seems to be a common pathological process in astrocytic and ependymal glial tumors, proportional to the level of malignancy and neovascularization.
  • Therefore, HNE might be involved in the damage of brain cells and the induction of malignancy.
  • [MeSH-major] Aldehydes / analysis. Astrocytoma / chemistry. Biomarkers, Tumor / analysis. Brain Neoplasms / chemistry. Brain Neoplasms / pathology. Ependymoma / chemistry. Lipid Peroxidation. Neoplasm Proteins / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20210242.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Aldehydes; 0 / Biomarkers, Tumor; 0 / Cross-Linking Reagents; 0 / Neoplasm Proteins; 29343-52-0 / 4-hydroxy-2-nonenal
  •  go-up   go-down


31. Psaras T, Pantazis G, Steger V, Meyermann R, Honegger J, Beschorner R: Benign meningioma developing late lung metastases: case report and review of the literature. Clin Neuropathol; 2009 Nov-Dec;28(6):453-9
The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for benign meningioma .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign meningioma developing late lung metastases: case report and review of the literature.
  • Here we report the case of a 65-year-old female with a histologically benign parietal falcine meningioma who developed multiple lung metastases 15 years after tumor resection.
  • Since it was diagnosed as a benign meningothelial meningioma Grade I WHO, the residual tumor was followed with serial imaging without adjuvant treatment.
  • A repeat brain MRI revealed the known residual meningioma with no signs of interval tumor growth, but did demonstrate occlusion of the sagittal sinus.
  • A review of the literature revealed only 15 well-documented cases of benign meningiomas that metastasized in an interval of up to 12 years after primary tumor resection.
  • This case illustrates that histologically benign meningiomas Grade I WHO with stable disease of the primary tumor have the potential to develop hematogenous metastases even after a long time interval.
  • [MeSH-major] Lung Neoplasms / secondary. Meningeal Neoplasms / pathology. Meningioma / secondary
  • [MeSH-minor] Aged. Female. Humans. Neoplasm, Residual. Time Factors

  • Genetic Alliance. consumer health - Meningioma.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19919820.001).
  • [ISSN] 0722-5091
  • [Journal-full-title] Clinical neuropathology
  • [ISO-abbreviation] Clin. Neuropathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 25
  •  go-up   go-down


32. Monleón D, Morales JM, Gonzalez-Darder J, Talamantes F, Cortés O, Gil-Benso R, López-Ginés C, Cerdá-Nicolás M, Celda B: Benign and atypical meningioma metabolic signatures by high-resolution magic-angle spinning molecular profiling. J Proteome Res; 2008 Jul;7(7):2882-8
Genetic Alliance. consumer health - Meningioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign and atypical meningioma metabolic signatures by high-resolution magic-angle spinning molecular profiling.
  • Meningiomas are neoplasms that arise from the leptomeningeal covering of the brain and spinal cord, accounting for 15%-20% of CNS tumors.
  • The WHO classifies meningiomas into three histological grades: benign, atypical, and anaplasic in accordance with the clinical prognosis.
  • Sometimes, meningiomas with histological diagnosis of benign meningioma show clinical characteristics of atypical meningioma.
  • In this context, high-resolution magic-angle spinning (HR-MAS) spectroscopy of intact tissue from brain tumor biopsies has shown great potential as a support diagnostic tool.
  • In this work, we show differences between benign and atypical meningiomas in HR-MAS molecular profiles of meningioma biopsies.
  • Glutamine and glutamate, which are related to glutathione metabolism and have been associated with tumor recurrence, are also increased in atypical meningiomas.
  • Other metabolites associated with tumor malignancy that show statistically significant differences between benign and atypical meningiomas include phosphocholine and phosphoethanolamine.
  • Overall, this work suggests that the additional information obtained by NMR metabolomics applied to biopsies of human meningiomas may be useful for assessing tumor grade and determining optimum treatment strategies.
  • [MeSH-major] Meningeal Neoplasms / metabolism. Meningioma / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / metabolism. Female. Gene Expression Profiling. Humans. Magnetic Resonance Spectroscopy. Male. Middle Aged. Principal Component Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18507434.001).
  • [ISSN] 1535-3893
  • [Journal-full-title] Journal of proteome research
  • [ISO-abbreviation] J. Proteome Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


33. Kravets LIa, Trofimov AO: [Delayed surgical operations in benign supratentorial gliomas]. Zh Vopr Neirokhir Im N N Burdenko; 2009 Jan-Mar;(1):24-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Delayed surgical operations in benign supratentorial gliomas].
  • Benign gliomas are slowly growing primary brain tumors with prolonged natural course and tendency to malignization.
  • The paper describes results of treatment of 19 patients with benign supratentorial gliomas.
  • Aspects of volume evolution and surgical excision of tumor are highlighted.
  • [MeSH-major] Glioma / surgery. Neurosurgical Procedures / methods. Supratentorial Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19505027.001).
  • [ISSN] 0042-8817
  • [Journal-full-title] Zhurnal voprosy neĭrokhirurgii imeni N. N. Burdenko
  • [ISO-abbreviation] Zh Vopr Neirokhir Im N N Burdenko
  • [Language] rus
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


34. Tuniz F, Soltys SG, Choi CY, Chang SD, Gibbs IC, Fischbein NJ, Adler JR Jr: Multisession cyberknife stereotactic radiosurgery of large, benign cranial base tumors: preliminary study. Neurosurgery; 2009 Nov;65(5):898-907; discussion 907
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multisession cyberknife stereotactic radiosurgery of large, benign cranial base tumors: preliminary study.
  • OBJECTIVE: Although radiosurgery plays an important role in managing benign cranial base lesions, the potential for increased toxicity with single-session treatment of large tumors is a concern.
  • In this retrospective study, we report the intermediate-term rate of local control, morbidity, and clinical outcomes of patients with large cranial base tumors treated with multisession stereotactic radiosurgery with the CyberKnife (Accuray, Inc., Sunnyvale, CA).
  • METHODS: Between 1999 and 2008, 34 consecutive patients with large (>15 cm), benign cranial base tumors (21 meningiomas, 9 schwannomas, 4 glomus jugulare tumors) underwent primary or postoperative radiosurgical treatment using a multisession approach at Stanford University and were considered in this retrospective study.
  • CyberKnife radiosurgery was delivered in 2 to 5 sessions (median, 3 sessions) to a median tumor volume of 19.3 cm (range, 15.8-69.3 cm).
  • To date, all tumors remain locally controlled.
  • CONCLUSION: Over our modest length of follow-up, multisession radiosurgery appears to be a safe and effective option for selected large, benign brain and cranial base lesions.
  • [MeSH-major] Radiosurgery / methods. Skull Base Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19834402.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


35. Aghi M, Barker FG 2nd: Benign adult brain tumors: an evidence-based medicine review. Prog Neurol Surg; 2006;19:80-96
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign adult brain tumors: an evidence-based medicine review.
  • BACKGROUND: Benign adult brain tumors can be managed conservatively or using surgery, radiation, or medicines.
  • While randomized comparisons assessing tumor recurrence, quality of life, or survival are the ideal means of comparing treatments, it can be difficult to recruit patients to such trials and lengthy follow-up periods are needed because of the slowly progressive natural history of these tumors.
  • METHODS: Review of the literature on benign adult brain tumors using evidence-based standards and focusing on meningiomas, pituitary adenomas, and vestibular schwannomas, which together represent the majority of WHO grade 1 adult brain tumors.
  • RESULTS: Nearly all studies of benign adult brain tumors were of relatively poor quality (level 3 or poorer).
  • CONCLUSIONS: While randomized clinical trials comparing conservative management, surgery, radiation, and medical management of benign adult benign tumors are unlikely to occur, there is some level 3 evidence that can assist in their treatment.
  • [MeSH-major] Brain Neoplasms / therapy. Evidence-Based Medicine
  • [MeSH-minor] Adenoma / therapy. Adult. Humans. Meningeal Neoplasms / therapy. Meningioma / therapy. Neuroma, Acoustic / therapy. Neurosurgical Procedures. Phototherapy. Pituitary Neoplasms / therapy. Radiosurgery

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17033148.001).
  • [ISSN] 0079-6492
  • [Journal-full-title] Progress in neurological surgery
  • [ISO-abbreviation] Prog Neurol Surg
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  • [Number-of-references] 58
  •  go-up   go-down


36. Pappalardo EM, Militello M, Rapisarda G, Imbruglia L, Recupero S, Ermito S, Dinatale A, Carrara S, Cavaliere A: Fetal intracranial cysts: prenatal diagnosis and outcome. J Prenat Med; 2009 Apr;3(2):28-30

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fetal intracranial cysts: prenatal diagnosis and outcome.
  • Intracranial cysts are central nervous system malformations involving different brain regions, and commonly diagnosed during prenatal period by ultrasound scan (US).
  • A malformative cyst is a nontumoral fluid-filled collection exerting a mass effect on the brain parenchyma and/or on the ventricles, regardless of its location within subarachnoid spaces, brain or ventricles, and of the nature of its limiting membrane, which is always unknown prenatally.
  • Most of these lesions, if not associated with other fetal anomalies, are benign in nature, remain clinically silent, do not evolve or even frequently regress spontaneously and do not impair physiologic neurodevelopment.
  • The normality of the adjacent brain is the major argument in favour of a malformative lesion.
  • The correct diagnosis is of crucial importance to exclude the presence of other rare lesions (e.g. cystic neoplasms or intracranial hemorrhage) that could negatively affect neurodevelopmental outcome of the child.
  • To establish a correct prognosis all efforts must aim to precisely interpret the US images accurately analyzing the brain anatomy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22439038.001).
  • [ISSN] 1971-3282
  • [Journal-full-title] Journal of prenatal medicine
  • [ISO-abbreviation] J Prenat Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Other-IDs] NLM/ PMC3279101
  • [Keywords] NOTNLM ; cysti brain / fetal / intracranial
  •  go-up   go-down


37. Wang XY, Xu SJ, Li XG: Post-operative implantation metastasis of craniopharyngioma: a case report. J Int Med Res; 2010 Sep-Oct;38(5):1876-82
MedlinePlus Health Information. consumer health - Pituitary Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Craniopharyngiomas are histologically benign epithelial tumours arising from squamous epithelial remnants of Rathke's pouch, which have a tendency to invade surrounding structures and recur after apparently complete resection.
  • They represent the most frequent non-glial tumour in children, accounting for approximately 5% of paediatric brain neoplasms.
  • [MeSH-major] Craniopharyngioma / secondary. Neoplasm Recurrence, Local / pathology. Pituitary Neoplasms / pathology

  • Genetic Alliance. consumer health - Craniopharyngioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21309505.001).
  • [ISSN] 0300-0605
  • [Journal-full-title] The Journal of international medical research
  • [ISO-abbreviation] J. Int. Med. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


38. Sundgren PC, Cao Y: Brain irradiation: effects on normal brain parenchyma and radiation injury. Neuroimaging Clin N Am; 2009 Nov;19(4):657-68
MedlinePlus Health Information. consumer health - Diagnostic Imaging.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Brain irradiation: effects on normal brain parenchyma and radiation injury.
  • Radiation therapy is a major treatment modality for malignant and benign brain tumors.
  • Concerns of radiation effects on the brain tissue and neurocognitive function and quality of life increase as survival of patients treated for brain tumors improves.
  • In this article, the clinical and neurobehavioral symptoms and signs of radiation-induced brain injury, possible histopathology, and the potential of functional, metabolic, and molecular imaging as a biomarker for assessment and prediction of neurotoxicity after brain irradiation and imaging findings in radiation necrosis are discussed.
  • [MeSH-major] Brain / radiation effects. Brain Injuries / diagnosis. Brain Injuries / etiology. Diagnostic Imaging / methods. Radiation Injuries / diagnosis. Radiation Injuries / etiology. Radiotherapy, Conformal / adverse effects

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19959011.001).
  • [ISSN] 1557-9867
  • [Journal-full-title] Neuroimaging clinics of North America
  • [ISO-abbreviation] Neuroimaging Clin. N. Am.
  • [Language] eng
  • [Grant] United States / NINDS NIH HHS / NS / R01 NS064973
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS167505; NLM/ PMC5000393
  •  go-up   go-down


39. Ryu SI, Tafti BA, Skirboll SL: Pituitary adenomas can appear as hypermetabolic lesions in (18) F-FDG PET imaging. J Neuroimaging; 2010 Oct;20(4):393-6
MedlinePlus Health Information. consumer health - Pituitary Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: The 2-deoxy-2-[(18) F] fluoro-D-glucose positron emission tomography (FDG-PET) scan is commonly used in detection and staging of many malignant neoplasms.
  • However, several benign or non-neoplastic conditions avidly accumulate (18) F-FDG, causing ambiguity in interpretation of results.
  • Here, we present 2 cases of benign pituitary adenoma with elevated metabolic activity in (18) F-FDG PET scan.
  • [MeSH-major] Adenoma / radionuclide imaging. Fluorodeoxyglucose F18. Pituitary Neoplasms / radionuclide imaging. Positron-Emission Tomography / methods
  • [MeSH-minor] Aged. Brain Diseases, Metabolic / radionuclide imaging. Diagnosis, Differential. Humans. Male. Middle Aged. Radiopharmaceuticals

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2009 by the American Society of Neuroimaging.
  • (PMID = 19453834.001).
  • [ISSN] 1552-6569
  • [Journal-full-title] Journal of neuroimaging : official journal of the American Society of Neuroimaging
  • [ISO-abbreviation] J Neuroimaging
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


40. Cianfoni A, Wintermark M, Piludu F, D'Alessandris QG, Lauriola L, Visocchi M, Colosimo C: Morphological and functional MR imaging of Lhermitte-Duclos disease with pathology correlate. J Neuroradiol; 2008 Dec;35(5):297-300
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Lhermitte-Duclos disease (LDD) is a rare benign lesion of uncertain pathogenesis characterised by distortion of the normal cerebellar laminar cytoarchitecture.
  • Imaging showed restricted diffusion consistent with high cellularity, high degree of vascularity and preserved blood-brain barrier permeability, correlating with pathology.
  • [MeSH-major] Brain Neoplasms / diagnosis. Hamartoma Syndrome, Multiple / diagnosis. Magnetic Resonance Imaging / methods
  • [MeSH-minor] Contrast Media. Diagnosis, Differential. Female. Humans. Middle Aged

  • Genetic Alliance. consumer health - Lhermitte-Duclos disease.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18692898.001).
  • [ISSN] 0150-9861
  • [Journal-full-title] Journal of neuroradiology. Journal de neuroradiologie
  • [ISO-abbreviation] J Neuroradiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


41. Balasubramaniam A, Shannon P, Hodaie M, Laperriere N, Michaels H, Guha A: Glioblastoma multiforme after stereotactic radiotherapy for acoustic neuroma: case report and review of the literature. Neuro Oncol; 2007 Oct;9(4):447-53
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Indications for the use of radiotherapy in the management of a variety of benign intracranial neoplastic and nonneoplastic pathologies are increasing.
  • Although the short-term risks are minimal, the long-term risks of radiation-induced de novo secondary neoplasms or malignant progression of the primary benign tumor need to be considered.
  • There are currently 19 reported cases of tumors linked with stereotactic radiotherapy/radiosurgery, to which we add our second institutional experience of a patient who succumbed to a glioblastoma multiforme (GBM) after stereotactic radiotherapy for an acoustic neuroma (AN).
  • Review of these 20 cases revealed 10 de novo secondary tumors, of which eight were malignant, with six being malignant gliomas.
  • Accelerated growth of the primary benign AN, some 2 to 6 years after focused radiotherapy, was found in six of eight NF2 patients, with pathological verification of a malignant nerve sheath tumor documented in most.
  • [MeSH-major] Brain Neoplasms / etiology. Glioblastoma / etiology. Neoplasms, Radiation-Induced / etiology. Neoplasms, Second Primary / etiology. Neuroma, Acoustic / surgery. Radiosurgery / adverse effects

  • Genetic Alliance. consumer health - Acoustic Neuroma.
  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Acoustic Neuroma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Stereotact Funct Neurosurg. 1999;72 Suppl 1:2-10 [10681685.001]
  • [Cites] Otol Neurotol. 2006 Feb;27(2):213-9 [16436992.001]
  • [Cites] Am J Otol. 2000 May;21(3):364-70 [10821550.001]
  • [Cites] Br J Neurosurg. 2000 Apr;14(2):93-5 [10889878.001]
  • [Cites] Lancet. 2000 Nov 4;356(9241):1576-7 [11075777.001]
  • [Cites] J Neurosurg. 2001 May;94(5):816-21 [11354416.001]
  • [Cites] J Neurosurg. 2001 Sep;95(3):518-21 [11565878.001]
  • [Cites] J Neurosurg. 2001 Oct;95(4):710-3 [11596968.001]
  • [Cites] Neoplasia. 2002 Jul-Aug;4(4):279-90 [12082543.001]
  • [Cites] Lancet. 2002 Jul 27;360(9329):309-10 [12147377.001]
  • [Cites] Laryngoscope. 2002 Jun;112(6):948-50 [12160289.001]
  • [Cites] Br J Neurosurg. 2002 Jun;16(3):284-9 [12201399.001]
  • [Cites] Neurosurgery. 2003 Feb;52(2):296-307; discussion 307-8 [12535357.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Apr 29;100(9):5057-62 [12679524.001]
  • [Cites] Neurosurgery. 2003 Jun;52(6):1291-6; discussion 1296-7 [12762874.001]
  • [Cites] Neurosurgery. 2003 Jun;52(6):1436-40; discussion 1440-2 [12762888.001]
  • [Cites] Surg Neurol. 2003 Jul;60(1):60-7; discussion 67 [12865017.001]
  • [Cites] Minim Invasive Neurosurg. 2003 Aug;46(4):254-6 [14506573.001]
  • [Cites] J Clin Pathol. 2004 Jan;57(1):109-10 [14693854.001]
  • [Cites] Neurol Med Chir (Tokyo). 2004 Jan;44(1):29-32 [14959934.001]
  • [Cites] J Neurooncol. 2004 Feb;66(3):301-5 [15015661.001]
  • [Cites] Neurochirurgie. 2004 Jun;50(2-3 Pt 2):414-20 [15179297.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Jul 15;59(4):928-42 [15234026.001]
  • [Cites] Oncogene. 2004 Aug 26;23(39):6541-7 [15221010.001]
  • [Cites] Cancer. 1984 Feb 1;53(3):426-9 [6581853.001]
  • [Cites] Neurosurgery. 1985 Sep;17(3):436-45 [2995867.001]
  • [Cites] Cancer. 1987 Apr 1;59(7):1274-82 [3815303.001]
  • [Cites] N Engl J Med. 1990 Jul 12;323(2):127-9 [2359422.001]
  • [Cites] BMJ. 1992 May 23;304(6838):1343-6 [1611331.001]
  • [Cites] Tumori. 1992 Apr 30;78(2):143-6 [1523707.001]
  • [Cites] Cancer. 1993 Oct 1;72(7):2227-33 [8374881.001]
  • [Cites] Cancer. 1998 Jan 1;82(1):8-34 [9428476.001]
  • [Cites] J Neurosurg. 1998 Oct;89(4):653-8 [9761063.001]
  • [Cites] Cancer Res. 1999 Mar 1;59(5):1008-14 [10070956.001]
  • [Cites] J Neurooncol. 2004 Aug-Sep;69(1-3):335-49 [15527099.001]
  • [Cites] Radiat Res. 2005 Apr;163(4):424-32 [15799699.001]
  • [Cites] Cancer Cell. 2005 Oct;8(4):271-3 [16226702.001]
  • [Cites] Br J Cancer. 2000 Feb;82(4):998 [10732777.001]
  • (PMID = 17704364.001).
  • [ISSN] 1522-8517
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC1994102
  •  go-up   go-down


42. Baggenstos MA, Butman JA, Oldfield EH, Lonser RR: Role of edema in peritumoral cyst formation. Neurosurg Focus; 2007;22(5):E9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Peritumoral cysts (those arising immediately adjacent to the tumor mass) are frequently associated with benign and malignant tumors of the brain and spinal cord (syringomyelia).
  • The cystic component of central nervous system (CNS) tumors and associated peritumoral cysts are often the cause of clinical symptoms.
  • Because of the common occurrence of peritumoral cysts with CNS neoplasms and the morbidity associated with them, advanced imaging, histological, and molecular techniques have been used to determine the mechanism underlying cyst formation and propagation.
  • Mediators of vascular permeability acting locally in the tumor and/or hydrodynamic forces within abnormal tumor vasculature appear to drive fluid extravasation.
  • These findings support the concept that the tumor itself is the source of the edema that precedes cyst formation and that resection of tumors or medical therapies directed at decreasing their vascular permeability will result in the resolution of edema and cysts.
  • [MeSH-major] Brain Edema / etiology. Brain Edema / pathology. Brain Neoplasms / complications. Central Nervous System Cysts / complications
  • [MeSH-minor] Blood-Brain Barrier / drug effects. Blood-Brain Barrier / physiopathology. Diagnostic Imaging. Humans. Neovascularization, Pathologic. Spinal Cord Diseases / pathology

  • Genetic Alliance. consumer health - Edema.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17613240.001).
  • [ISSN] 1092-0684
  • [Journal-full-title] Neurosurgical focus
  • [ISO-abbreviation] Neurosurg Focus
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural; Review
  • [Publication-country] United States
  • [Number-of-references] 59
  •  go-up   go-down


43. Takahashi H, Harada M, Kimura M, Kato H: Thymolipoma combined with hyperthyroidism discovered by neurological symptoms. Ann Thorac Cardiovasc Surg; 2007 Apr;13(2):114-7
MedlinePlus Health Information. consumer health - Thymus Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Thymolipomas are rare slow-growing mediastinal thymic neoplasms.
  • Central nervous system disorder was suggested but no significant abnormalities were found on brain MR nor were there any neurological signs.
  • Several months later, neurological and systemic examinations on admission revealed hyperthyroidism and an anterior mediastinal tumor, 9.0x5.0x3.0 cm in size on chest CT films.
  • Neurologists recommended resection of the mediastinal tumor.
  • Malignancy could not be ruled out because of the irregularity of the tumor appearance on contrast-enhanced chest CT.
  • Furthermore, the tumor appeared to be attached to the ascending aorta, so cytological and/or pathological diagnosis by CT-guided needle biopsy before operation were contraindicated.
  • The pathological diagnosis was benign thymolipoma consisting of mature fatty tissue and thymic tissue structures with Hassall's corpuscles.
  • [MeSH-major] Hyperthyroidism / complications. Lipoma / complications. Thymus Neoplasms / complications

  • MedlinePlus Health Information. consumer health - Hyperthyroidism.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17505419.001).
  • [ISSN] 1341-1098
  • [Journal-full-title] Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia
  • [ISO-abbreviation] Ann Thorac Cardiovasc Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


44. Payne GS, Leach MO: Applications of magnetic resonance spectroscopy in radiotherapy treatment planning. Br J Radiol; 2006 Sep;79 Spec No 1:S16-26
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • While MRI and CT provide images of excellent spatial resolution, they do not always provide sufficient contrast to identify tumour extent or to identify regions of high cellular activity that might be targeted with boost doses.
  • The method is currently under evaluation, in particular in brain (where MRS has been shown to differentiate between many tumour types and grades) and in prostate (where cancer may be distinguished from normal tissue and benign prostatic hypertrophy).
  • The contrast achieved with MRS, based on tissue biochemistry, therefore provides a promising alternative for identifying tumour extent and regions of high metabolic activity.
  • [MeSH-major] Brain Neoplasms / radiotherapy. Magnetic Resonance Spectroscopy. Patient Care Planning. Prostatic Neoplasms / radiotherapy
  • [MeSH-minor] Diagnosis, Differential. Humans. Male

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16980681.001).
  • [ISSN] 1748-880X
  • [Journal-full-title] The British journal of radiology
  • [ISO-abbreviation] Br J Radiol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Number-of-references] 65
  •  go-up   go-down


45. Reddy JS, Mishra AM, Behari S, Husain M, Gupta V, Rastogi M, Gupta RK: The role of diffusion-weighted imaging in the differential diagnosis of intracranial cystic mass lesions: a report of 147 lesions. Surg Neurol; 2006 Sep;66(3):246-50; discussion 250-1
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of diffusion-weighted imaging in the differential diagnosis of intracranial cystic mass lesions: a report of 147 lesions.
  • BACKGROUND: The objective of this study is to evaluate the sensitivity and specificity of DWI in differentiating brain abscesses from other intracranial cystic lesions.
  • Lesions appearing hyperintense on DWI with the ADC values of lower than 0.9 +/- 0.13 x 10(-3) mm(2)/s (mean +/- SD) were considered as brain abscess, whereas hypointense lesions on DWI with the ADC values 2.2 +/- 0.9 x 10(-3) mm(2)/s were categorized as nonabscess cystic lesions.
  • RESULTS: Ninety-three of 97 brain abscess lesions were hyperintense on DWI, with significantly low (P = .0001) ADC value (0.87 +/- 0.05 x 10(-3) mm(2)/s) (mean +/- SEM), compared with 48 nonabscess lesions (2.89 +/- 0.05 x 10(-3) mm(2)/s).
  • Four of 97 brain abscess lesions in 65 patients were false negative, and 2 of 50 nonabscess lesions in 50 patients were false positive for the diagnosis of brain abscess.
  • The ADC value of the tumor cysts (2.9 +/- 0.05 x 10(-3) mm(2)/s) was significantly lower (P = .02) compared with benign cysts and neurocysticercosis (3.2 +/- 0.05 x 10(-3) mm(2)/s) among nonabscess group.
  • The sensitivity of DWI for the differentiation of brain abscesses from nonabscesses was 96%; specificity, 96%; positive predictive value, 98%; negative predictive value, 92%; and accuracy of the test, 96%.
  • CONCLUSIONS: Diffusion-weighted imaging has high sensitivity and specificity for the differentiation of brain abscess from other nonabscess intracranial cystic lesions.
  • [MeSH-major] Brain Abscess / diagnosis. Brain Neoplasms / diagnosis. Central Nervous System Cysts / diagnosis. Diffusion Magnetic Resonance Imaging / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Body Water / metabolism. Brain / pathology. Child. Child, Preschool. Diagnosis, Differential. Diffusion. Female. Humans. Infant. Male. Middle Aged. Nerve Fibers, Myelinated / metabolism. Nerve Fibers, Myelinated / pathology. Predictive Value of Tests. Prospective Studies

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16935625.001).
  • [ISSN] 0090-3019
  • [Journal-full-title] Surgical neurology
  • [ISO-abbreviation] Surg Neurol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


46. Aoki T, Tashiro Y, Fujita K, Kajiwara M, Matsuda Y: [The evaluation of preoperative and postoperative frontal lobe functions in three operative cases of meningioma]. No Shinkei Geka; 2006 Feb;34(2):161-7
Genetic Alliance. consumer health - Meningioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report three cases of frontal meningioma with their pre- and post-operative evaluations of higher brain functions, especially of frontal lobe functions.
  • All of the cases showed the improvement of the frontal lobe functions after the tumor removal.
  • The evaluations of frontal lobe functions in benign brain tumors such as a meningioma are reported only in a few cases.
  • The evaluations of frontal lobe functions in the operative cases of benign brain tumors provide many interesting and valuable informations about frontal lobe functions.
  • So we must be more interest in evaluations in higher brain functions and accumulate cases for the further analysis of higher brain functions.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16485561.001).
  • [ISSN] 0301-2603
  • [Journal-full-title] No shinkei geka. Neurological surgery
  • [ISO-abbreviation] No Shinkei Geka
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


47. Badr El-Din NK, Settin A, Ali N, Abdel-Hady el-SK, Salem FK: Cytokine gene polymorphisms in egyptian cases with brain tumors. J Egypt Natl Canc Inst; 2009 Jun;21(2):101-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytokine gene polymorphisms in egyptian cases with brain tumors.
  • BACKGROUND: Cytokines are proposed to play important roles in brain tumor biology as well as neurodegeneration or impaired neuronal function.
  • OBJECTIVES: This work aimed to check the association of polymorphisms of cytokine genes in Egyptian cases with brain tumors.
  • METHODS: This work included 45 cases affected by brain tumors diagnosed as 24 benign and 21 malignant.
  • RESULTS: Cases affected with benign brain tumors showed a significant higher frequency of IL-10-1082 A/A [odds ratio (OR=8.0), p<0.001] and IL-6-174 C/C (OR=6.3, p=0.002) homozygous genotypes as compared to controls.
  • CONCLUSIONS: Cytokine gene polymorphisms showed a pattern of association with brain tumors which may have potential impact on family counseling and disease management.
  • [MeSH-major] Biomarkers, Tumor / genetics. Brain Neoplasms / genetics. Cytokines / genetics. Polymorphism, Genetic / genetics
  • [MeSH-minor] Case-Control Studies. DNA / genetics. Egypt. Female. Genotype. Humans. Interleukin 1 Receptor Antagonist Protein / genetics. Interleukin-10 / genetics. Interleukin-6 / genetics. Male. Middle Aged. Polymerase Chain Reaction. Prognosis. Tumor Necrosis Factor-alpha / genetics

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21057561.001).
  • [ISSN] 1110-0362
  • [Journal-full-title] Journal of the Egyptian National Cancer Institute
  • [ISO-abbreviation] J Egypt Natl Canc Inst
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] Egypt
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cytokines; 0 / Interleukin 1 Receptor Antagonist Protein; 0 / Interleukin-6; 0 / Tumor Necrosis Factor-alpha; 130068-27-8 / Interleukin-10; 9007-49-2 / DNA
  •  go-up   go-down


48. Callu D, Viguier D, Laroussinie F, Puget S, Boddaert N, Kieffer V, Piana H, Escolano S, Renier D, Sainte-Rose C, Grill J, Dellatolas G: Cognitive and academic outcome after benign or malignant cerebellar tumor in children. Cogn Behav Neurol; 2009 Dec;22(4):270-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cognitive and academic outcome after benign or malignant cerebellar tumor in children.
  • OBJECTIVE: To examine the impact of malignancy and location of the cerebellar tumor on motor, cognitive, and psychologic outcome.
  • BACKGROUND: Although many studies focus on long-term outcome after cerebellar tumor treatment in childhood, the impact of its precise location remains unclear.
  • PATIENTS AND METHODS: Children, aged from 6 to 13 years, with a cerebellar malignant tumor (MT; MT group, n=20) or a cerebellar benign tumor (BT; BT group, n=19) were examined at least 6 months after the end of treatment using the international cooperative ataxia rating scale, the Purdue pegboard for manual skill assessment and the age-adapted Weschler scale.
  • Structural changes in brain anatomy were evaluated and parents and teachers answered 2 independent questionnaires.
  • RESULTS: Parents and teachers reported high rate of learning and academic difficulties, but without any difference with respect to the type of tumor.
  • [MeSH-major] Achievement. Cerebellar Neoplasms / therapy. Cognition. Glioma / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19996881.001).
  • [ISSN] 1543-3641
  • [Journal-full-title] Cognitive and behavioral neurology : official journal of the Society for Behavioral and Cognitive Neurology
  • [ISO-abbreviation] Cogn Behav Neurol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


49. Elia AE, Shih HA, Loeffler JS: Stereotactic radiation treatment for benign meningiomas. Neurosurg Focus; 2007;23(4):E5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stereotactic radiation treatment for benign meningiomas.
  • Meningiomas are the second most common primary tumor of the brain.
  • For incompletely resected or inoperable benign meningiomas, 3D conformal external-beam radiation therapy can provide durable local tumor control in 90 to 95% of cases.
  • Although SRS has longer follow-up than SRT, both techniques have excellent 5-year tumor control rates of greater than 90% for benign meningiomas.
  • [MeSH-major] Meningeal Neoplasms / pathology. Meningeal Neoplasms / surgery. Meningioma / pathology. Meningioma / surgery. Radiosurgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17961042.001).
  • [ISSN] 1092-0684
  • [Journal-full-title] Neurosurgical focus
  • [ISO-abbreviation] Neurosurg Focus
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 47
  •  go-up   go-down


50. Georgiadis P, Cavouras D, Kalatzis I, Glotsos D, Athanasiadis E, Kostopoulos S, Sifaki K, Malamas M, Nikiforidis G, Solomou E: Enhancing the discrimination accuracy between metastases, gliomas and meningiomas on brain MRI by volumetric textural features and ensemble pattern recognition methods. Magn Reson Imaging; 2009 Jan;27(1):120-30
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Enhancing the discrimination accuracy between metastases, gliomas and meningiomas on brain MRI by volumetric textural features and ensemble pattern recognition methods.
  • Three-dimensional (3D) texture analysis of volumetric brain magnetic resonance (MR) images has been identified as an important indicator for discriminating among different brain pathologies.
  • The purpose of this study was to evaluate the efficiency of 3D textural features using a pattern recognition system in the task of discriminating benign, malignant and metastatic brain tissues on T1 postcontrast MR imaging (MRI) series.
  • The dataset consisted of 67 brain MRI series obtained from patients with verified and untreated intracranial tumors.
  • The latter, in conjunction with using 3D textural features, enabled boosting up the performance of the system in discriminating metastatic, malignant and benign brain tumors with 77.14%, 89.19% and 93.33% accuracy, respectively.
  • The proposed system might be used as an assisting tool for brain tumor characterization on volumetric MRI series.
  • [MeSH-major] Brain Neoplasms / diagnosis. Glioma / diagnosis. Image Enhancement / methods. Imaging, Three-Dimensional. Magnetic Resonance Imaging / methods. Meningioma / diagnosis. Pattern Recognition, Automated / methods
  • [MeSH-minor] Diagnosis, Differential. Humans. Least-Squares Analysis. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18602785.001).
  • [ISSN] 0730-725X
  • [Journal-full-title] Magnetic resonance imaging
  • [ISO-abbreviation] Magn Reson Imaging
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


51. Widdel L, Kleinschmidt-DeMasters BK, Kindt G: Tumor-to-tumor metastasis from hematopoietic neoplasms to meningiomas: report of two patients with significant cerebral edema. World Neurosurg; 2010 Jul;74(1):165-71
MedlinePlus Health Information. consumer health - Multiple Myeloma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor-to-tumor metastasis from hematopoietic neoplasms to meningiomas: report of two patients with significant cerebral edema.
  • BACKGROUND: Tumor-to-tumor metastasis is a rare, but well-reported, curiosity in which one type of primary neoplasm metastasizes to another primary tumor type within the same person.
  • OBJECTIVE: To report two examples of benign meningiomas in which metastatic tumor deposits from the patient's hematopoietic neoplasm to the meningioma caused significant peritumoral edema, necessitating semiemergent surgical resection.
  • RESULTS: One patient had multiple myeloma associated with extensive necrosis within his otherwise benign convexity meningioma; first diagnosis of his IgG, kappa-restricted plasma cell dyscrasia was made from this tumor-to-tumor meningioma specimen.
  • The second patient carried a diagnosis of marginal zone lymphoma but then presented 5 years later with symptoms referable to a large dural-based mass with significant surrounding edema, prompting surgical removal.
  • Dural marginal zone lymphoma was identified within epidural, intradural, and subdural spaces, in the same location as an underlying benign meningioma.
  • CONCLUSIONS: Although rare, neurosurgeons should be aware of the entity of tumor-to-tumor metastasis as, in large series, meningiomas are the third most frequent recipient tumor type and pituitary adenomas, the fifth most frequent, probably reflecting their rich vascularity.
  • In examples where the donor tumor type is a hematopoietic neoplasm, significant edema can be produced by the tumor-to-tumor metastasis.
  • [MeSH-major] Brain Edema / etiology. Image Processing, Computer-Assisted. Lymphoma, B-Cell, Marginal Zone / diagnosis. Magnetic Resonance Imaging. Meningeal Neoplasms / diagnosis. Meningeal Neoplasms / secondary. Meningioma / diagnosis. Multiple Myeloma / diagnosis. Multiple Myeloma / secondary. Neoplasms, Second Primary / diagnosis. Tomography, X-Ray Computed
  • [MeSH-minor] Brain / pathology. Brain / surgery. Diagnosis, Differential. Female. Humans. Male. Meninges / pathology. Meninges / surgery. Middle Aged

  • Genetic Alliance. consumer health - Edema.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • (PMID = 21300009.001).
  • [ISSN] 1878-8769
  • [Journal-full-title] World neurosurgery
  • [ISO-abbreviation] World Neurosurg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


52. Nagata S, Jin YF, Yoshizato K, Kitamura M, Iizuka N, Song M, Tomoeda M, Yuki M, Kubo C, Yoshizawa H, Outani H, Hamada K, Araki N, Funauchi M, Tomita Y: Early uptake and continuous accumulation of thallium-201 chloride in a benign mixed tumor of soft tissue: case report. Diagn Pathol; 2010;5:34
Hazardous Substances Data Bank. THALLOUS CHLORIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early uptake and continuous accumulation of thallium-201 chloride in a benign mixed tumor of soft tissue: case report.
  • A case of benign mixed tumor of the soft tissue in a 64-year-old Japanese male is presented.
  • The patient underwent a resection of tumor, and the pathological diagnosis was a benign mixed tumor of soft tissue without high vascularity, characterized by histological features similar to pleomorphic adenomas in the salivary glands.
  • Immunohistochemical study proved expression of Na+/K+-ATPase of tumor cells.
  • Overexpression of Na+/K+-ATPase of the tumor might be responsible for the early uptake of Tl-201, and poor vascular structure in this tumor might lead to continuous accumulation.
  • The Tl-201 scintigraphic features of mixed tumor of soft tissue are assessed to resemble those of malignant soft tissue tumors.
  • [MeSH-major] Neoplasms, Complex and Mixed / radionuclide imaging. Radiopharmaceuticals. Soft Tissue Neoplasms / radionuclide imaging. Thallium. Tomography, Emission-Computed

  • Hazardous Substances Data Bank. THALLIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2001 Aug;92(2):228-35 [11505272.001]
  • [Cites] J Orthop Sci. 2002;7(3):304-12 [12077654.001]
  • [Cites] Am J Surg Pathol. 2003 Sep;27(9):1183-96 [12960802.001]
  • [Cites] Brain Res. 1989 Feb 20;480(1-2):259-67 [2469513.001]
  • [Cites] Biochem Pharmacol. 1992 Feb 18;43(4):803-7 [1311590.001]
  • [Cites] Am J Physiol. 1994 Feb;266(2 Pt 1):C515-23 [8141265.001]
  • [Cites] Ann Diagn Pathol. 2007 Jun;11(3):190-8 [17498593.001]
  • [Cites] J Nucl Med. 1996 Jun;37(6):955-8 [8683319.001]
  • [Cites] Am J Surg Pathol. 1997 Jan;21(1):13-22 [8990137.001]
  • [Cites] J Orthop Sci. 1998;3(6):297-303 [9811980.001]
  • [Cites] Virchows Arch. 1999 May;434(5):393-400 [10389622.001]
  • [Cites] Dentomaxillofac Radiol. 2005 Jul;34(4):212-7 [15961594.001]
  • [Cites] Ann Nucl Med. 2005 Sep;19(6):461-8 [16248382.001]
  • [Cites] J Cell Physiol. 1994 Jul;160(1):113-20 [8021291.001]
  • (PMID = 20509963.001).
  • [ISSN] 1746-1596
  • [Journal-full-title] Diagnostic pathology
  • [ISO-abbreviation] Diagn Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 7791-12-0 / thallium chloride; AD84R52XLF / Thallium; EC 3.6.3.9 / Sodium-Potassium-Exchanging ATPase
  • [Other-IDs] NLM/ PMC2887811
  •  go-up   go-down


53. Wöhrer A, Waldhör T, Heinzl H, Hackl M, Feichtinger J, Gruber-Mösenbacher U, Kiefer A, Maier H, Motz R, Reiner-Concin A, Richling B, Idriceanu C, Scarpatetti M, Sedivy R, Bankl HC, Stiglbauer W, Preusser M, Rössler K, Hainfellner JA: The Austrian Brain Tumour Registry: a cooperative way to establish a population-based brain tumour registry. J Neurooncol; 2009 Dec;95(3):401-411
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The Austrian Brain Tumour Registry: a cooperative way to establish a population-based brain tumour registry.
  • In Austria, registration of malignant brain tumours is legally mandatory, whereas benign and borderline tumours are not reported.
  • The Austrian Brain Tumour Registry (ABTR) was initiated under the auspices of the Austrian Society of Neuropathology for the registration of malignant and non-malignant brain tumours.
  • All Austrian neuropathology units involved in brain tumour diagnostics contribute data on primary brain tumours.
  • In 2005, we registered a total of 1,688 newly diagnosed primary brain tumours in a population of 8.2 million inhabitants with an overall age-adjusted incidence rate of 18.1/100,000 person-years.
  • Comparison with the Central Brain Tumor Registry of the United States (CBTRUS) database showed high congruency of findings.
  • The ABTR model led by neuropathologists in collaboration with epidemiologists and the Austrian National Cancer Registry presents a cooperative way to establish a population-based brain tumour registry with high quality data.
  • The continued operation of ABTR will aid in monitoring changes in incidence and in identifying regional disease clusters or geographic variations in brain tumour morbidity/mortality.
  • [MeSH-major] Brain Neoplasms / epidemiology. Glioblastoma / epidemiology. Registries / standards. Registries / statistics & numerical data
  • [MeSH-minor] Adenoma / epidemiology. Adenoma / pathology. Adolescent. Adult. Age Distribution. Aged. Aged, 80 and over. Austria / epidemiology. Child. Child, Preschool. Ependymoma / epidemiology. Ependymoma / pathology. Female. Geographic Information Systems. Humans. Incidence. Male. Meningeal Neoplasms / epidemiology. Meningeal Neoplasms / pathology. Middle Aged. Oligodendroglioma / epidemiology. Oligodendroglioma / pathology. Reproducibility of Results. Sex Distribution. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 2004 Jan 20;108(3):450-5 [14648713.001]
  • [Cites] J Neurooncol. 1999 May;42(3):195-204 [10433103.001]
  • [Cites] J Clin Oncol. 2000 Jan;18(2):348-57 [10637249.001]
  • [Cites] Br J Cancer. 2005 Oct 3;93(7):842-8 [16136046.001]
  • [Cites] Epidemiology. 2004 Nov;15(6):653-9 [15475713.001]
  • [Cites] Neuro Oncol. 2002 Oct;4(4):278-99 [12356358.001]
  • [Cites] J Clin Oncol. 2007 Sep 10;25(26):4104-9 [17827460.001]
  • [Cites] Neurol Clin. 2007 Nov;25(4):925-46, viii [17964021.001]
  • [Cites] AIDS Read. 2000 Aug;10(8):486-91 [10967810.001]
  • [Cites] Dis Nerv Syst. 1967 Feb;28(2):89-93 [5336568.001]
  • [Cites] Neurosurgery. 1987 Jul;21(1):21-6 [3039398.001]
  • [Cites] Neurosurgery. 1994 Jan;34(1):68-78 [8121571.001]
  • [Cites] Neurosurg Focus. 2005 Apr 15;18(4):e12 [15844864.001]
  • [Cites] J Natl Cancer Inst. 1998 Oct 7;90(19):1473-9 [9776413.001]
  • [Cites] J Epidemiol Biostat. 2000;5(2):99-107 [10890281.001]
  • [Cites] Acta Neuropathol. 2007 Aug;114(2):97-109 [17618441.001]
  • [Cites] J Neurooncol. 2007 Sep;84(2):189-99 [17431547.001]
  • [Cites] J Neurooncol. 1994;18(1):69-81 [8057137.001]
  • [Cites] J Neurooncol. 2002 Oct;60(1):61-9 [12416547.001]
  • [Cites] Int J Oncol. 2008 May;32(5):1097-103 [18425337.001]
  • [Cites] Surg Neurol. 2006 Sep;66(3):258-63; discussion 263 [16935629.001]
  • [Cites] Neuro Oncol. 2006 Jan;8(1):27-37 [16443945.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Mar;17(3):484-9 [18349266.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10 ):997-1003 [15758010.001]
  • [Cites] Neuroepidemiology. 2006;27(1):22-7 [16770081.001]
  • [Cites] Int J Clin Oncol. 2008 Apr;13(2):90-6 [18463950.001]
  • [Cites] Radiat Res. 2005 Apr;163(4):424-32 [15799699.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10 ):987-96 [15758009.001]
  • [Cites] N Engl J Med. 2001 Jan 11;344(2):79-86 [11150357.001]
  • (PMID = 19562257.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


54. Vankalakunti M, Vasishta RK, Das Radotra B, Khosla VK: MIB-1 immunolabeling: a valuable marker in prediction of benign recurring meningiomas. Neuropathology; 2007 Oct;27(5):407-12

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MIB-1 immunolabeling: a valuable marker in prediction of benign recurring meningiomas.
  • We investigated the utility of cell proliferative indicator in the evaluation of histologically benign meningiomas.
  • We selected 25 benign non-recurrent meningiomas, 15 benign recurrent meningiomas after complete surgical resection, 30 atypical meningiomas, and 15 anaplastic meningiomas out of 384 cases studied.
  • There was no dependable histological parameter to predict recurrence among benign-looking meningiomas.
  • The mean MIB-1 HLI values +/- SD were 3.47 +/- 2.0% for benign meningiomas, 5.08 +/- 4.0% for atypical meningiomas and 11.66 +/- 7.06% for anaplastic meningiomas.
  • In comparison, the mean MIB-1 HLI of benign non-recurrent meningiomas were 2.66 +/- 1.7% and with recurrence were 4.21 +/- 2.78% (P = 0.0339).
  • Using receiver operating characteristic, it was seen that neoplasm recurred with the MIB-1 HLI of > 2.6 having the sensitivity of 64.6% and specificity of 68% among benign (grade I) meningiomas.
  • MIB-1 positive tumor cells were maximally aggregated at the periphery of excised specimen.
  • MIB-1 HLI, integrated with standard histopathology can provide better information about the disease biological nature in benign meningiomas.
  • [MeSH-major] Biomarkers / analysis. Ki-67 Antigen / analysis. Meningeal Neoplasms / pathology. Meningioma / pathology
  • [MeSH-minor] Brain Neoplasms / pathology. Humans. Mitotic Index. Neoplasm Invasiveness. Probability. Recurrence. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18018472.001).
  • [ISSN] 0919-6544
  • [Journal-full-title] Neuropathology : official journal of the Japanese Society of Neuropathology
  • [ISO-abbreviation] Neuropathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Ki-67 Antigen
  •  go-up   go-down


55. Gallina P, Buccoliero AM, Mariotti F, Mennonna P, Di Lorenzo N: Oncocytic meningiomas: Cases with benign histopathological features and a favorable clinical course. J Neurosurg; 2006 Nov;105(5):736-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oncocytic meningiomas: Cases with benign histopathological features and a favorable clinical course.
  • OBJECT: Oncocytic meningioma has recently been recognized as a distinct morphological variant of intracranial meningothelial neoplasms, and only a few cases have been reported in the literature.
  • The first description of this lesion, which was based on data in six cases, revealed a potentially aggressive nature with a tendency to infiltrate the brain and to recur.
  • Histologically, the tumors were composed of sheets, nests, and cords of large polygonal neoplastic cells with finely granular cytoplasm.
  • Mitosis was also absent or exceedingly rare, and no brain cortex infiltration was observed.
  • At the last follow-up evaluation, all patients were asymptomatic and magnetic resonance imaging examinations demonstrated no evidence of tumor recurrence.
  • In fact, the histological features as well as the long-term favorable clinical course may suggest benign behavior of such neoplasms, as in the common forms of meningiomas.
  • [MeSH-major] Meningeal Neoplasms / pathology. Meningeal Neoplasms / surgery. Meningioma / pathology. Meningioma / surgery. Oxyphil Cells / physiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17121136.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Antinuclear; 0 / Antibodies, Monoclonal; 0 / MIB-1 antibody
  •  go-up   go-down


56. Patil VM, Kapoor R, Chakraborty S, Ghoshal S, Oinam AS, Sharma SC: Dosimetric risk estimates of radiation-induced malignancies after intensity modulated radiotherapy. J Cancer Res Ther; 2010 Oct-Dec;6(4):442-7
MedlinePlus Health Information. consumer health - Radiation Therapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In these patients, selected infield organs around the planning target volume were contoured, viz. brain and thyroid in patients with head and neck cancer and bladder, rectum and small intestine in patients with carcinoma prostate.
  • RESULTS: The modal estimated incidence of radiation-induced malignancies was 129.87, 1.4, 0.10, 3.42, 7.789 and 129.85 per 10,000 person-years for the brain, thyroid, bladder, rectum, small intestine and whole body respectively.
  • However, the calculated risk of radiation-induced tumors of the brain was more than that reported with conventional radiation therapy.
  • We propose that estimation of the risk of radiation-induced malignancies should be a part of the plan evaluation process and special care should be taken before using this modality in young patients with benign tumors in the head and neck region.
  • [MeSH-major] Neoplasms, Radiation-Induced / etiology. Neoplasms, Second Primary / etiology. Radiotherapy / adverse effects. Radiotherapy Dosage
  • [MeSH-minor] Adult. Aged. Female. Humans. Incidence. Male. Middle Aged. Neoplasms / radiotherapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21358077.001).
  • [ISSN] 1998-4138
  • [Journal-full-title] Journal of cancer research and therapeutics
  • [ISO-abbreviation] J Cancer Res Ther
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  •  go-up   go-down


57. Min ZG, Liu HJ, Li M, Liu LH, Jin CW, Zhang M: [Accuracy of MR perfusion weighted imaging for cerebral glioma grading: a meta-analysis]. Zhonghua Yi Xue Za Zhi; 2010 Nov 9;90(41):2927-31
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Accuracy of MR perfusion weighted imaging for cerebral glioma grading: a meta-analysis].
  • CONCLUSION: the relative cerebral blood volume (rCBV) of MR PWI can be referred to differentiate malignant cerebral gliomas from benign ones with sound sensitivity and specificity.
  • [MeSH-major] Brain Neoplasms / pathology. Glioma / pathology. Magnetic Resonance Spectroscopy
  • [MeSH-minor] Humans. Neoplasm Staging

  • Genetic Alliance. consumer health - Glioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21211399.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Meta-Analysis
  • [Publication-country] China
  •  go-up   go-down


58. Dumortier J, Guillaud O, Walter T, Ber CE, Partensky C, Boillot O, Scoazec JY: Liver transplantation for multiple angiomyolipomas complicating tuberous sclerosis complex. Gastroenterol Clin Biol; 2010 Sep;34(8-9):494-8
MedlinePlus Health Information. consumer health - Tuberous Sclerosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tuberous sclerosis complex is a genetic multisystem disorder characterised by widespread hamartomas in several organs, including the brain, heart, skin, eyes, kidney, lung, and liver.
  • Seventeen tumors, from 2 to 16 cm in diameter, were identified at examination of the liver explant.
  • In conclusion, this unusual indication of liver transplantation underlines the interest of this therapeutic approach for benign tumors for which the multiplicity of the lesions and their huge volume prevent any attempt at surgical resection.
  • [MeSH-major] Angiomyolipoma / surgery. Liver Neoplasms / surgery. Liver Transplantation. Neoplasms, Multiple Primary / surgery. Tuberous Sclerosis / complications


59. Sibulesky L, Satyanarayana R, Menke D, Nguyen JH: Reactive nodular hyperplasia mimicking malignant lymphoma in donor liver allograft. Transplant Proc; 2010 Jun;42(5):1970-2
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Further workup revealed a rare benign lesion in the liver known as reactive lymphoid hyperplasia.
  • [MeSH-major] Hepatectomy / methods. Hyperplasia / diagnosis. Liver Neoplasms / diagnosis. Lymphoma, B-Cell, Marginal Zone / diagnosis. Tissue and Organ Procurement / standards
  • [MeSH-minor] Adult. Brain Death. Cadaver. Diagnosis, Differential. Female. Humans. Tissue Donors

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20620558.001).
  • [ISSN] 1873-2623
  • [Journal-full-title] Transplantation proceedings
  • [ISO-abbreviation] Transplant. Proc.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


60. Cho JM, Ahn JY, Kim SH, Lee KS, Chang JH: An endodermal cyst mimicking an intra-axial tumor in the medulla oblongata. Childs Nerv Syst; 2010 Jun;26(6):853-6
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An endodermal cyst mimicking an intra-axial tumor in the medulla oblongata.
  • INTRODUCTION: Endodermal cysts, also known as enterogenous, neurenteric, foregut, epithelial, bronchogenic, or respiratory cysts, are rare benign lesions lined by columnar epithelium of a presumed endodermal origin.
  • [MeSH-major] Brain Diseases / diagnosis. Brain Neoplasms / diagnosis. Cysts / diagnosis. Medulla Oblongata
  • [MeSH-minor] Diagnosis, Differential. Follow-Up Studies. Humans. Magnetic Resonance Imaging. Male. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Childs Nerv Syst. 2011 Jun;27(6):861-2; author reply 863 [21503756.001]
  • [Cites] Neurosurgery. 1999 Feb;44(2):401-4; discussion 404-5 [9932896.001]
  • [Cites] AMA Am J Dis Child. 1952 Apr;83(4):500-7 [14902104.001]
  • [Cites] Australas Radiol. 2006 Feb;50(1):59-62 [16499730.001]
  • [Cites] Surg Gynecol Obstet. 1954 Aug;99(2):135-41 [13187191.001]
  • [Cites] Can J Neurol Sci. 1989 May;16(2):206-10 [2731091.001]
  • [Cites] J Neurosurg Spine. 2005 Mar;2(3):372-6 [15796365.001]
  • [Cites] J Neurosurg. 2004 Jun;100(6):1091-3 [15200128.001]
  • [Cites] Neurosurgery. 1991 Apr;28(4):583-7; discussion 587-8 [2034355.001]
  • [Cites] AMA Arch Pathol. 1952 Aug;54(2):132-8 [14943345.001]
  • [Cites] Childs Nerv Syst. 1988 Feb;4(1):47-9 [3401868.001]
  • [Cites] Neurosurgery. 2003 Jan;52(1):243-5; discussion 246 [12493126.001]
  • [Cites] Clin Radiol. 1985 May;36(3):245-51 [4064506.001]
  • [Cites] AJNR Am J Neuroradiol. 2006 Jun-Jul;27(6):1211-6 [16775266.001]
  • [Cites] J Neurosurg. 1998 Aug;89(2):326-35 [9688132.001]
  • [Cites] Arq Neuropsiquiatr. 1993 Jun;51(2):253-7 [8274091.001]
  • [Cites] Neurosurgery. 2000 Sep;47(3):764-7 [10981766.001]
  • [Cites] Pediatr Clin North Am. 1958 May;:457-74 [13542070.001]
  • [Cites] Pediatr Neurosurg. 1992;18(5-6):229-53 [1476931.001]
  • [Cites] Br J Surg. 1954 Mar;41(169):520-33 [13149822.001]
  • [Cites] Neurol Med Chir (Tokyo). 2008 Feb;48(2):86-9 [18296879.001]
  • (PMID = 20217097.001).
  • [ISSN] 1433-0350
  • [Journal-full-title] Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
  • [ISO-abbreviation] Childs Nerv Syst
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


61. Bosnjak J, Budisić M, Azman D, Strineka M, Crnjaković M, Demarin V: Pineal gland cysts--an overview. Acta Clin Croat; 2009 Sep;48(3):355-8
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The diagnosis of pineal cyst is usually established by MRI with defined radiological criteria to distinguish benign pineal cyst from tumors of this area.
  • [MeSH-major] Brain Neoplasms. Central Nervous System Cysts. Pineal Gland

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20055263.001).
  • [ISSN] 0353-9466
  • [Journal-full-title] Acta clinica Croatica
  • [ISO-abbreviation] Acta Clin Croat
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Croatia
  •  go-up   go-down


62. Miller SJ, Jessen WJ, Mehta T, Hardiman A, Sites E, Kaiser S, Jegga AG, Li H, Upadhyaya M, Giovannini M, Muir D, Wallace MR, Lopez E, Serra E, Nielsen GP, Lazaro C, Stemmer-Rachamimov A, Page G, Aronow BJ, Ratner N: Integrative genomic analyses of neurofibromatosis tumours identify SOX9 as a biomarker and survival gene. EMBO Mol Med; 2009 Jul;1(4):236-48
Guide to Pharmacology. gene/protein/disease-specific - ADGRG6 - data and references .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Understanding the biological pathways critical for common neurofibromatosis type 1 (NF1) peripheral nerve tumours is essential, as there is a lack of tumour biomarkers, prognostic factors and therapeutics.
  • We used gene expression profiling to define transcriptional changes between primary normal Schwann cells (n = 10), NF1-derived primary benign neurofibroma Schwann cells (NFSCs) (n = 22), malignant peripheral nerve sheath tumour (MPNST) cell lines (n = 13), benign neurofibromas (NF) (n = 26) and MPNST (n = 6).

  • Genetic Alliance. consumer health - Neurofibromatosis.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurosci Res. 2004 Dec 15;78(6):796-802 [15523643.001]
  • [Cites] J Neurosci. 1998 Jan 1;18(1):237-50 [9412504.001]
  • [Cites] Dev Cell. 2005 Feb;8(2):179-92 [15691760.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jun 14;102(24):8633-8 [15932943.001]
  • [Cites] Nat Rev Neurosci. 2005 Sep;6(9):671-82 [16136171.001]
  • [Cites] Nucleic Acids Res. 2005;33(20):e175 [16284200.001]
  • [Cites] Genes Chromosomes Cancer. 2006 Mar;45(3):265-76 [16283621.001]
  • [Cites] J Clin Pathol. 2006 Feb;59(2):160-5 [16443732.001]
  • [Cites] BMC Bioinformatics. 2006;7:35 [16430768.001]
  • [Cites] Cancer Res. 2006 Mar 1;66(5):2584-91 [16510576.001]
  • [Cites] BMC Bioinformatics. 2006;7:84 [16504070.001]
  • [Cites] Hum Mutat. 2006 Jul;27(7):716 [16786508.001]
  • [Cites] Development. 2006 Aug;133(15):2875-86 [16790476.001]
  • [Cites] Nat Rev Cancer. 2006 Aug;6(8):593-602 [16862190.001]
  • [Cites] Nucleic Acids Res. 2007 Jan;35(Database issue):D116-21 [17178752.001]
  • [Cites] Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):398-407 [17202312.001]
  • [Cites] Oncogene. 2007 Jul 12;26(32):4609-16 [17297459.001]
  • [Cites] Neuroscience. 2007 Jul 29;147(4):928-37 [17582688.001]
  • [Cites] Development. 2007 Sep;134(18):3271-81 [17699610.001]
  • [Cites] Genome Biol. 2007;8(9):R183 [17784955.001]
  • [Cites] Cancer Cell. 2008 Feb;13(2):105-16 [18242511.001]
  • [Cites] Cancer Cell. 2008 Feb;13(2):129-40 [18242513.001]
  • [Cites] Clin Cancer Res. 2008 Feb 15;14(4):1015-24 [18281533.001]
  • [Cites] Cell Stem Cell. 2008 Jul 3;3(1):33-43 [18593557.001]
  • [Cites] Glia. 2008 Nov 1;56(14):1590-605 [18803326.001]
  • [Cites] Cell Stem Cell. 2008 Dec 4;3(6):658-69 [19041782.001]
  • [Cites] Cell Stem Cell. 2009 May 8;4(5):453-63 [19427294.001]
  • [Cites] Nucleic Acids Res. 1999 Mar 1;27(5):1359-64 [9973626.001]
  • [Cites] Hum Mol Genet. 2000 Jan 22;9(2):237-47 [10607834.001]
  • [Cites] Genes Chromosomes Cancer. 2000 Feb;27(2):117-23 [10612798.001]
  • [Cites] Am J Epidemiol. 2000 Jan 1;151(1):33-40 [10625171.001]
  • [Cites] Mol Cell Biol. 2000 May;20(9):3198-209 [10757804.001]
  • [Cites] J Clin Invest. 2000 May;105(9):1233-41 [10791998.001]
  • [Cites] J Biol Chem. 2000 Sep 29;275(39):30740-5 [10900196.001]
  • [Cites] Hum Mol Genet. 2000 Dec 12;9(20):3055-64 [11115850.001]
  • [Cites] Genes Dev. 2001 Jan 1;15(1):66-78 [11156606.001]
  • [Cites] Cell. 2001 Feb 23;104(4):593-604 [11239415.001]
  • [Cites] Nat Genet. 2001 Jul;28(3):294-6 [11431704.001]
  • [Cites] Behav Brain Res. 2001 Nov 1;125(1-2):279-84 [11682119.001]
  • [Cites] J Biol Chem. 2001 Nov 2;276(44):41229-36 [11514554.001]
  • [Cites] Science. 2002 May 3;296(5569):920-2 [11988578.001]
  • [Cites] J Med Genet. 2002 May;39(5):311-4 [12011145.001]
  • [Cites] J Neuropathol Exp Neurol. 2002 Aug;61(8):702-9 [12152785.001]
  • [Cites] Mol Cell Biol. 2003 Mar;23(6):2213-24 [12612091.001]
  • [Cites] Spine (Phila Pa 1976). 2003 Apr 15;28(8):755-63 [12698117.001]
  • [Cites] Biostatistics. 2003 Apr;4(2):249-64 [12925520.001]
  • [Cites] J Neurosci. 2004 Mar 10;24(10):2357-65 [15014110.001]
  • [Cites] Clin Cancer Res. 2004 Jun 1;10(11):3763-71 [15173083.001]
  • [Cites] Brain Pathol. 2004 Jul;14(3):258-64 [15446580.001]
  • [Cites] J Cell Biol. 1990 Aug;111(2):645-53 [1696266.001]
  • [Cites] Glia. 1996 Aug;17(4):327-38 [8856329.001]
  • [Cites] JAMA. 1997 Jul 2;278(1):51-7 [9207339.001]
  • [CommentIn] EMBO Mol Med. 2009 Jul;1(4):198-200 [20049721.001]
  • (PMID = 20049725.001).
  • [ISSN] 1757-4684
  • [Journal-full-title] EMBO molecular medicine
  • [ISO-abbreviation] EMBO Mol Med
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / K01 NS049191; United States / NCI NIH HHS / CA / T32 CA059268; United States / NINDS NIH HHS / NS / K01-NS049191; United States / NCI NIH HHS / CA / T32 CA 59268
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / SOX9 Transcription Factor; 0 / SOX9 protein, human
  • [Other-IDs] NLM/ PMC3378132
  •  go-up   go-down


63. Patterson CR, Acland K, Khooshabeh R: Cutaneous malignant melanoma arising in an acquired naevus of Ota. Australas J Dermatol; 2009 Nov;50(4):294-6
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Naevus of Ota is a dermal melanocytosis most commonly found in black or Asian skin and is usually a benign malformation, but with a low risk of melanoma.
  • The lesion, deceptively, had no clinically suspicious features, but investigation revealed an aggressive cutaneous malignant melanoma, extensive orbital ring melanocytosis and metastatic brain and subsequent liver disease.
  • [MeSH-major] Melanoma / pathology. Neoplasms, Second Primary / pathology. Nevus of Ota / pathology. Orbital Neoplasms / pathology. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19916976.001).
  • [ISSN] 1440-0960
  • [Journal-full-title] The Australasian journal of dermatology
  • [ISO-abbreviation] Australas. J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


64. Deryugina EI, Quigley JP: Pleiotropic roles of matrix metalloproteinases in tumor angiogenesis: contrasting, overlapping and compensatory functions. Biochim Biophys Acta; 2010 Jan;1803(1):103-20

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pleiotropic roles of matrix metalloproteinases in tumor angiogenesis: contrasting, overlapping and compensatory functions.
  • A number of extensive reviews are available discussing the roles of MMPs in various aspects of cancer progression from benign tumor formation to overt cancer present with deadly metastases.
  • This review will focus specifically on the evidence functionally linking the MMPs and tumor-induced angiogenesis in various in vivo models.
  • Emphasis has been placed on the cellular origin of the MMPs in tumor tissue, the requirement of proMMP activation and the resulting proteolytic activity for the induction and progression of tumor angiogenesis, and the pleiotropic roles for some of the MMPs.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier B.V. All rights reserved.
  • [Cites] Cancer Res. 2006 Aug 15;66(16):7968-75 [16912171.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Aug 15;103(33):12493-8 [16891410.001]
  • [Cites] Cell Cycle. 2006 Aug;5(15):1597-601 [16880743.001]
  • [Cites] J Cell Biol. 2006 Oct 9;175(1):179-91 [17030988.001]
  • [Cites] Curr Opin Cell Biol. 2004 Oct;16(5):558-64 [15363807.001]
  • [Cites] Cancer Res. 2004 Oct 1;64(19):6965-72 [15466188.001]
  • [Cites] Cancer Cell. 2004 Oct;6(4):409-21 [15488763.001]
  • [Cites] Nature. 1989 May 4;339(6219):58-61 [2469964.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1992 Sep-Oct;1(6):475-9 [1302560.001]
  • [Cites] J Cell Biol. 1993 Sep;122(6):1351-9 [8376467.001]
  • [Cites] Hybridoma. 1993 Aug;12(4):349-63 [8244415.001]
  • [Cites] Nature. 1994 Jul 7;370(6484):61-5 [8015608.001]
  • [Cites] Microvasc Res. 1994 Jan;47(1):31-40 [7517489.001]
  • [Cites] Cell. 1994 Oct 21;79(2):315-28 [7525077.001]
  • [Cites] J Biol Chem. 1995 Mar 10;270(10):5331-8 [7890645.001]
  • [Cites] Cell. 1996 May 31;85(5):683-93 [8646777.001]
  • [Cites] Cell. 1996 Aug 9;86(3):353-64 [8756718.001]
  • [Cites] J Biol Chem. 1996 Nov 22;271(47):30174-80 [8939968.001]
  • [Cites] Cell. 1997 Jan 24;88(2):277-85 [9008168.001]
  • [Cites] Endocr Rev. 1997 Feb;18(1):26-45 [9034785.001]
  • [Cites] Cell. 1997 Mar 21;88(6):801-10 [9118223.001]
  • [Cites] J Clin Invest. 1997 Apr 1;99(7):1534-45 [9119997.001]
  • [Cites] Lab Invest. 1997 Oct;77(4):345-55 [9354769.001]
  • [Cites] Cell. 1998 Feb 6;92(3):391-400 [9476898.001]
  • [Cites] Cancer Res. 1998 Mar 1;58(5):1048-51 [9500469.001]
  • [Cites] Cell. 1998 May 1;93(3):411-22 [9590175.001]
  • [Cites] Eur J Immunol. 1998 Jun;28(6):1773-84 [9645358.001]
  • [Cites] Am J Pathol. 1998 Sep;153(3):757-65 [9736026.001]
  • [Cites] Am J Pathol. 2008 Dec;173(6):1736-46 [18988801.001]
  • [Cites] Histochem Cell Biol. 2008 Dec;130(6):1119-30 [19005674.001]
  • [Cites] Nature. 2008 Dec 11;456(7223):809-13 [18997771.001]
  • [Cites] Nature. 2008 Dec 11;456(7223):814-8 [18997773.001]
  • [Cites] Cancer Cell. 2009 Jan 6;15(1):21-34 [19111878.001]
  • [Cites] Matrix Biol. 2009 Jan;28(1):3-10 [19010413.001]
  • [Cites] J Cell Biol. 2009 Feb 9;184(3):399-408 [19188491.001]
  • [Cites] Dev Cell. 2009 Feb;16(2):222-31 [19217424.001]
  • [Cites] Cancer Res. 2009 Feb 15;69(4):1517-26 [19208838.001]
  • [Cites] Cancer Cell. 2009 Mar 3;15(3):220-31 [19249680.001]
  • [Cites] Cancer Cell. 2009 Mar 3;15(3):232-9 [19249681.001]
  • [Cites] Cell. 2009 Mar 6;136(5):839-51 [19217150.001]
  • [Cites] Clin Exp Metastasis. 2009;26(4):381-97 [18958576.001]
  • [Cites] J Cell Biol. 2009 Apr 6;185(1):11-9 [19332889.001]
  • [Cites] Int J Exp Pathol. 2009 Jun;90(3):222-31 [19563607.001]
  • [Cites] J Biol Chem. 2009 Sep 18;284(38):25854-66 [19608737.001]
  • [Cites] Curr Opin Cell Biol. 2009 Oct;21(5):645-53 [19616423.001]
  • [Cites] J Leukoc Biol. 2009 Nov;86(5):1065-73 [19741157.001]
  • [Cites] FASEB J. 2005 Feb;19(2):234-6 [15550552.001]
  • [Cites] Breast Dis. 2004;20:145-53 [15687715.001]
  • [Cites] Cancer Cell. 2005 Mar;7(3):211-7 [15766659.001]
  • [Cites] Biochimie. 2005 Mar-Apr;87(3-4):265-72 [15781313.001]
  • [Cites] Cancer Res. 2005 Apr 15;65(8):3200-8 [15833851.001]
  • [Cites] Genes Dev. 2005 Apr 15;19(8):979-91 [15805464.001]
  • [Cites] Cytokine Growth Factor Rev. 2005 Apr;16(2):159-78 [15863032.001]
  • [Cites] Circ Res. 2005 May 13;96(9):930-8 [15890980.001]
  • [Cites] J Cell Sci. 2005 May 15;118(Pt 10):2143-53 [15855236.001]
  • [Cites] Cancer Res. 2005 May 15;65(10):3967-79 [15899784.001]
  • [Cites] Int J Cancer. 2005 Jul 20;115(6):849-60 [15729716.001]
  • [Cites] J Cell Biol. 2005 May 23;169(4):681-91 [15911882.001]
  • [Cites] J Biol Chem. 2005 Jun 10;280(23):21882-92 [15824107.001]
  • [Cites] Exp Cell Res. 2005 Jul 15;307(2):292-304 [15950618.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Jul 29;333(2):292-8 [15979458.001]
  • [Cites] Cell. 2005 Jul 1;121(7):1109-21 [15989959.001]
  • [Cites] Nature. 2005 Jul 28;436(7050):518-24 [16049480.001]
  • [Cites] J Immunol. 2005 Sep 1;175(5):2890-9 [16116175.001]
  • [Cites] J Exp Med. 2005 Sep 5;202(5):663-71 [16147977.001]
  • [Cites] Anticancer Drugs. 2005 Oct;16(9):997-1002 [16162976.001]
  • [Cites] Cancer Cell. 2005 Sep;8(3):211-26 [16169466.001]
  • [Cites] Mol Cancer Ther. 2005 Sep;4(9):1399-408 [16170032.001]
  • [Cites] J Exp Med. 2005 Sep 19;202(6):739-50 [16157686.001]
  • [Cites] Cancer Cell. 2005 Oct;8(4):299-309 [16226705.001]
  • [Cites] J Cell Biochem. 2005 Dec 1;96(5):897-905 [16149080.001]
  • [Cites] J Cell Physiol. 2006 Jan;206(1):1-8 [15920734.001]
  • [Cites] Circ Res. 2005 Nov 25;97(11):1093-107 [16306453.001]
  • [Cites] Nature. 2005 Dec 8;438(7069):820-7 [16341007.001]
  • [Cites] Am J Pathol. 2002 Oct;161(4):1429-37 [12368215.001]
  • [Cites] Nat Rev Cancer. 2002 Nov;2(11):826-35 [12415253.001]
  • [Cites] J Cell Mol Med. 2002 Jul-Sep;6(3):439-46 [12417062.001]
  • [Cites] Nature. 2002 Dec 19-26;420(6917):860-7 [12490959.001]
  • [Cites] Differentiation. 2002 Dec;70(9-10):561-73 [12492497.001]
  • [Cites] J Cell Biol. 2003 Jan 20;160(2):267-77 [12527751.001]
  • [Cites] Crit Rev Biochem Mol Biol. 2002 Dec;37(6):375-536 [12540195.001]
  • [Cites] Nat Rev Cancer. 2003 May;3(5):362-74 [12724734.001]
  • [Cites] Vet Pathol. 2003 May;40(3):227-36 [12724562.001]
  • [Cites] Cancer Res. 2003 May 15;63(10):2454-61 [12750266.001]
  • [Cites] Nat Med. 2003 Jun;9(6):702-12 [12778169.001]
  • [Cites] Nat Rev Cancer. 2003 Jun;3(6):401-10 [12778130.001]
  • [Cites] Nat Rev Cancer. 2003 Jun;3(6):422-33 [12778132.001]
  • [Cites] Nat Rev Cancer. 2003 Jun;3(6):453-8 [12778135.001]
  • [Cites] Cancer Metastasis Rev. 2003 Jun-Sep;22(2-3):153-66 [12784994.001]
  • [Cites] Ann N Y Acad Sci. 2003 May;996:49-60 [12799282.001]
  • [Cites] Trends Cell Biol. 2003 Jul;13(7):366-75 [12837607.001]
  • [Cites] Cancer Cell. 2003 Jun;3(6):589-601 [12842087.001]
  • [Cites] Nature. 2005 Dec 15;438(7070):932-6 [16355210.001]
  • [Cites] Blood. 2006 Jan 1;107(1):317-27 [16174763.001]
  • [Cites] Cancer Res. 2006 Jan 1;66(1):259-66 [16397239.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 2006;46:301-15 [16402907.001]
  • [Cites] Cell. 2006 Jan 13;124(1):175-89 [16413490.001]
  • [Cites] Cancer Res. 2006 Jan 15;66(2):605-12 [16423985.001]
  • [Cites] Cell. 2006 Jan 27;124(2):263-6 [16439202.001]
  • [Cites] Eur J Cancer. 2006 Feb;42(3):310-8 [16406506.001]
  • [Cites] Nat Methods. 2006 Apr;3(4):259-61 [16554829.001]
  • [Cites] Eur J Cancer. 2006 Apr;42(6):728-34 [16524717.001]
  • [Cites] Cancer Metastasis Rev. 2006 Mar;25(1):9-34 [16680569.001]
  • [Cites] Cancer Metastasis Rev. 2006 Mar;25(1):35-43 [16680570.001]
  • [Cites] Cancer Metastasis Rev. 2006 Mar;25(1):77-86 [16680574.001]
  • [Cites] Cell Cycle. 2006 Apr;5(8):812-7 [16627996.001]
  • [Cites] Cancer Res. 2006 May 15;66(10):5234-41 [16707448.001]
  • [Cites] Cancer Res. 2006 Jun 15;66(12):6149-55 [16778188.001]
  • [Cites] Cancer Res. 2006 Aug 1;66(15):7766-74 [16885380.001]
  • [Cites] Biochim Biophys Acta. 2006 Aug;1766(1):159-66 [16857321.001]
  • [Cites] FASEB J. 2007 Aug;21(10):2580-91 [17392479.001]
  • [Cites] Nat Cell Biol. 2007 Aug;9(8):893-904 [17618273.001]
  • [Cites] Nat Rev Cancer. 2007 Oct;7(10):800-8 [17851543.001]
  • [Cites] Bioessays. 2007 Nov;29(11):1159-68 [17935210.001]
  • [Cites] Mol Biol Cell. 2007 Nov;18(11):4222-31 [17699594.001]
  • [Cites] Cancer Metastasis Rev. 2007 Dec;26(3-4):717-24 [17717634.001]
  • [Cites] Mol Cell Biol. 2007 Dec;27(24):8454-65 [17908800.001]
  • [Cites] Matrix Biol. 2007 Oct;26(8):587-96 [17669641.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Dec 18;104(51):20262-7 [18077379.001]
  • [Cites] Science. 2008 Jan 11;319(5860):163-4 [18187643.001]
  • [Cites] Science. 2008 Jan 11;319(5860):195-8 [18187653.001]
  • [Cites] Cancer Cell. 2008 Mar;13(3):181-3 [18328420.001]
  • [Cites] Cancer Cell. 2008 Mar;13(3):193-205 [18328424.001]
  • [Cites] Cancer Cell. 2008 Mar;13(3):206-20 [18328425.001]
  • [Cites] Curr Opin Hematol. 2008 May;15(3):197-203 [18391785.001]
  • [Cites] Neoplasia. 2008 Apr;10(4):329-40 [18392134.001]
  • [Cites] Cardiovasc Res. 2008 May 1;78(2):203-12 [18079100.001]
  • [Cites] Annu Rev Biochem. 2008;77:383-414 [18366325.001]
  • [Cites] J Biol Chem. 2008 Jun 20;283(25):17740-8 [18441011.001]
  • [Cites] Am J Pathol. 2008 Jul;173(1):144-53 [18556780.001]
  • [Cites] Nat Rev Cancer. 2008 Aug;8(8):579-91 [18596824.001]
  • [Cites] Nat Rev Cancer. 2008 Aug;8(8):592-603 [18650835.001]
  • [Cites] Cancer Res. 2008 Aug 1;68(15):6251-9 [18676849.001]
  • [Cites] Cell. 2008 Aug 22;134(4):679-91 [18724940.001]
  • [Cites] J Biol Chem. 2008 Nov 7;283(45):30433-7 [18650443.001]
  • [Cites] Methods Enzymol. 2008;444:21-41 [19007659.001]
  • [Cites] Methods Enzymol. 2008;444:255-69 [19007668.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2008 Dec;28(12):2108-14 [18772495.001]
  • [Cites] J Immunol. 2003 Oct 15;171(8):4340-51 [14530359.001]
  • [Cites] Blood. 2003 Nov 1;102(9):3262-9 [12855577.001]
  • [Cites] Nat Genet. 2003 Nov;35(3):252-7 [14517555.001]
  • [Cites] Cell Tissue Res. 2003 Oct;314(1):15-23 [12883993.001]
  • [Cites] Brain. 2003 Dec;126(Pt 12):2738-49 [14506071.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2003 Dec;44(12):5370-5 [14638740.001]
  • [Cites] Blood. 2004 Jan 1;103(1):110-9 [12958067.001]
  • [Cites] Leuk Res. 2004 Mar;28(3):221-2 [14687614.001]
  • [Cites] Nat Rev Cancer. 2004 Jan;4(1):71-8 [14708027.001]
  • [Cites] Circ Res. 2004 Feb 6;94(2):262-8 [14670843.001]
  • [Cites] Cancer Res. 2004 Mar 1;64(5):1675-86 [14996727.001]
  • [Cites] Cancer Res. 2004 Mar 1;64(5):1687-94 [14996728.001]
  • [Cites] Semin Thromb Hemost. 2004 Feb;30(1):109-17 [15034802.001]
  • [Cites] J Biol Chem. 2004 Apr 2;279(14):13564-74 [14729679.001]
  • [Cites] J Cell Sci. 2004 Apr 1;117(Pt 9):1847-57 [15075244.001]
  • [Cites] J Cell Physiol. 2004 Jul;200(1):11-9 [15137053.001]
  • [Cites] J Histochem Cytochem. 2004 Jun;52(6):711-22 [15150280.001]
  • [Cites] Mol Cell Biol. 2004 Jun;24(12):5304-13 [15169894.001]
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • [Cites] Genes Dev. 2000 Jan 15;14(2):163-76 [10652271.001]
  • [Cites] Am J Pathol. 2000 Feb;156(2):361-81 [10666364.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Feb 29;97(5):2202-7 [10681423.001]
  • [Cites] Am J Pathol. 1998 Nov;153(5):1641-6 [9811357.001]
  • [Cites] J Immunol. 1998 Dec 15;161(12):6845-52 [9862716.001]
  • [Cites] Genes Dev. 1999 Jan 1;13(1):35-48 [9887098.001]
  • [Cites] APMIS. 1999 Jan;107(1):38-44 [10190278.001]
  • [Cites] Blood. 1999 May 1;93(9):3064-73 [10216103.001]
  • [Cites] J Biol Chem. 1999 May 7;274(19):13066-76 [10224058.001]
  • [Cites] Genes Dev. 1999 Jun 1;13(11):1382-97 [10364156.001]
  • [Cites] Exp Cell Res. 1999 Jul 10;250(1):122-30 [10388526.001]
  • [Cites] EMBO J. 1999 Jul 15;18(14):3964-72 [10406801.001]
  • [Cites] Cell. 1999 Jul 23;98(2):137-46 [10428026.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):332-7 [15549095.001]
  • [Cites] J Cell Biol. 2004 Nov 22;167(4):757-67 [15545316.001]
  • [Cites] J Cell Biol. 2004 Nov 22;167(4):769-81 [15557125.001]
  • [Cites] J Biol Chem. 2005 Jan 14;280(2):1292-8 [15516694.001]
  • [Cites] Oncogene. 2004 Jun 10;23(27):4681-9 [15122332.001]
  • [Cites] J Biol Chem. 2004 Jun 25;279(26):27633-45 [15066996.001]
  • [Cites] Nat Rev Immunol. 2004 Aug;4(8):617-29 [15286728.001]
  • [Cites] J Clin Invest. 2004 Sep;114(5):623-33 [15343380.001]
  • [Cites] Oncogene. 2000 Feb 21;19(8):1102-13 [10713697.001]
  • [Cites] Int J Cancer. 2000 Apr 1;86(1):15-23 [10728589.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Apr 11;97(8):3884-9 [10760260.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Apr 11;97(8):4052-7 [10737763.001]
  • [Cites] Clin Cancer Res. 2000 May;6(5):1647-54 [10815882.001]
  • [Cites] J Biol Chem. 2000 Aug 25;275(34):26411-5 [10827175.001]
  • [Cites] Exp Cell Res. 2000 Oct 10;260(1):73-84 [11010812.001]
  • [Cites] Nat Cell Biol. 2000 Oct;2(10):737-44 [11025665.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Oct 24;97(22):12227-32 [11035804.001]
  • [Cites] Cell. 2000 Oct 27;103(3):481-90 [11081634.001]
  • [Cites] FEBS Lett. 2000 Dec 15;486(3):247-51 [11119712.001]
  • [Cites] Hybridoma. 2000 Oct;19(5):375-85 [11128027.001]
  • [Cites] Cancer Metastasis Rev. 2000;19(1-2):109-20 [11191049.001]
  • [Cites] Biochim Biophys Acta. 2000 Dec 11;1499(1-2):19-33 [11118636.001]
  • [Cites] Methods Mol Biol. 2001;151:411-5 [11217316.001]
  • [Cites] Exp Cell Res. 2001 Feb 15;263(2):209-23 [11161720.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2001 Mar;42(3):853-9 [11222550.001]
  • [Cites] J Exp Med. 2001 Mar 19;193(6):727-40 [11257139.001]
  • [Cites] Blood. 2001 Apr 15;97(8):2323-32 [11290594.001]
  • [Cites] Biochem Biophys Res Commun. 2001 Mar 30;282(2):463-73 [11401482.001]
  • [Cites] J Leukoc Biol. 2001 Jun;69(6):851-9 [11404367.001]
  • [Cites] J Clin Invest. 2001 Aug;108(3):349-55 [11489925.001]
  • [Cites] J Cell Biol. 2001 Sep 3;154(5):1069-79 [11535623.001]
  • [Cites] Cancer Lett. 2001 Nov 28;173(2):175-82 [11597792.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Oct 23;98(22):12485-90 [11606713.001]
  • [Cites] Radiology. 2001 Nov;221(2):523-9 [11687699.001]
  • [Cites] Nat Med. 2001 Nov;7(11):1194-201 [11689883.001]
  • [Cites] Cell. 2001 Dec 14;107(6):789-800 [11747814.001]
  • [Cites] Oncogene. 2002 Jan 10;21(2):272-81 [11803470.001]
  • [Cites] Cancer Res. 2002 Jan 15;62(2):580-8 [11809713.001]
  • [Cites] Acta Haematol. 2001;106(4):162-9 [11815713.001]
  • [Cites] J Biol Chem. 2002 Mar 1;277(9):7377-85 [11741954.001]
  • [Cites] FASEB J. 2002 Mar;16(3):379-89 [11874987.001]
  • [Cites] J Biol Chem. 2002 Mar 22;277(12):9749-56 [11724803.001]
  • [Cites] FASEB J. 2002 Apr;16(6):555-64 [11919158.001]
  • [Cites] Science. 2002 Mar 29;295(5564):2387-92 [11923519.001]
  • [Cites] J Hematother Stem Cell Res. 2002 Apr;11(2):207-14 [11983094.001]
  • [Cites] Nat Rev Cancer. 2002 Mar;2(3):161-74 [11990853.001]
  • [Cites] Cell. 2002 May 31;109(5):625-37 [12062105.001]
  • [Cites] J Natl Cancer Inst. 2002 Aug 7;94(15):1134-42 [12165638.001]
  • [Cites] J Biol Chem. 2002 Sep 27;277(39):36288-95 [12114504.001]
  • [Cites] Cancer Res. 2002 Oct 1;62(19):5580-9 [12359771.001]
  • [Cites] Cell. 2003 Jul 11;114(1):33-45 [12859896.001]
  • [Cites] Cancer Res. 2003 Aug 15;63(16):5060-4 [12941835.001]
  • [Cites] Eur J Biochem. 2003 Sep;270(18):3739-49 [12950257.001]
  • [Cites] Cancer Res. 2003 Sep 1;63(17):5224-9 [14500349.001]
  • [Cites] J Leukoc Biol. 2006 Dec;80(6):1183-96 [16997855.001]
  • [Cites] Cancer Res. 2006 Dec 1;66(23):11089-93 [17145848.001]
  • [Cites] Clin Exp Metastasis. 2006;23(7-8):335-44 [17136575.001]
  • [Cites] Nat Rev Mol Cell Biol. 2007 Mar;8(3):221-33 [17318226.001]
  • [Cites] Biochim Biophys Acta. 2007 Mar;1773(3):400-7 [17187878.001]
  • [Cites] J Biol Chem. 2007 Mar 2;282(9):6899-905 [17204469.001]
  • [Cites] Cancer Res. 2007 Mar 15;67(6):2649-56 [17363585.001]
  • [Cites] Cancer Res. 2007 Apr 1;67(7):3310-9 [17409440.001]
  • [Cites] Mol Cell Proteomics. 2007 Apr;6(4):611-23 [17200105.001]
  • [Cites] Nature. 2007 Apr 12;446(7137):765-70 [17429393.001]
  • [Cites] J Cell Sci. 2007 May 1;120(Pt 9):1607-14 [17405818.001]
  • [Cites] Lancet Oncol. 2007 May;8(5):444-8 [17466902.001]
  • [Cites] Cancer Res. 2007 May 1;67(9):4353-63 [17483349.001]
  • [Cites] Clin Cancer Res. 2007 May 15;13(10):3068-78 [17505010.001]
  • (PMID = 19800930.001).
  • [ISSN] 0006-3002
  • [Journal-full-title] Biochimica et biophysica acta
  • [ISO-abbreviation] Biochim. Biophys. Acta
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA105412; United States / NCI NIH HHS / CA / R01 CA055852-16; United States / NCI NIH HHS / CA / CA055852-16; United States / NCI NIH HHS / CA / R01 CA055852; United States / NCI NIH HHS / CA / R01 CA129484
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] EC 3.4.24.- / Matrix Metalloproteinases
  • [Number-of-references] 240
  • [Other-IDs] NLM/ NIHMS154042; NLM/ PMC2824055
  •  go-up   go-down


65. Kim MS, Muratore C, Snelling L, Mandelbaum DE, McEachern R, Mangray S, Faizan M, Quintos JB: Ischemic stroke and rhabdomyolysis in a 15-year-old girl with paraganglioma due to an SDHB exon 6 (Q214X) mutation. J Pediatr Endocrinol Metab; 2009 Jun;22(6):565-71
MedlinePlus Health Information. consumer health - Stroke.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: We report a 15-year-old girl with a recent diagnosis of type 2 diabetes mellitus who presented in malignant hypertensive crisis (BP 210/120 mm Hg).
  • RESULTS: Pathology showed a Zellballen pattern, negative tumor margins and benign para-aortic lymph nodes.
  • Mutation analysis of the succinate dehydrogenase type B (SDHB) gene revealed a heterozygous change of C to T at position 640 in exon 6 (Q214X) predicting an amino acid change to a stop codon.
  • [MeSH-major] Brain Ischemia / etiology. Germ-Line Mutation. Paraganglioma, Extra-Adrenal / genetics. Retroperitoneal Neoplasms / genetics. Rhabdomyolysis / etiology. Stroke / etiology. Succinate Dehydrogenase / genetics

  • Genetic Alliance. consumer health - Ischemic stroke.
  • Genetic Alliance. consumer health - Rhabdomyolysis.
  • MedlinePlus Health Information. consumer health - Ischemic Stroke.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19694205.001).
  • [ISSN] 0334-018X
  • [Journal-full-title] Journal of pediatric endocrinology & metabolism : JPEM
  • [ISO-abbreviation] J. Pediatr. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] EC 1.3.5.1 / SDHB protein, human; EC 1.3.99.1 / Succinate Dehydrogenase
  •  go-up   go-down


66. Passer BJ, Wu CL, Wu S, Rabkin SD, Martuza RL: Analysis of genetically engineered oncolytic herpes simplex viruses in human prostate cancer organotypic cultures. Gene Ther; 2009 Dec;16(12):1477-82
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In benign prostate tissues, G207 and G47Delta titers were notably reduced, whereas strain F titers were maintained at similar levels compared with prostate cancer specimens.

  • Genetic Alliance. consumer health - Prostate cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Virol. 2000 Apr;74(8):3832-41 [10729157.001]
  • [Cites] Nat Rev Microbiol. 2008 Jul;6(7):529-40 [18552863.001]
  • [Cites] Urology. 2000 Jul;56(1):160-6 [10869659.001]
  • [Cites] Rev Med Virol. 2000 Sep-Oct;10(5):305-19 [11015742.001]
  • [Cites] Cancer Res. 2000 Oct 15;60(20):5714-22 [11059765.001]
  • [Cites] Hum Gene Ther. 2000 Dec 10;11(18):2465-72 [11119418.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 May 22;98(11):6396-401 [11353831.001]
  • [Cites] Hum Gene Ther. 2001 May 20;12(8):999-1010 [11387063.001]
  • [Cites] Urology. 2001 Oct;58(4):619-24 [11597556.001]
  • [Cites] Neoplasia. 2001 Sep-Oct;3(5):451-6 [11687957.001]
  • [Cites] Dev Biol. 2004 Mar 15;267(2):387-98 [15013801.001]
  • [Cites] Cancer Res. 1993 Nov 1;53(21):5199-207 [7693334.001]
  • [Cites] Nat Med. 1995 Sep;1(9):938-43 [7585221.001]
  • [Cites] J Clin Invest. 1997 Feb 15;99(4):618-27 [9045863.001]
  • [Cites] J Virol. 1997 Aug;71(8):6049-54 [9223497.001]
  • [Cites] J Virol. 1998 Sep;72(9):7005-11 [9696792.001]
  • [Cites] J Virol. 1998 Sep;72(9):7064-74 [9696799.001]
  • [Cites] Hum Gene Ther. 1999 Sep 1;10(13):2237-43 [10498254.001]
  • [Cites] Gene Ther. 1999 Oct;6(10):1751-8 [10516725.001]
  • [Cites] Cancer Res. 2005 Feb 15;65(4):1532-40 [15735042.001]
  • [Cites] J Exp Med. 2005 Apr 18;201(8):1257-68 [15824085.001]
  • [Cites] Cancer Gene Ther. 2006 Mar;13(3):253-65 [16179929.001]
  • [Cites] Arch Pathol Lab Med. 2006 Aug;130(8):1193-5 [16879022.001]
  • [Cites] Mol Ther. 2007 Jan;15(1):103-13 [17164781.001]
  • [Cites] J Virol. 2007 Apr;81(7):3455-64 [17229694.001]
  • [Cites] J Virol. 2008 Jan;82(2):999-1010 [17977977.001]
  • [Cites] FASEB J. 2008 Jun;22(6):1839-48 [18234972.001]
  • [Cites] Gene Ther. 2000 May;7(10):867-74 [10845725.001]
  • (PMID = 19693098.001).
  • [ISSN] 1476-5462
  • [Journal-full-title] Gene therapy
  • [ISO-abbreviation] Gene Ther.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA102139-06A1; United States / NCI NIH HHS / CA / R01 CA102139; United States / NCI NIH HHS / CA / R01 CA102139-06A1
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Other-IDs] NLM/ NIHMS180783; NLM/ PMC2836587
  •  go-up   go-down


67. Keshavarzi S, Meltzer H, Ben-Haim S, Newman CB, Lawson JD, Levy ML, Murphy K: Initial clinical experience with frameless optically guided stereotactic radiosurgery/radiotherapy in pediatric patients. Childs Nerv Syst; 2009 Jul;25(7):837-44
MedlinePlus Health Information. consumer health - Radiation Therapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: The objective of this study is to report our initial experience treating pediatric patients with central nervous system tumors using a frameless, optically guided linear accelerator.
  • RESULTS: Nine patients, ages ranging from 12 to 19 years old (median age 15 years old), with a variety of tumors have been treated.
  • CONCLUSION: Frameless stereotactic optically guided radiosurgery and radiotherapy provides a feasible and accurate tool to treat a number of benign and malignant tumors in children with minimal treatment-related morbidity.
  • [MeSH-major] Brain Neoplasms / radiotherapy. Brain Neoplasms / surgery. Radiosurgery / methods. Radiotherapy / methods
  • [MeSH-minor] Adolescent. Astrocytoma / pathology. Astrocytoma / radiotherapy. Astrocytoma / surgery. Child. Female. Follow-Up Studies. Humans. Magnetic Resonance Imaging. Male. Medulloblastoma / radiotherapy. Medulloblastoma / surgery. Neoplasm Metastasis / radiotherapy. Pineal Gland / pathology. Pineal Gland / surgery. Pinealoma / radiotherapy. Pinealoma / surgery. Pituitary Neoplasms / radiotherapy. Pituitary Neoplasms / surgery. Prolactinoma / radiotherapy. Prolactinoma / surgery. Tomography, X-Ray Computed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Childs Nerv Syst. 2001 May;17(6):341-6; discussion 347 [11417414.001]
  • [Cites] Pediatr Neurol. 1996 Oct;15(3):193-9 [8916155.001]
  • [Cites] Med Phys. 2002 Aug;29(8):1729-38 [12201420.001]
  • [Cites] Neurosurgery. 2003 Jan;52(1):140-6; discussion 146-7 [12493111.001]
  • [Cites] Strahlenther Onkol. 2003 Sep;179(9):585-97 [14628124.001]
  • [Cites] Neurosurgery. 2004 Jul;55(1):89-98; discussion 98-9 [15214977.001]
  • [Cites] Neurosurgery. 2004 Oct;55(4):916-24; discussion 924-5 [15458600.001]
  • [Cites] Br J Neurosurg. 1989;3(3):305-12 [2506900.001]
  • [Cites] Pediatr Neurosurg. 1990-1991;16(4-5):219-21 [2135190.001]
  • [Cites] Neurosurg Clin N Am. 1992 Jan;3(1):167-90 [1633445.001]
  • [Cites] Acta Neurochir Suppl. 1994;62:83-7 [7717143.001]
  • [Cites] J Neurosurg Anesthesiol. 1995 Apr;7(2):100-8 [7772962.001]
  • [Cites] Neurosurgery. 1996 Apr;38(4):696-701; discussion 701-2 [8692387.001]
  • [Cites] Pediatr Neurosurg. 1996;24(3):139-44 [8870017.001]
  • [Cites] Pediatr Neurosurg. 1996;24(4):193-201 [8873161.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Jul 1;38(4):875-82 [9240657.001]
  • [Cites] Anaesth Intensive Care. 1997 Dec;25(6):691-5 [9452856.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Oct 1;42(3):573-80 [9806517.001]
  • [Cites] Neurosurg Clin N Am. 1999 Apr;10(2):181-202 [10099088.001]
  • [Cites] Nature. 1958 Nov 1;182(4644):1222-3 [13590280.001]
  • [Cites] Childs Nerv Syst. 2005 Apr;21(4):301-7; discussion 308 [15654635.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Apr 1;61(5):1467-72 [15817352.001]
  • [Cites] Pediatr Blood Cancer. 2005 Sep;45(3):304-10 [15558704.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Mar 1;64(3):914-21 [16338096.001]
  • [Cites] NeuroRx. 2006 Apr;3(2):276-91 [16554265.001]
  • [Cites] Cancer Radiother. 2006 Sep;10(5):283-7 [16859948.001]
  • [Cites] Semin Oncol Nurs. 2006 Nov;22(4):221-32 [17095398.001]
  • [Cites] Med Dosim. 2007 Summer;32(2):121-33 [17472891.001]
  • [Cites] Cancer J. 2007 Mar-Apr;13(2):87-94 [17476136.001]
  • [Cites] Neurosurgery. 2007 Sep;61(3 Suppl):130-40; discussion 140-1 [17876243.001]
  • [Cites] Clin Lung Cancer. 2007 Sep;8(8):488-92 [17922973.001]
  • [Cites] Med Phys. 2007 Oct;34(10):3962-70 [17985641.001]
  • [Cites] Expert Rev Anticancer Ther. 2007 Nov;7(11):1507-15 [18020920.001]
  • [Cites] Expert Rev Anticancer Ther. 2007 Dec;7(12 Suppl):S69-77 [18076312.001]
  • [Cites] J Clin Anesth. 2007 Dec;19(8):616-8 [18083476.001]
  • [Cites] Neurosurg Focus. 2007;23(6):E4 [18081481.001]
  • [Cites] Neurosurg Focus. 2007;23(6):E5 [18081482.001]
  • [Cites] J Neurosurg Pediatr. 2008 Apr;1(4):296-304 [18377305.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008;71(1 Suppl):S131-5 [18406912.001]
  • [Cites] Neurosurgery. 2008 Mar;62(3):647-55; discussion 647-55 [18425011.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Nov 15;51(4):1152-8 [11704340.001]
  • (PMID = 19326128.001).
  • [ISSN] 1433-0350
  • [Journal-full-title] Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
  • [ISO-abbreviation] Childs Nerv Syst
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Other-IDs] NLM/ PMC2691523
  •  go-up   go-down


68. García-Reyna JC, Rico Martínez G, Vega González IF, Linares LM, Delgado Cedillo EA, Romero Ramírez R: [Musculoskeletal tumor evaluation with 99mTc-Tetrofosmin]. Acta Ortop Mex; 2008 Nov-Dec;22(6):390-6
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Musculoskeletal tumor evaluation with 99mTc-Tetrofosmin].
  • [Transliterated title] 99mTc-Tetrofosmin en la evaluación de tumores musculoesqueléticos.
  • INTRODUCTION: (99m)Tc-tetrofosmin is an efficient agent as a tumor marker.
  • Several studies have proven its efficiency in detection and localization of tumors of the breast, larynx, thyroid, parathyroid glands, lung, brain, skin, lymphatic and musculoskeletal tissues with a sensitivity and specificity of 95% to 100%.
  • Nevertheless, benign pathology such as active inflammation is a source of false positives and the attending physician must consider the aid of complementary studies such as histopathology.
  • [MeSH-major] Bone Neoplasms / radionuclide imaging. Muscle Neoplasms / radionuclide imaging. Organophosphorus Compounds. Organotechnetium Compounds. Radiopharmaceuticals

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19280840.001).
  • [ISSN] 2306-4102
  • [Journal-full-title] Acta ortopédica mexicana
  • [ISO-abbreviation] Acta Ortop Mex
  • [Language] spa
  • [Publication-type] Clinical Trial; Comparative Study; English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Mexico
  • [Chemical-registry-number] 0 / Organophosphorus Compounds; 0 / Organotechnetium Compounds; 0 / Radiopharmaceuticals; 0 / technetium Tc 99m 1,2-bis(bis(2-ethoxyethyl)phosphino)ethane
  •  go-up   go-down


69. Kondziolka D, Madhok R, Lunsford LD, Mathieu D, Martin JJ, Niranjan A, Flickinger JC: Stereotactic radiosurgery for convexity meningiomas. J Neurosurg; 2009 Sep;111(3):458-63
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECT: Meningiomas of the cerebral convexity are often surgically curable because both the mass and involved dura mater can be removed.
  • Tumors were located in frontal (80 patients), parietal (24 patients), temporal (12 patients), and occipital (9 patients) areas.
  • The WHO tumor grades in patients with prior resections were Grade I in 34 patients, Grade II in 15 patients, and Grade III in 6 patients.
  • Seventy patients underwent primary radiosurgery and therefore had no prior histological tumor diagnosis.
  • The mean tumor volume was 7.6 ml.
  • Radiosurgery was performed using the Leksell Gamma Knife with a mean tumor margin dose of 14.2 Gy.
  • After primary radiosurgery, the tumor control rate was 92%.
  • After adjuvant radiosurgery, the control rate was 97% for Grade I tumors.
  • The actuarial tumor control rates at 3 and 5 years for the entire series were 86.1+/-3.8% and 71.6+/-8.6%, respectively.
  • For patients with benign tumors (Grade I) and those without prior surgery, the actuarial tumor control rate was 95.3+/-2.3% and 85.8+/-9.3%, respectively.
  • No patient developed a subsequent radiation-induced tumor.
  • CONCLUSIONS: Stereotactic radiosurgery provides satisfactory control rates either after resection or as an alternate to resection, particularly for histologically benign meningiomas.
  • Its role is most valuable for patients whose tumors affect critical neurological regions and who are poor candidates for resection.
  • Both temporary and permanent morbidity are related to brain location and tumor volume.
  • [MeSH-major] Meningeal Neoplasms / surgery. Meningioma / surgery. Radiosurgery
  • [MeSH-minor] Female. Humans. Male. Neurofibromatosis 2 / complications. Treatment Outcome. Tumor Burden

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19199473.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


70. Avci E, Oztürk A, Baba F, Torun F, Karabağ H, Yücetaş S: Desmoplastic infantile ganglioglioma: case report. Turk J Pediatr; 2008 Sep-Oct;50(5):495-9
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • These tumors are benign tumors of childhood that become symptomatic when they reach giant sizes.
  • [MeSH-major] Brain Neoplasms / diagnosis. Ganglioglioma / diagnosis
  • [MeSH-minor] Cranial Fossa, Anterior. Craniotomy / methods. Diagnosis, Differential. Humans. Infant. Magnetic Resonance Imaging. Male. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Desmoplastic Infantile Ganglioglioma.
  • Genetic Alliance. consumer health - Ganglioglioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19102059.001).
  • [ISSN] 0041-4301
  • [Journal-full-title] The Turkish journal of pediatrics
  • [ISO-abbreviation] Turk. J. Pediatr.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Turkey
  •  go-up   go-down


71. Tsurubuchi T, Yamamoto T, Tsukada Y, Matsuda M, Nakai K, Matsumura A: Meningioma associated with Werner syndrome--case report--. Neurol Med Chir (Tokyo); 2008 Oct;48(10):470-3
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Screening brain magnetic resonance (MR) imaging with gadolinium had detected multiple homogeneously enhanced tumors in the right convexity and in the anterior and posterior thirds of the falx cerebri after surgery for osteosarcoma in his right leg at age 52 years.
  • Ten months later, the right convexity tumor was removed because follow-up MR imaging detected tumor growth.
  • The histological diagnosis was transitional meningioma.
  • Most meningiomas associated with Werner syndrome are benign, but are sometimes complicated with extracranial tumors such as sarcoma, thyroid carcinoma, and others.
  • Patients with meningioma associated with Werner syndrome should be carefully followed up to detect the occurrence of other extracranial tumors such as sarcoma by brain MR imaging, echography, or body computed tomography.
  • [MeSH-major] Meningeal Neoplasms / genetics. Meningeal Neoplasms / pathology. Meningioma / genetics. Meningioma / pathology. Werner Syndrome / complications

  • Genetic Alliance. consumer health - Meningioma.
  • Genetic Alliance. consumer health - Werner's syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18948683.001).
  • [ISSN] 1349-8029
  • [Journal-full-title] Neurologia medico-chirurgica
  • [ISO-abbreviation] Neurol. Med. Chir. (Tokyo)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


72. Gu TF, Xiao XL, Sun F, Yin JH, Zhao H: Diagnostic value of whole body diffusion weighted imaging for screening primary tumors of patients with metastases. Chin Med Sci J; 2008 Sep;23(3):145-50

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic value of whole body diffusion weighted imaging for screening primary tumors of patients with metastases.
  • OBJECTIVE: To evaluate the values of whole body diffusion weighted imaging (DWI) in screening primary unknown tumor in patients with metastases.
  • METHODS: Totally, 34 patients with metastases of primary unknown tumors were scanned with whole body DWI, and conventional magnetic resonance (MR) imaging was performed if suspected lesions were detected.
  • All the metastases including 27 cases of osseous metastases, 2 brain metastases, 2 liver metastases, 1 pulmonary multiple metastasis, 1 neck metastasis and 1 malignant ascites, were diagnosed by computed tomography, single photon emission computed tomography, or MR imaging.
  • For the proven primary tumors diagnosed by biopsy or pathology of surgical specimens, apparent diffusion coefficient (ADC) values of the primary and metastatic lesions were measured respectively.
  • The sensitivity and specificity of this technique for screening primary tumors were evaluated.
  • RESULTS: We found 24 cases with suspected primary lesions, in which 23 lesions were proved to be primary tumors, and 1 was proved to be benign lesion.
  • And no definite primary lesion was found in 10 cases on whole body DWI, but in which 1 case was diagnosed with primary tumor by biopsy later, and the other 9 cases remained unknown within follow-up of over half a year.
  • The sensitivity and specificity of whole body DWI for searching primary tumors was 95.8% and 90.0%, respectively.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18853848.001).
  • [ISSN] 1001-9294
  • [Journal-full-title] Chinese medical sciences journal = Chung-kuo i hsueh k'o hsueh tsa chih
  • [ISO-abbreviation] Chin. Med. Sci. J.
  • [Language] ENG
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] China
  •  go-up   go-down


73. Morokoff AP, Zauberman J, Black PM: Surgery for convexity meningiomas. Neurosurgery; 2008 Sep;63(3):427-33; discussion 433-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Meningiomas that occur over the convexity of the brain are the most common meningiomas, but little has been published about their contemporary management.
  • RESULTS: Convexity tumors represented 22% of all meningiomas operated on.
  • The pathology of the tumors was benign in 144 (88.3%), atypical in 16 (9.8%), and anaplastic/malignant in 3 (1.8%).
  • In six of the cases designated "benign," there were borderline atypical features.
  • The 5-year recurrence rate for benign meningiomas was 1.8%, atypical meningiomas 27.2%, and anaplastic meningiomas 50%.
  • The two cases of benign tumor recurrences involved tumors with borderline atypia and high MIB-1 indices.
  • The borderline atypical cases had a 5-year recurrence-free survival rate of only 55.9%, more closely approximating that of tumors designated "atypical."
  • Benign convexity meningiomas having a Simpson Grade I complete excision have a very low recurrence rate.
  • The recurrence rates of atypical and malignant tumors are significantly higher, and borderline atypical tumors should be considered to behave more like atypical rather than benign lesions.
  • Longer-term follow-up data are needed to more accurately determine the recurrence rates of benign meningiomas.
  • [MeSH-major] Meningeal Neoplasms / surgery. Meningioma / surgery. Microsurgery / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Craniotomy / methods. Craniotomy / mortality. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / mortality. Neoplasm Recurrence, Local / prevention & control. Neoplasm Recurrence, Local / surgery. Retrospective Studies. Survival Rate / trends. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18812953.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


74. Rodriguez FJ, Scheithauer BW, Roncaroli F, Silva AI, Kovacs K, Brat DJ, Jin L: Galectin-3 expression is ubiquitous in tumors of the sellar region, nervous system, and mimics: an immunohistochemical and RT-PCR study. Am J Surg Pathol; 2008 Sep;32(9):1344-52
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Galectin-3 expression is ubiquitous in tumors of the sellar region, nervous system, and mimics: an immunohistochemical and RT-PCR study.
  • We evaluated galectin-3 protein expression by immunohistochemistry in 201 cases of a variety of nervous system and sellar tumors, as well as mRNA expression by reverse transcription-polymerase chain reaction in formalin-fixed paraffin-embedded tissue in a subset (20 cases).
  • Galectin-3 was also strongly expressed in benign nerve sheath tumors but only moderately expressed in malignant peripheral nerve sheath tumors (P=0.0009, Fisher exact test).
  • Although galectin-3 positivity is a key feature of the immunophenotype of spindle cell oncocytoma, its consistent expression in other morphologically similar tumors (meningioma, pituicytoma, nerve sheath tumors, granular cell tumor, metastases) makes it of little use in the differential diagnosis of sellar region tumors, a setting in which it should be discouraged.
  • Diagnostic uses of this marker may be limited to specific settings, including some meningioma subtypes and nerve sheath tumors.
  • [MeSH-major] Brain Neoplasms / metabolism. Galectin 3 / biosynthesis. Nerve Sheath Neoplasms / metabolism. Sella Turcica / pathology
  • [MeSH-minor] Biomarkers, Tumor / analysis. Diagnosis, Differential. Humans. Immunohistochemistry. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18670355.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Galectin 3
  •  go-up   go-down


75. Saito R, Kumabe T, Watanabe M, Jokura H, Shibuya M, Nakazato Y, Tominaga T: Low-grade fibromyxoid sarcoma of intracranial origin. J Neurosurg; 2008 Apr;108(4):798-802
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The low-grade fibromyxoid sarcoma is a rare sarcoma of the deep soft tissue that is characterized as an indolent but metastasizing soft-tissue neoplasm with a deceptively benign histological appearance.
  • A high rate of local recurrence and eventual metastasis has been demonstrated for this tumor in deep soft tissue.
  • The tumor is still under control without any evidence of extracranial metastasis.
  • [MeSH-major] Brain Neoplasms / diagnosis. Brain Neoplasms / therapy. Sarcoma / diagnosis. Sarcoma / therapy
  • [MeSH-minor] Adult. Combined Modality Therapy. Humans. Magnetic Resonance Imaging. Male. Neoplasm Recurrence, Local / prevention & control. Radiosurgery. Radiotherapy, Adjuvant. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18377261.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


76. Bodi I, Hortobágyi T, Buk S: A 72-year-old woman with right frontal extra-axial mass. Brain Pathol; 2008 Apr;18(2):279-82
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Histology showed a benign meningioma with multifocal accumulation of numerous large cells with abundant eosinophilic cytoplasm, filled with lamellar inclusions and bipyramidal crystals.
  • Plasma cell inclusions have been reported occasionally in reactive inflammatory lesions but more frequently in plasma cell tumors and lymphoplasmacytic lymphoma, maybe associated with crystal-storing histiocytosis.
  • [MeSH-major] Brain Neoplasms / pathology. Frontal Lobe / pathology. Meningeal Neoplasms / pathology. Meningioma / pathology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18363938.001).
  • [ISSN] 1015-6305
  • [Journal-full-title] Brain pathology (Zurich, Switzerland)
  • [ISO-abbreviation] Brain Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Switzerland
  •  go-up   go-down


77. Wickremesekera A, Hovens CM, Kaye AH: Expression of ErbB-1 and 2 in vestibular schwannomas. J Clin Neurosci; 2007 Dec;14(12):1199-206
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • These findings implicate a functional role of ErbB-2 in the benign nature of VS and that a rationale for using ErbB targeted therapies in VS may be warranted.
  • [MeSH-major] Cranial Nerve Neoplasms / metabolism. Neuroma, Acoustic / metabolism. Receptor, Epidermal Growth Factor / biosynthesis. Receptor, ErbB-2 / biosynthesis
  • [MeSH-minor] Animals. Blotting, Western. Brain Neoplasms / metabolism. Brain Neoplasms / pathology. Cells, Cultured. Glioblastoma / metabolism. Glioblastoma / pathology. Humans. Immunohistochemistry. Immunoprecipitation. Mice. Neoplasm Proteins / chemistry. Neoplasm Proteins / isolation & purification

  • MedlinePlus Health Information. consumer health - Acoustic Neuroma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17964790.001).
  • [ISSN] 0967-5868
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / Neoplasm Proteins; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


78. Karbowniczek M, Spittle CS, Morrison T, Wu H, Henske EP: mTOR is activated in the majority of malignant melanomas. J Invest Dermatol; 2008 Apr;128(4):980-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In contrast, only 3/67 benign nevi (4%) were moderately positive, and none were strongly positive.
  • These data indicate that mTOR activation is very strongly associated with malignant, compared to benign, melanocytic lesions.
  • The proliferation of three melanoma-derived lines was blocked by the mTOR inhibitor rapamycin, indicating that mTOR activation is a growth-promoting factor in melanoma-derived cells. mTOR is directly activated by the small guanosine triphosphatase Ras homolog enriched in brain (Rheb), in a farnesylation-dependent manner.
  • [MeSH-major] Melanoma / enzymology. Melanoma / pathology. Protein Kinases / metabolism. Skin Neoplasms / enzymology. Skin Neoplasms / pathology
  • [MeSH-minor] Cell Line, Tumor. Cell Proliferation / drug effects. DNA Mutational Analysis. Humans. Nevus / enzymology. Nevus / pathology. Phosphorylation. Protein Kinase Inhibitors / pharmacology. Proto-Oncogene Proteins B-raf / genetics. Proto-Oncogene Proteins p21(ras) / genetics. Ribosomal Protein S6 / metabolism. Sirolimus / pharmacology. TOR Serine-Threonine Kinases

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. SIROLIMUS .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17914450.001).
  • [ISSN] 1523-1747
  • [Journal-full-title] The Journal of investigative dermatology
  • [ISO-abbreviation] J. Invest. Dermatol.
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / DK 51052
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Protein Kinase Inhibitors; 0 / Ribosomal Protein S6; EC 2.7.- / Protein Kinases; EC 2.7.1.1 / MTOR protein, human; EC 2.7.1.1 / TOR Serine-Threonine Kinases; EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf; EC 3.6.5.2 / Proto-Oncogene Proteins p21(ras); W36ZG6FT64 / Sirolimus
  •  go-up   go-down


79. Bougrine F, Bacha D, Chouchane O, Laabidi B, Yeades M, Bouziani A: [Intracerebral schwannoma: case report]. Neurochirurgie; 2007 Nov;53(5):387-90
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The tumor was removed through a right parietal craniotomy.
  • The most popular hypothesis argues that these tumors arise from the proliferation of Schwann cells in the perivascular nerve plexii.
  • CONCLUSIONS: Intracerebral schwannoma is an extremely rare benign tumor.
  • The importance of recognizing this tumor is stressed, particularly in younger patients, given its benign nature, radiological resemblance to other tumors and favorable response to resection without toxic treatment.
  • [MeSH-major] Brain Neoplasms / pathology. Neurilemmoma / pathology
  • [MeSH-minor] Adult. Female. Humans. Immunohistochemistry. Intracranial Hypertension / etiology. Magnetic Resonance Imaging. Neoplasm Metastasis. Neurosurgical Procedures. Seizures / etiology

  • Genetic Alliance. consumer health - Schwannoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17884108.001).
  • [ISSN] 0028-3770
  • [Journal-full-title] Neuro-Chirurgie
  • [ISO-abbreviation] Neurochirurgie
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


80. Wang F, Wang Z, Yao W, Xie H, Xu J, Tian L: Role of 99mTc-octreotide acetate scintigraphy in suspected lung cancer compared with 18F-FDG dual-head coincidence imaging. J Nucl Med; 2007 Sep;48(9):1442-8
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Forty-four consecutive patients with suspected pulmonary neoplasms underwent tomographic (99m)Tc-octreotide scintigraphy and (18)F-FDG coincidence imaging using the same gantry.
  • The tumor-to-normal tissue tracer values for both (99m)Tc-octreotide and (18)F-FDG were determined using region of interests and expressed as T/N(r) and T/N(m), respectively.
  • Final diagnosis was confirmed by histopathologic analysis or clinical follow-up.
  • Thirteen of the 44 patients had benign lung lesions.
  • In the 31 patients with malignant tumors, all 38 abnormal lymph nodes in 20 patients showed abnormal high focal uptake of (18)F-FDG; only 7 patients with 10 regional lymph adenopathies showed moderate uptake of (99m)Tc-octreotide.
  • Thirteen patients with 39 distant sites of abnormal uptake visualized (imaging stage IV) with (99m)Tc-octreotide included 2 patients with brain metastases, 6 patients with pleural invasion and multiple bone metastasis, 2 patients with contralateral internal lung metastasis and pleural invasion, and 3 patients with only multiple bone metastasis.
  • The final diagnosis was confirmed by histopathology or clinical follow-up.
  • [MeSH-major] Fluorodeoxyglucose F18. Lung Neoplasms / radionuclide imaging. Octreotide / analogs & derivatives. Organotechnetium Compounds. Radiopharmaceuticals
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Neoplasm Metastasis

  • Genetic Alliance. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17704242.001).
  • [ISSN] 0161-5505
  • [Journal-full-title] Journal of nuclear medicine : official publication, Society of Nuclear Medicine
  • [ISO-abbreviation] J. Nucl. Med.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 99mTc-octreotide; 0 / Organotechnetium Compounds; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18; RWM8CCW8GP / Octreotide
  •  go-up   go-down


81. Galanov AV, Konovalov AN, Kornienko VN, Il'ialov SR, Kostiuchenko VV, Pronin IN, Mariashev SA, Iakovlev SB, Lubnin AIu, Serova NK, Nikonova NG: [First experience with a Gamma-knife unit used for radiosurgical treatment for intracranial space-occupying lesions]. Zh Vopr Neirokhir Im N N Burdenko; 2007 Jan-Mar;(1):3-10
MedlinePlus Health Information. consumer health - Brain Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Three hundred and six patients with various intracranial diseases (137 with malignant tumors, 136 with benign tumors, and 33 patients with vascular diseases) underwent radiosurgery on a Gamma-Knife unit for over 1.5 years, from May 2005 to October 2006.
  • [MeSH-major] Brain Diseases / surgery. Radiosurgery / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Brain Neoplasms / pathology. Brain Neoplasms / radiotherapy. Brain Neoplasms / surgery. Child. Child, Preschool. Equipment Design. Eye Diseases / surgery. Female. Humans. Male. Meningioma / radiotherapy. Meningioma / surgery. Middle Aged. Neoplasm Metastasis. Neuroma, Acoustic / radiotherapy. Neuroma, Acoustic / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17526246.001).
  • [ISSN] 0042-8817
  • [Journal-full-title] Zhurnal voprosy neĭrokhirurgii imeni N. N. Burdenko
  • [ISO-abbreviation] Zh Vopr Neirokhir Im N N Burdenko
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


82. Pulukuri SM, Estes N, Patel J, Rao JS: Demethylation-linked activation of urokinase plasminogen activator is involved in progression of prostate cancer. Cancer Res; 2007 Feb 1;67(3):930-9
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Here, we show that uPA is aberrantly expressed in a high percentage of human prostate cancer tissues but rarely expressed either in tumor-matched nonneoplastic adjacent tissues or benign prostatic hyperplasia samples.
  • Furthermore, treatment with demethylation inhibitor S-adenosylmethionine or stable expression of uPA short hairpin RNA significantly inhibits uPA expression and tumor cell invasion in vitro and tumor growth and incidence of lung metastasis in vivo.
  • Collectively, these findings strongly suggest that DNA demethylation is a common mechanism underlying the abnormal expression of uPA and is a critical contributing factor to the malignant progression of human prostate tumors.

  • Genetic Alliance. consumer health - Prostate cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] CA Cancer J Clin. 2003 Jan-Feb;53(1):5-26 [12568441.001]
  • [Cites] Int J Oncol. 2003 Feb;22(2):289-94 [12527924.001]
  • [Cites] Cancer Res. 2003 Apr 1;63(7):1684-95 [12670923.001]
  • [Cites] FASEB J. 2003 Jun;17(9):1081-8 [12773490.001]
  • [Cites] J Biol Chem. 2003 Jun 6;278(23):20812-20 [12676953.001]
  • [Cites] Nat Rev Cancer. 2003 Jul;3(7):489-501 [12835669.001]
  • [Cites] Oncogene. 2003 Sep 4;22(38):5967-75 [12955075.001]
  • [Cites] CA Cancer J Clin. 2004 Jan-Feb;54(1):8-29 [14974761.001]
  • [Cites] Clin Cancer Res. 2004 May 1;10(9):3035-41 [15131040.001]
  • [Cites] Mol Cancer Ther. 2004 Jun;3(6):671-8 [15210852.001]
  • [Cites] J Biol Chem. 2004 Jul 23;279(30):31735-44 [15150277.001]
  • [Cites] Reprod Biol Endocrinol. 2004 Jan 7;2:2 [14711377.001]
  • [Cites] J Biol Chem. 2004 Aug 6;279(32):33613-22 [15150279.001]
  • [Cites] J Cell Biol. 1984 Aug;99(2):753-7 [6378927.001]
  • [Cites] J Urol. 1988 Dec;140(6):1466-9 [3193516.001]
  • [Cites] J Urol. 1989 Jul;142(1):193-8 [2659823.001]
  • [Cites] Carcinogenesis. 1989 Jul;10(7):1183-92 [2472229.001]
  • [Cites] Cancer Res. 1990 Oct 1;50(19):6130-8 [1698118.001]
  • [Cites] Prostate. 1991;18(3):201-14 [1902292.001]
  • [Cites] Am J Pathol. 1991 May;138(5):1059-67 [1850957.001]
  • [Cites] Cancer Commun. 1991 Aug;3(8):255-64 [1653586.001]
  • [Cites] Cancer Res. 1994 Jul 15;54(14):3656-61 [8033079.001]
  • [Cites] Gynecol Oncol. 1994 Dec;55(3 Pt 1):401-9 [7835780.001]
  • [Cites] Am J Pathol. 1995 Jul;147(1):114-23 [7604873.001]
  • [Cites] Am J Med Sci. 1996 Jul;312(1):8-11 [8686732.001]
  • [Cites] Adv Cancer Res. 1998;72:141-96 [9338076.001]
  • [Cites] Int J Oncol. 1999 Mar;14(3):535-41 [10024688.001]
  • [Cites] APMIS. 1999 Jan;107(1):150-9 [10190292.001]
  • [Cites] Clin Cancer Res. 2004 Dec 15;10(24):8743-50 [15623660.001]
  • [Cites] Clin Prostate Cancer. 2004 Dec;3(3):150-6 [15636681.001]
  • [Cites] Clin Cancer Res. 2005 Feb 1;11(3):1028-36 [15709168.001]
  • [Cites] Cancer Res. 2005 Mar 15;65(6):2115-24 [15781621.001]
  • [Cites] Cancer Res. 2005 May 15;65(10):4218-27 [15899813.001]
  • [Cites] Biochemistry (Mosc). 2005 May;70(5):533-49 [15948707.001]
  • [Cites] Clin Cancer Res. 2005 Aug 15;11(16):5793-801 [16115918.001]
  • [Cites] Clin Cancer Res. 2005 Aug 15;11(16):5869-77 [16115928.001]
  • [Cites] Cancer Res. 2005 Sep 1;65(17):7635-43 [16140929.001]
  • [Cites] J Biol Chem. 2005 Oct 28;280(43):36529-40 [16127174.001]
  • [Cites] Brain Pathol. 2005 Oct;15(4):327-41 [16389945.001]
  • [Cites] Oncogene. 2006 Aug 3;25(33):4559-72 [16786000.001]
  • [Cites] Hum Pathol. 2000 May;31(5):578-83 [10836297.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Sep 1;48(2):507-12 [10974469.001]
  • [Cites] Int J Cancer. 2000 Sep 20;89(5):431-9 [11008205.001]
  • [Cites] J Natl Cancer Inst. 2000 Nov 1;92(21):1717-30 [11058615.001]
  • [Cites] Int J Oncol. 2001 Jan;18(1):71-9 [11115541.001]
  • [Cites] Exp Cell Res. 2001 Apr 1;264(2):326-36 [11262189.001]
  • [Cites] J Urol. 2002 Feb;167(2 Pt 1):528-34 [11792912.001]
  • [Cites] Nat Rev Mol Cell Biol. 2002 Dec;3(12):932-43 [12461559.001]
  • [Cites] J Clin Oncol. 2003 Apr 1;21(7):1232-7 [12663709.001]
  • (PMID = 17283123.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / NS 47699; United States / NCI NIH HHS / CA / R01 CA075557; United States / NINDS NIH HHS / NS / NS 57529; United States / NCI NIH HHS / CA / CA 75557; United States / NCI NIH HHS / CA / CA 92393; United States / NCI NIH HHS / CA / CA 95058; United States / NCI NIH HHS / CA / R01 CA116708; United States / NINDS NIH HHS / NS / R01 NS047699; United States / NCI NIH HHS / CA / R01 CA095058; United States / NCI NIH HHS / CA / R01 CA092393; United States / NCI NIH HHS / CA / CA 116708
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 7LP2MPO46S / S-Adenosylmethionine; EC 3.4.21.73 / Urokinase-Type Plasminogen Activator
  • [Other-IDs] NLM/ NIHMS14046; NLM/ PMC1832148
  •  go-up   go-down


83. Perrone G, Vincenzi B, Zagami M, Santini D, Panteri R, Flammia G, Verzì A, Lepanto D, Morini S, Russo A, Bazan V, Tomasino RM, Morello V, Tonini G, Rabitti C: Reelin expression in human prostate cancer: a marker of tumor aggressiveness based on correlation with grade. Mod Pathol; 2007 Mar;20(3):344-51
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reelin expression in human prostate cancer: a marker of tumor aggressiveness based on correlation with grade.
  • Reelin is a glycoprotein that plays a critical role in the regulation of neuronal migration during brain development and, since reelin has a role in the control of cell migration, it might represents an important factor in cancer pathology.
  • Stromal tissues, normal epithelial cells and prostate intraepithelial neoplasia (PIN) of any grade around and distant from cancer were always negative for reelin.
  • Our results demonstrated for the first time that reelin is expressed in prostate cancer and not in benign prostate tissue and its expression occurs in higher Gleason score and correlates significantly with increasing of single Gleason patterns.
  • [MeSH-major] Biomarkers, Tumor / analysis. Cell Adhesion Molecules, Neuronal / biosynthesis. Extracellular Matrix Proteins / biosynthesis. Nerve Tissue Proteins / biosynthesis. Prostatic Neoplasms / metabolism. Prostatic Neoplasms / pathology. Serine Endopeptidases / biosynthesis

  • Genetic Alliance. consumer health - Prostate cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17277764.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cell Adhesion Molecules, Neuronal; 0 / Extracellular Matrix Proteins; 0 / Nerve Tissue Proteins; EC 3.4.21.- / Serine Endopeptidases; EC 3.4.21.- / reelin protein
  •  go-up   go-down


84. Rajesh LS, Jain D, Radotra BD, Banerjee AK, Khosla VK, Vasishta RK: Central neurocytoma: a clinico-pathological study of eight cases. Indian J Pathol Microbiol; 2006 Oct;49(4):543-5
Genetic Alliance. consumer health - Central Neurocytoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Central neurocytomas are benign neuronal tumours generally found in the lateral or third ventricles.
  • They are rare, comprising < 1% of all brain tumours.
  • The tumour in extraventricular location showed atypical features.
  • The present series highlights the characteristic clinical and pathological findings of this rare brain tumour.
  • Immunostaining for neuronal markers are essential for distinguishing them from other small round cell tumours of the brain.
  • [MeSH-major] Cerebral Ventricle Neoplasms / pathology. Cerebral Ventricle Neoplasms / physiopathology. Neurocytoma / pathology. Neurocytoma / physiopathology. Neurons / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17183847.001).
  • [ISSN] 0377-4929
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Nerve Tissue Proteins; 0 / Synaptophysin
  •  go-up   go-down


85. Benatiya AI, Bouayed MA, Touiza E, Daoudi K, Mernissi FZ, Tahri H: [Bourneville's tuberous sclerosis. A case report]. J Fr Ophtalmol; 2005 Dec;28(10):e11
MedlinePlus Health Information. consumer health - Tuberous Sclerosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] La sclérose tubéreuse de Bourneville. A propos d'un cas.
  • INTRODUCTION: Bourneville's tuberous sclerosis (BTS) is an autosomal dominant phakomatosis characterized by the development of a benign hamartoma-like tumor, which is usually located in the skin, kidney, heart, brain, and eyes.
  • We present here a case of a retinal BTS of late diagnosis.
  • The chest X-ray, renal scan, heart scan and a CT scan of the brain failed to show any other localizations of the disease.
  • They are often an incidental diagnosis and evolve slowly.
  • [MeSH-major] Retinal Neoplasms / diagnosis. Tuberous Sclerosis / diagnosis

  • Genetic Alliance. consumer health - Tuberous sclerosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16395191.001).
  • [ISSN] 1773-0597
  • [Journal-full-title] Journal français d'ophtalmologie
  • [ISO-abbreviation] J Fr Ophtalmol
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


86. Caffo M, Caruso G, Germanò A, Galatioto S, Meli F, Tomasello F: CD68 and CR3/43 immunohistochemical expression in secretory meningiomas. Neurosurgery; 2005 Sep;57(3):551-7; discussion 551-7
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Secretory meningiomas (SMs) are unusual benign meningiomas.
  • Microglia have been called the brain's immune system, although the specific role and prognostic significance of microglia remain uncertain.
  • Immunohistochemistry was used to analyze the expression of CD68 and CR3/43 in tumor specimens.
  • A correlation between immunohistochemical expression and the occurrence of brain edema was studied.
  • [MeSH-major] Antigens, CD / metabolism. Antigens, Differentiation, Myelomonocytic / metabolism. Brain Neoplasms / metabolism. Immunohistochemistry / methods. Macrophage-1 Antigen / metabolism. Meningioma / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16145535.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, Differentiation, Myelomonocytic; 0 / CD68 antigen, human; 0 / Macrophage-1 Antigen
  •  go-up   go-down


87. Bertalanffy A, Roessler K, Koperek O, Gelpi E, Prayer D, Knosp E: Recurrent central neurocytomas. Cancer; 2005 Jul 1;104(1):135-42
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Since the first description of Central neurocytomas (CNs) as a benign tumor entity in 1982, there has been great enthusiasm regarding the benign course and the curative surgical approach to this disease.
  • The MIB-1 proliferation index ranged from 0.8-11% (median of 4.6%), but was reported to be 46.8% in the malignant transformed tumor.
  • [MeSH-major] Brain Neoplasms / epidemiology. Neoplasm Recurrence, Local / epidemiology. Neurocytoma / epidemiology
  • [MeSH-minor] Adolescent. Adult. Biomarkers, Tumor / analysis. Female. Follow-Up Studies. Humans. Male. Retrospective Studies. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15880432.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


88. Nomori H, Watanabe K, Ohtsuka T, Naruke T, Suemasu K, Uno K: Visual and semiquantitative analyses for F-18 fluorodeoxyglucose PET scanning in pulmonary nodules 1 cm to 3 cm in size. Ann Thorac Surg; 2005 Mar;79(3):984-8; discussion 989
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Positron emission tomography data were analyzed for 161 pulmonary nodules from 1 to 3 cm in size (108 malignant and 53 benign nodules).
  • In addition, FDG uptake was measured by the standard uptake value (SUV), the contrast ratio to the contralateral lung (CR-lung), and the contrast ratio to the cerebellum (CR-brain).
  • Cut-off values for each variable were determined from receiver operating characteristics (ROC) curves, and the values were 2.5 for the SUV, 0.4 for the CR-lung, and 0.25 for the CR-brain.
  • RESULTS: Visual assessment showed definitely positive for 80 nodules (64 malignant and 16 benign), faintly positive for 22 (17 malignant and 5 benign), and negative for 59 nodules (27 malignant and 32 benign).
  • In the 139 nodules that were definitely positive or negative by visual assessment, there were no significant differences of sensitivity and specificity among the four methods (visual assessment, SUV, CR-lung, and CR-brain).
  • In the 17 malignant nodules that were faintly positive, the SUV did not detect any true-positive nodules, but the CR-lung and CR-brain showed 9 and 5 true-positive nodules, respectively, resulting in a significantly higher sensitivity than the SUV (p < 0.001 and p = 0.02, respectively).
  • CONCLUSIONS: The semiquantitative methods (SUV, CR-lung, and CR-brain) do not improve the efficacy of visual assessment alone for nodules graded as definitely positive or negative.
  • However, faintly positive nodules on visual assessment should be evaluated by the CR-lung or CR-brain rather than the SUV, and are often differentiated adenocarcinomas.
  • [MeSH-major] Fluorodeoxyglucose F18. Lung Neoplasms / pathology. Lung Neoplasms / radionuclide imaging. Positron-Emission Tomography / methods. Radiopharmaceuticals

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15734419.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


89. Shuto T, Inomori S, Fujino H, Nagano H, Hasegawa N, Kakuta Y: Cyst formation following gamma knife surgery for intracranial meningioma. J Neurosurg; 2005 Jan;102 Suppl:134-9
MedlinePlus Health Information. consumer health - Brain Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECT: The authors conducted a study to evaluate the clinical significance of cyst formation or enlargement after gamma knife surgery (GKS) for intracranial benign meningiomas.
  • METHODS: The medical records of 160 patients with 184 tumors were examined for those with follow-up data of more than 2 years among 270 patients who underwent GKS for intracranial meningiomas between February 1992 and November 2001.
  • The tumor location was the sphenoid ridge in one case, petroclival in two, tentorium in one, and parasagittal region in one.
  • The mean tumor volume was 10.5 cm3, the mean margin dose was 13.4 Gy (median 14 Gy), and the mean maximum dose was 27.5 Gy (median 24.1 Gy).
  • At the time of GKS three tumors were associated with cyst, of which two enlarged after radiosurgery.
  • Three cysts developed de novo after GKS.
  • Histological examination demonstrated various findings such as tumor necrosis, proliferation of small vessels, vascular obliteration, and hemosiderin deposits.
  • CONCLUSIONS: New cyst formation following GKS for benign intracranial meningioma is relatively rare; however, both preexisting and newly developed cysts tend to enlarge after GKS and often require surgery.
  • [MeSH-major] Brain Diseases / etiology. Brain Diseases / surgery. Cysts / etiology. Cysts / surgery. Meningeal Neoplasms / surgery. Meningioma / surgery. Postoperative Complications. Radiosurgery / instrumentation

  • Genetic Alliance. consumer health - Meningioma.
  • MedlinePlus Health Information. consumer health - After Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15662796.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


90. McKinsey RD, Moritz CH, Meyerand ME, Tomé WA: Assessment of multiple task activation and reproducibility in patients with benign and low-grade neoplasm. Technol Cancer Res Treat; 2010 Aug;9(4):319-26
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessment of multiple task activation and reproducibility in patients with benign and low-grade neoplasm.
  • Twenty-four patients with proven benign and low-grade brain neoplasms each performed two iterations of four fMRI paradigms: language (word generation), primary and association auditory (text listening), upper limb fine motor control (alternating-limb bilateral finger tapping), and primary visual perception (reversing checkerboard).
  • [MeSH-major] Brain Mapping. Brain Neoplasms / diagnosis. Magnetic Resonance Imaging / methods

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neurosurgery. 1996 Feb;38(2):329-38 [8869061.001]
  • [Cites] Comput Biomed Res. 1996 Jun;29(3):162-73 [8812068.001]
  • [Cites] AJNR Am J Neuroradiol. 1997 Sep;18(8):1529-39 [9296196.001]
  • [Cites] Magn Reson Imaging. 1998;16(2):105-13 [9508267.001]
  • [Cites] Neuroimage. 1998 Oct;8(3):249-61 [9758739.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2005 Aug;76(8):1152-7 [16024896.001]
  • [Cites] AJNR Am J Neuroradiol. 2006 Apr;27(4):938-44 [16611797.001]
  • [Cites] J Neurol. 2006 Apr;253(4):471-6 [16283098.001]
  • [Cites] J Magn Reson Imaging. 2006 Jun;23(6):808-15 [16649200.001]
  • [Cites] Head Face Med. 2006;2:20 [16817959.001]
  • [Cites] Neuropsychol Rev. 2007 Jun;17(2):145-55 [17484055.001]
  • [Cites] AJNR Am J Neuroradiol. 2008 Mar;29(3):528-35 [18184849.001]
  • [Cites] Med Phys. 2000 Jul;27(7):1563-72 [10947259.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Aug 15;97(17):9718-23 [10931954.001]
  • [Cites] AJNR Am J Neuroradiol. 2002 Jun-Jul;23(6):1030-7 [12063237.001]
  • [Cites] J Neurosurg. 2002 Jul;97(1):21-32 [12134916.001]
  • [Cites] AJNR Am J Neuroradiol. 2003 Apr;24(4):652-7 [12695198.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Dec;87(24):9868-72 [2124706.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Jul 1;89(13):5951-5 [1631079.001]
  • [Cites] Radiology. 1994 Jan;190(1):85-92 [8259434.001]
  • [Cites] AJNR Am J Neuroradiol. 1997 Aug;18(7):1317-22 [9282862.001]
  • (PMID = 20626198.001).
  • [ISSN] 1533-0338
  • [Journal-full-title] Technology in cancer research & treatment
  • [ISO-abbreviation] Technol. Cancer Res. Treat.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA109656; United States / NCI NIH HHS / CA / R01 CA109656-03; United States / NINDS NIH HHS / NS / 1F31NS5297-01; United States / NCI NIH HHS / CA / R01-CA109656
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS216845; NLM/ PMC2906819
  •  go-up   go-down


91. Nikitin KV, Shishkina LV, Pronin IN, Il'ialov SR, Kostiuchenko VV, Golanov AV: [Radiation necrosis after stereotactic radiosurgery for benign glioma]. Zh Vopr Neirokhir Im N N Burdenko; 2009 Jul-Sep;(3):37-42; discussion 42
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Radiation necrosis after stereotactic radiosurgery for benign glioma].
  • Stereotactic radiosurgery (SRS) becomes more widely used in treatment of patients with intracranial tumors.
  • Authors report a case of radiation-induced necrosis occurred in a patient treated for benign glioma using Leksell Gamma-Knife.
  • Morphological features, risk factors, incidence, differential diagnosis and treatment of cerebral radiation-induced necroses are briefly discussed in this article.
  • [MeSH-major] Brain Neoplasms / radiotherapy. Gamma Rays / adverse effects. Glioma / radiotherapy. Radiation Injuries / etiology
  • [MeSH-minor] Diagnosis, Differential. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Radiotherapy / adverse effects. Radiotherapy / methods. Treatment Outcome

  • Genetic Alliance. consumer health - Glioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20088448.001).
  • [ISSN] 0042-8817
  • [Journal-full-title] Zhurnal voprosy neĭrokhirurgii imeni N. N. Burdenko
  • [ISO-abbreviation] Zh Vopr Neirokhir Im N N Burdenko
  • [Language] rus
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


92. Xu Q, Yuan X, Tunici P, Liu G, Fan X, Xu M, Hu J, Hwang JY, Farkas DL, Black KL, Yu JS: Isolation of tumour stem-like cells from benign tumours. Br J Cancer; 2009 Jul 21;101(2):303-11
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isolation of tumour stem-like cells from benign tumours.
  • We set out to test whether tumour stem-like cells can be identified from benign tumours.
  • METHODS: Tumour sphere cultures were derived from hormone-positive and -negative pituitary adenomas.
  • Characterisation of tumour stem-like cells in vitro was performed using self-renewal assays, stem cell-associated marker expression analysis, differentiation, and stimulated hormone production assays.
  • The tumour-initiating capability of these tumour stem-like cells was tested in serial brain tumour transplantation experiments using SCID mice.
  • RESULTS: In this study, we isolated sphere-forming, self-renewable, and multipotent stem-like cells from pituitary adenomas, which are benign tumours.
  • Finally, we demonstrated that PASCs are pituitary tumour-initiating cells in serial transplantation animal experiments.
  • CONCLUSION: This study for the first time indicates that stem-like cells are present in benign tumours.
  • The conclusions from this study may have applications to understanding pituitary tumour biology and therapies, as well as implications for the notion of tumour-initiating cells in general.

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Invest. 2003 Dec;112(11):1603-18 [14660734.001]
  • [Cites] Nature. 2003 May 15;423(6937):255-60 [12714970.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2004 Sep;75 Suppl 3:iii47-52 [15316045.001]
  • [Cites] Curr Opin Genet Dev. 2004 Oct;14(5):567-74 [15380249.001]
  • [Cites] Mol Endocrinol. 1994 Jul;8(7):878-85 [7527122.001]
  • [Cites] Annu Rev Med. 1996;47:95-106 [8712806.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):396-401 [15549107.001]
  • [Cites] Oncogene. 2004 Dec 16;23(58):9392-400 [15558011.001]
  • [Cites] J Endocrinol. 2005 Jan;184(1):41-50 [15642781.001]
  • [Cites] Mol Endocrinol. 2005 Apr;19(4):964-71 [15637144.001]
  • [Cites] Endocrinology. 2005 May;146(5):2376-87 [15677762.001]
  • [Cites] Mol Endocrinol. 2005 May;19(5):1383-91 [15677710.001]
  • [Cites] J Neurosci Res. 2005 May 15;80(4):456-66 [15795928.001]
  • [Cites] Exp Cell Res. 2005 Aug 1;308(1):166-76 [15916758.001]
  • [Cites] J Clin Pharmacol. 2005 Aug;45(8):872-7 [16027397.001]
  • [Cites] Nature. 2008 Apr 3;452(7187):650-3 [18385740.001]
  • [Cites] Breast Cancer Res. 2008;10(1):R10 [18241344.001]
  • [Cites] Breast Cancer Res. 2008;10(2):105 [18423071.001]
  • [Cites] J Clin Invest. 2008 Jun;118(6):2111-20 [18497886.001]
  • [Cites] Neuroscience. 2008 Jun 23;154(2):541-50 [18462887.001]
  • [Cites] Nature. 2008 Dec 4;456(7222):593-8 [19052619.001]
  • [Cites] Stem Cells. 2008 Dec;26(12):3018-26 [18787206.001]
  • [Cites] Endocrinology. 2005 Sep;146(9):3985-98 [15932930.001]
  • [Cites] Cancer Res. 2005 Dec 1;65(23):10946-51 [16322242.001]
  • [Cites] Glia. 2006 Feb;53(3):294-303 [16265670.001]
  • [Cites] Clin Adv Hematol Oncol. 2006 Jan;4(1):63-72 [16562373.001]
  • [Cites] Cancer Cell. 2006 May;9(5):391-403 [16697959.001]
  • [Cites] Genes Dev. 2006 Oct 1;20(19):2739-53 [17015435.001]
  • [Cites] Stem Cells. 2006 Nov;24(11):2382-90 [16857898.001]
  • [Cites] Nature. 2006 Dec 7;444(7120):756-60 [17051156.001]
  • [Cites] Mol Cancer. 2006;5:67 [17140455.001]
  • [Cites] Nature. 2007 Jan 4;445(7123):111-5 [17122771.001]
  • [Cites] Nature. 2007 Jan 4;445(7123):106-10 [17122772.001]
  • [Cites] Neuroendocrinology. 2007;85(2):110-30 [17337880.001]
  • [Cites] Physiol Rev. 2007 Jul;87(3):933-63 [17615393.001]
  • [Cites] Science. 2007 Jul 20;317(5836):337 [17641192.001]
  • [Cites] Cell. 2007 Dec 14;131(6):1109-23 [18083101.001]
  • [Cites] Dev Neurosci. 2000;22(1-2):139-53 [10657706.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Mar;85(3):1180-7 [10720059.001]
  • [Cites] Mod Pathol. 2001 Sep;14(9):892-9 [11557786.001]
  • [Cites] Clin Neurosurg. 2001;48:306-19 [11692649.001]
  • [Cites] Science. 2002 Mar 22;295(5563):2231-5 [11910101.001]
  • [Cites] Ultrastruct Pathol. 2002 Jul-Aug;26(4):219-28 [12227947.001]
  • [Cites] Exp Neurol. 2002 Dec;178(2):288-93 [12504887.001]
  • [Cites] Pituitary. 2002;5(2):89-98 [12675506.001]
  • [Cites] Nat Rev Cancer. 2004 Apr;4(4):285-95 [15057288.001]
  • (PMID = 19568241.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / NS048959-04; United States / NINDS NIH HHS / NS / R01 NS048959; United States / NINDS NIH HHS / NS / NS048959; United States / NINDS NIH HHS / NS / R01 NS048959-04; United States / NINDS NIH HHS / NS / R56 NS048959; United States / NINDS NIH HHS / NS / R21 NS048879-02; United States / NINDS NIH HHS / NS / NS048879-02; United States / NINDS NIH HHS / NS / R21 NS048879; United States / NINDS NIH HHS / NS / NS048879
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Hypothalamic Hormones; 0 / Pituitary Hormones
  • [Other-IDs] NLM/ PMC2720199
  •  go-up   go-down


93. Moliterno JA, Sood S, Zambrano E, Kim JH, Piepmeier JM, Baehring JM: Intracranial benign fibrous histiocytomas: a case report and review. J Neurooncol; 2009 Apr;92(2):203-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intracranial benign fibrous histiocytomas: a case report and review.
  • Although there have been several reports about malignant fibrous histiocytomas, less is known about the benign variant of these intracranial tumors as they are often misclassified as other types of tumors.
  • Pathology revealed benign fibrous histiocytoma.
  • We also review other cases reported in the literature in an effort to provide further insight into the diagnosis and management of this rare tumor.
  • [MeSH-major] Brain Neoplasms / pathology. Brain Neoplasms / surgery. Histiocytoma, Benign Fibrous / pathology. Histiocytoma, Benign Fibrous / surgery

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neurosurg Rev. 1999 Dec;22(4):215-8 [10682930.001]
  • [Cites] Acta Neurochir (Wien). 2006 Jan;148(1):73-6; discussion 76 [16200478.001]
  • [Cites] Neurol Med Chir (Tokyo). 1990 Oct;30(10 ):759-62 [1708451.001]
  • [Cites] Clin Neuropathol. 2002 May-Jun;21(3):93-8 [12049182.001]
  • [Cites] Hum Pathol. 1993 Mar;24(3):284-93 [7681032.001]
  • [Cites] Acta Neuropathol. 1973 Feb 19;23(3):187-99 [4348056.001]
  • [Cites] Surg Neurol. 1988 Jan;29(1):27-31 [3336836.001]
  • [Cites] No Shinkei Geka. 1984 Apr;12 (5):641-8 [6087179.001]
  • [Cites] J Neurooncol. 2001 Apr;52(2):157-60 [11508815.001]
  • [Cites] Cancer. 1979 Nov;44(5):1839-52 [498051.001]
  • [Cites] J Neurooncol. 2000 Aug;49(1):9-17 [11131990.001]
  • [Cites] No Shinkei Geka. 1991 Mar;19(3):267-71 [2038418.001]
  • (PMID = 19030779.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 13
  •  go-up   go-down


94. Zheng X, Liu W, Yang X, Gong J, Shen F, Shen G, Shen H, Zheng X, Fu W: Endoscope-assisted supraorbital keyhole approach for the resection of benign tumors of the sellar region. Minim Invasive Ther Allied Technol; 2007;16(6):363-6
MedlinePlus Health Information. consumer health - Pituitary Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endoscope-assisted supraorbital keyhole approach for the resection of benign tumors of the sellar region.
  • The objective of the study was to evaluate the effectiveness of the supraorbital "keyhole" approach with endoscope assistance in surgical treatment of benign tumors around the sellar region.
  • Thirty-five patients, including 19 pituitary tumors, 11 craniopharyngiomas and five tuberculum sellae meningiomas, were enrolled in this study.
  • The tumors were resected through an endoscope-assisted supraorbital keyhole approach via a small skin incision within the eyebrow.
  • Complete removal of the sellar region tumors was achieved in all 35 cases by endoscope-assisted supraorbital keyhole approach.
  • There was no patient with evidence of residual or recurrent tumor during the follow-up period.
  • The supraorbital "keyhole" approach with endoscopic assistance in the surgical treatment of benign tumors around the sellar region is an ideal pattern.
  • [MeSH-major] Endoscopy. Neoplasms / surgery. Pituitary Neoplasms / surgery. Treatment Outcome
  • [MeSH-minor] Adolescent. Adult. Aged. Brain Neoplasms / surgery. Female. Humans. Length of Stay. Male. Middle Aged. Prospective Studies

  • MedlinePlus Health Information. consumer health - Endoscopy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17852733.001).
  • [ISSN] 1364-5706
  • [Journal-full-title] Minimally invasive therapy & allied technologies : MITAT : official journal of the Society for Minimally Invasive Therapy
  • [ISO-abbreviation] Minim Invasive Ther Allied Technol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


95. Panagopoulos AT, Lancellotti CL, Veiga JC, de Aguiar PH, Colquhoun A: Expression of cell adhesion proteins and proteins related to angiogenesis and fatty acid metabolism in benign, atypical, and anaplastic meningiomas. J Neurooncol; 2008 Aug;89(1):73-87
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of cell adhesion proteins and proteins related to angiogenesis and fatty acid metabolism in benign, atypical, and anaplastic meningiomas.
  • Most meningiomas are benign tumours of arachnoidal origin, although a small number have high proliferative rates and invasive properties which complicate complete surgical resection and are associated with increased recurrence rates.
  • Few prognostic indicators exist for meningiomas and further research is necessary to identify factors that influence tumour invasion, oedema and recurrence.
  • Paraffin sections from 25 intracranial meningiomas were analysed for expression of the proteins vascular endothelial growth factor (VEGF), VEGF receptors Flt1 and Flk1, E-cadherin, metalloproteinases 2 and 9 (MMP2, MMP9), CD44, receptor for hyaluronic acid-mediated motility (RHAMM), hyaluronic acid (HA), CD45, cyclooxygenase 2 (COX2), brain fatty acid binding protein (BFABP), Ki67, and proliferating cell nuclear antigen (PCNA).
  • COX2 expression increased with increasing with tumour grade and correlated with Ki67, PCNA, MI, MVD, and BFABP.
  • In conclusion Ki67, PCNA, MI, MVD, BFABP, and COX2 were significantly correlated with meningioma tumour grade and with each other.
  • These findings, by correlating both intracellular fatty acid transport and eicosanoid metabolism with tumour proliferation, as determined by Ki67 labelling and mitotic index, suggest fatty acids are involved in the progression of meningiomas.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Cell Adhesion Molecules / biosynthesis. Fatty Acids / metabolism. Meningeal Neoplasms / metabolism. Meningioma / metabolism. Neoplasm Proteins / biosynthesis. Neovascularization, Pathologic / metabolism

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurosurg. 1997 Jan;86(1):113-20 [8988089.001]
  • [Cites] Acta Neuropathol. 1999 Sep;98(3):240-4 [10483780.001]
  • [Cites] Cancer. 2007 Feb 1;109(3):588-97 [17177201.001]
  • [Cites] Virchows Arch. 2006 Nov;449(5):529-38 [17016718.001]
  • [Cites] Neurosurg Focus. 2005 Nov 15;19(5):E9 [16398473.001]
  • [Cites] Neurosurgery. 2002 Jul;51(1):183-92; discussion 192-3 [12182416.001]
  • [Cites] J Neurosurg. 2005 Sep;103(3):508-17 [16235684.001]
  • [Cites] J Biol Chem. 2002 Feb 15;277(7):4589-92 [11717317.001]
  • [Cites] Br J Neurosurg. 1998 Oct;12(5):414-8 [10070443.001]
  • [Cites] J Neurosurg. 1997 May;86(5):793-800 [9126894.001]
  • [Cites] J Clin Pathol. 2004 Jan;57(1):6-13 [14693827.001]
  • [Cites] Histopathology. 2003 Sep;43(3):280-90 [12940781.001]
  • [Cites] J Neurooncol. 2002 Dec;60(3):235-45 [12510775.001]
  • [Cites] Neuropathol Appl Neurobiol. 2006 Dec;32(6):674-8 [17083481.001]
  • [Cites] Neuroradiology. 1982;23 (4):207-9 [7121811.001]
  • [Cites] Cell Biol Int. 2006 Sep;30(9):704-13 [16829143.001]
  • [Cites] Am J Clin Oncol. 2003 Aug;26(4):S98-102 [12902865.001]
  • [Cites] Cancer. 1993 Aug 1;72(3):639-48 [8334619.001]
  • [Cites] Histopathology. 2006 Aug;49(2):178-87 [16879395.001]
  • [Cites] Neurol Med Chir (Tokyo). 1992 Feb;32(2):65-71 [1376862.001]
  • [Cites] Pathol Int. 2005 Jan;55(1):1-7 [15660696.001]
  • [Cites] J Neuropathol Exp Neurol. 2001 Jun;60(6):628-36 [11398839.001]
  • [Cites] BMC Cancer. 2006 Apr 19;6:97 [16623952.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1957 Feb;20(1):22-39 [13406590.001]
  • [Cites] J Biochem Mol Biol. 2006 Sep 30;39(5):469-78 [17002866.001]
  • [Cites] J Cell Biol. 2006 Dec 18;175(6):1017-28 [17158951.001]
  • [Cites] Clinics (Sao Paulo). 2005 Jun;60(3):201-6 [15962080.001]
  • [Cites] Biochem Biophys Res Commun. 2005 May 6;330(2):489-97 [15796909.001]
  • [Cites] Virchows Arch. 1998 Feb;432(2):163-7 [9504862.001]
  • [Cites] J Neuropathol Exp Neurol. 2000 Oct;59(10):872-9 [11079777.001]
  • [Cites] Br J Neurosurg. 1995;9(1):47-50 [7786426.001]
  • [Cites] Lung Cancer. 2006 Jul;53(1):91-6 [16697074.001]
  • [Cites] Neuropathol Appl Neurobiol. 2004 Apr;30(2):118-25 [15043709.001]
  • [Cites] Trends Immunol. 2006 Mar;27(3):146-53 [16423560.001]
  • [Cites] J Histochem Cytochem. 1998 May;46(5):585-94 [9606106.001]
  • [Cites] J Cereb Blood Flow Metab. 2007 Mar;27(3):460-8 [16788715.001]
  • [Cites] J Clin Neurosci. 2007 Apr;14(4):359-63 [17236775.001]
  • [Cites] J Neurooncol. 2004 Jan;66(1-2):29-37 [15015767.001]
  • [Cites] Acta Neurochir (Wien). 2004 Jan;146(1):37-44; discussion 44 [14740263.001]
  • [Cites] J Neurosurg. 2002 Nov;97(5):1078-82 [12450029.001]
  • [Cites] Pathol Res Pract. 2006;202(5):365-72 [16563650.001]
  • [Cites] Childs Nerv Syst. 1995 Nov;11(11):661-3 [8608584.001]
  • [Cites] J Neurooncol. 2005 Jul;73(3):219-23 [15980972.001]
  • [Cites] Histopathology. 2006 Jun;48(7):836-45 [16722933.001]
  • [Cites] J Neurooncol. 2002 Nov;60(2):159-64 [12635663.001]
  • [Cites] Int J Biochem Cell Biol. 2004 Jun;36(6):1046-69 [15094120.001]
  • [Cites] Lancet. 2004 May 8;363(9420):1535-43 [15135603.001]
  • [Cites] J Neurooncol. 2005 Aug;74(1):19-30 [16078103.001]
  • [Cites] Curr Opin Neurol. 2004 Dec;17(6):687-92 [15542977.001]
  • [Cites] J Neurooncol. 2004 Nov;70(2):183-202 [15674477.001]
  • [Cites] Matrix Biol. 2007 Jan;26(1):58-68 [17055233.001]
  • [Cites] Cancer Res. 2006 Nov 1;66(21):10233-7 [17079438.001]
  • [Cites] Cancer. 1999 Feb 15;85(4):936-44 [10091773.001]
  • [Cites] Stroke. 2006 Jun;37(6):1399-406 [16690896.001]
  • [Cites] Int J Cancer. 2003 Feb 10;103(4):483-8 [12478663.001]
  • [Cites] J Neurooncol. 2004 Dec;70(3):349-57 [15662977.001]
  • [Cites] Cancer Res. 2002 Jul 15;62(14):3962-5 [12124327.001]
  • [Cites] Clin Mol Pathol. 1996 Jun;49(3):M140-6 [16696062.001]
  • [Cites] Cancer Genet Cytogenet. 2003 Jan 15;140(2):99-106 [12645646.001]
  • [Cites] J Appl Genet. 2006;47(1):39-48 [16424607.001]
  • [Cites] Hum Mol Genet. 2000 Jul 1;9(11):1567-74 [10861283.001]
  • [Cites] J Neurosurg. 1985 Jan;62(1):18-24 [3964853.001]
  • [Cites] Epilepsy Res. 2000 Jan;38(1):45-52 [10604605.001]
  • [Cites] Neurosurgery. 1992 Jul;31(1):2-12 [1641106.001]
  • [Cites] J Neurooncol. 2007 Jan;81(2):131-7 [16850103.001]
  • [Cites] Lancet Neurol. 2006 Dec;5(12):1045-54 [17110285.001]
  • (PMID = 18418552.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cell Adhesion Molecules; 0 / Eicosanoids; 0 / Fatty Acids; 0 / Ki-67 Antigen; 0 / Neoplasm Proteins; 0 / Proliferating Cell Nuclear Antigen; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS2 protein, human
  •  go-up   go-down


96. Riddle ND, Gorden L, Rojiani MV, Hakam A, Rojiani AM: CD44 and p53 immunoexpression patterns in NF1 neoplasms - indicators of malignancy and infiltration. Int J Clin Exp Pathol; 2010;3(5):515-21
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD44 and p53 immunoexpression patterns in NF1 neoplasms - indicators of malignancy and infiltration.
  • CD44 may play a vital role, either through under or overexpression, with invasion and metastases of tumors, altering their ability to infiltrate the adjacent tissue.
  • The tumor suppressor gene, p53, has also been implicated in malignant progression of various human tumors including malignant peripheral nerve sheath tumors (MPNST).
  • A total of 44 tumors from 33 patients with NF1 were evaluated with an anti-human CD44H, CD44 splice variant v6 and anti-p53 monoclonal antibodies.
  • Thirteen of 28 (46%) benign neurofibroma also had some expression of p53 above 'normal level', although much lower than the MPNST.
  • Plexiform neurofibroma did not differ from other benign lesions in their expression of p53.
  • 70% of benign neurofibroma demonstrated some, usually focal, CD44 positivity.
  • The pattern of CD44 expression in plexiform neurofibroma was revealing, as it was maximal in the 'nonencapsulated' portions of the tumors.
  • CD44v6 expression was positive in control tissues but was not identified in any of tumor samples.
  • Also, within the confines of encapsulated tumors CD44 expression is limited, while in poorly circumscribed neurofibroma CD44 expression is upregulated.
  • This is interpreted as a reflection of the interaction of CD44+ tumor cells with extracellular matrix, hence facilitating infiltrative behavior.
  • [MeSH-major] Antigens, CD44 / biosynthesis. Neurofibromatosis 1 / metabolism. Neurofibromatosis 1 / pathology. Tumor Suppressor Protein p53 / biosynthesis
  • [MeSH-minor] Biomarkers, Tumor / analysis. Disease Progression. Gene Expression. Gene Expression Profiling. Humans. Immunohistochemistry

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lab Invest. 2001 Jun;81(6):833-44 [11406645.001]
  • [Cites] Osteoarthritis Cartilage. 2010 Jun;18(6):849-56 [20171296.001]
  • [Cites] J Pathol. 2002 May;197(1):98-107 [12081210.001]
  • [Cites] Neurology. 2002 Dec 10;59(11):1759-65 [12473765.001]
  • [Cites] Nat Rev Mol Cell Biol. 2003 Jan;4(1):33-45 [12511867.001]
  • [Cites] Hum Genet. 2003 Mar;112(3):289-97 [12596053.001]
  • [Cites] Glia. 2003 Jun;42(4):350-8 [12730955.001]
  • [Cites] Glia. 2004 Feb;45(3):297-306 [14730703.001]
  • [Cites] Cancer. 1986 May 15;57(10):2006-21 [3082508.001]
  • [Cites] Nature. 1989 Dec 7;342(6250):705-8 [2531845.001]
  • [Cites] Lancet. 1990 Mar 24;335(8691):675-9 [1969059.001]
  • [Cites] J Clin Invest. 1990 Jul;86(1):363-9 [2164047.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Jul;87(14):5435-9 [2142531.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Oct;87(19):7555-9 [1699228.001]
  • [Cites] Oncogene. 1990 Oct;5(10):1603-10 [1979160.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Dec;87(24):9958-61 [2263646.001]
  • [Cites] Oncogene. 1991 Mar;6(3):413-21 [2011397.001]
  • [Cites] Science. 1991 Jul 5;253(5015):49-53 [1905840.001]
  • [Cites] J Natl Cancer Inst. 1991 Jul 17;83(14):1004-9 [1712853.001]
  • [Cites] Am J Pathol. 1992 Jan;140(1):145-53 [1731521.001]
  • [Cites] Genes Chromosomes Cancer. 1994 Aug;10(4):250-5 [7522538.001]
  • [Cites] Zhonghua Yi Xue Za Zhi. 1995 Sep;75(9):525-8, 573 [8556541.001]
  • [Cites] J Neurooncol. 1995 Dec;26(3):191-8 [8750185.001]
  • [Cites] Am J Clin Pathol. 1996 Sep;106(3):282-8 [8816583.001]
  • [Cites] Cancer Res. 1997 Nov 1;57(21):4889-97 [9354454.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Sep 1;42(2):351-60 [9788415.001]
  • [Cites] J Neuropathol Exp Neurol. 2005 Jan;64(1):1-9 [15715079.001]
  • [Cites] J Neuropathol Exp Neurol. 2005 Jan;64(1):74-81 [15715087.001]
  • [Cites] J Clin Oncol. 2005 Nov 20;23(33):8422-30 [16293873.001]
  • [Cites] Acta Neuropathol. 2007 Aug;114(2):97-109 [17618441.001]
  • [Cites] Neoplasia. 2007 Aug;9(8):671-7 [17786186.001]
  • [Cites] Brain Cell Biol. 2006 Jun;35(2-3):159-72 [17957481.001]
  • [Cites] J BUON. 2009 Jan-Mar;14(1):7-18 [19373941.001]
  • [Cites] Ann Surg. 2009 Jun;249(6):1014-22 [19474676.001]
  • [Cites] Gynecol Oncol. 2009 Jul;114(1):18-25 [19375154.001]
  • [Cites] Am J Surg Pathol. 2009 Aug;33(8):1157-63 [19542870.001]
  • [Cites] Laryngoscope. 2009 Aug;119(8):1518-30 [19507218.001]
  • [Cites] Neuro Oncol. 2009 Oct;11(5):514-28 [19182148.001]
  • [Cites] Histopathology. 2009 Nov;55(5):564-75 [19912362.001]
  • [Cites] J Pathol. 2010 Jan;220(1):58-70 [19890883.001]
  • [Cites] J Gastrointest Cancer. 2009;40(3-4):115-8 [19937401.001]
  • [Cites] J Pathol. 2010 Mar;220(4):401-3 [20044802.001]
  • [Cites] J Pathol. 2010 May;221(1):49-56 [20229506.001]
  • [Cites] J Med Genet. 2002 May;39(5):311-4 [12011145.001]
  • (PMID = 20606732.001).
  • [ISSN] 1936-2625
  • [Journal-full-title] International journal of clinical and experimental pathology
  • [ISO-abbreviation] Int J Clin Exp Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD44; 0 / Biomarkers, Tumor; 0 / Tumor Suppressor Protein p53
  • [Other-IDs] NLM/ PMC2897111
  • [Keywords] NOTNLM ; CD44 / Neurofibromatosis type 1 (NF1) / immunohistochemistry / infiltration / p53 / tumor markers
  •  go-up   go-down


97. Gratzinger D, Zhao S, West R, Rouse RV, Vogel H, Gil EC, Levy R, Lossos IS, Natkunam Y: The transcription factor LMO2 is a robust marker of vascular endothelium and vascular neoplasms and selected other entities. Am J Clin Pathol; 2009 Feb;131(2):264-78
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The transcription factor LMO2 is a robust marker of vascular endothelium and vascular neoplasms and selected other entities.
  • The transcription factor LMO2 is involved in vascular and hematopoietic development and hematolymphoid neoplasia.
  • Vasculature is LMO2- in adult and fetal heart, brain of older adults, hepatic sinusoids, and hepatocellular carcinoma.
  • LMO2 is uniformly expressed in benign vascular and lymphatic neoplasms and in most malignant vascular neoplasms with the exception of epithelioid vascular neoplasms of pleura and bone.
  • Among nonvascular neoplasms, LMO2 reactivity is present in giant cell tumor of tendon sheath, juvenile xanthogranuloma, a subset of gastrointestinal stromal tumors, small round blue cell tumors, and myoepithelial-derived neoplasms.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19141387.001).
  • [ISSN] 1943-7722
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P01 CA034233; United States / NCI NIH HHS / CA / CA34233; United States / NCI NIH HHS / CA / CA122105; United States / NCI NIH HHS / CA / CA33399; United States / NCI NIH HHS / CA / R37 CA033399; United States / NCI NIH HHS / CA / R01 CA109335; United States / NCI NIH HHS / CA / R01 CA122105; United States / NCI NIH HHS / CA / CA109335; United States / NCI NIH HHS / CA / P30 CA124435
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / LIM Domain Proteins; 0 / LMO2 protein, human; 0 / Metalloproteins; 0 / Proto-Oncogene Proteins
  • [Other-IDs] NLM/ NIHMS636776; NLM/ PMC4305438
  •  go-up   go-down


98. Nakasu S, Fukami T, Jito J, Nozaki K: Recurrence and regrowth of benign meningiomas. Brain Tumor Pathol; 2009;26(2):69-72

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrence and regrowth of benign meningiomas.
  • However, even benign meningiomas sometimes show relatively rapid growth and may recur after total removal.
  • We investigated 135 benign meningiomas, of which 120 were totally removed (Simpson's grade I-III).
  • On the other hand, the histological features of sheet-like growth, prominent nucleoli, and necrosis did not correlate with recurrence, because they were relatively rare in grade I tumors.
  • The patients with recurrent or residual tumors did not always receive adjuvant treatment.
  • Including subtotally treated tumors, the retreatment rate was 9.8% at 10 years and 25.6% at 20 years.
  • [MeSH-major] Meningeal Neoplasms / pathology. Meningioma / pathology. Neoplasm Recurrence, Local / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19856217.001).
  • [ISSN] 1861-387X
  • [Journal-full-title] Brain tumor pathology
  • [ISO-abbreviation] Brain Tumor Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


99. Abe T, Inoue R, Isono M, Ishii K, Fujiki M, Kamida T, Kobayashi H, Kashima K, Kusakabe T, Nakazato Y: Benign pleomorphic astrocytoma in the hypothalamus--case report. Neurol Med Chir (Tokyo); 2006 Feb;46(2):101-3
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign pleomorphic astrocytoma in the hypothalamus--case report.
  • A 41-year-old woman presented with an unusual case of benign astrocytoma with marked pleomorphism manifesting as consciousness disturbance due to intraventricular hemorrhage.
  • Despite partial resection of the tumor without additional therapy, there have been no signs of tumor regrowth for 6 years.
  • The histological findings revealed solid proliferation of tumor cells with marked pleomorphism, contrary to the benign clinical course.
  • Immunohistochemical staining indicated the glial origin of the tumor.
  • The tumor was similar to pleomorphic xanthoastrocytoma, but the histological findings were not exactly identical, indicating a new histological entity.
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology. Hypothalamus / pathology
  • [MeSH-minor] Adult. Female. Humans. Magnetic Resonance Imaging. Neoplasm Invasiveness

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16498222.001).
  • [ISSN] 0470-8105
  • [Journal-full-title] Neurologia medico-chirurgica
  • [ISO-abbreviation] Neurol. Med. Chir. (Tokyo)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


100. Sadetzki S, Chetrit A, Freedman L, Stovall M, Modan B, Novikov I: Long-term follow-up for brain tumor development after childhood exposure to ionizing radiation for tinea capitis. Radiat Res; 2005 Apr;163(4):424-32
MedlinePlus Health Information. consumer health - Radiation Therapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term follow-up for brain tumor development after childhood exposure to ionizing radiation for tinea capitis.
  • Ionizing radiation is an established risk factor for brain tumors, yet quantitative information on the long-term risk of different types of brain tumors is sparse.
  • Our aims were to assess the risk of radiation-induced malignant brain tumors and benign meningiomas after childhood exposure and to investigate the role of potential modifiers of that risk.
  • The mean estimated radiation dose to the brain was 1.5 Gy.
  • Survival analysis using Poisson regression was performed to estimate the excess relative and absolute risks (ERR, EAR) for brain tumors.
  • After a median follow-up of 40 years, an ERR/Gy of 4.63 and 1.98 (95% CI = 2.43-9.12 and 0.73-4.69) and an EAR/Gy per 10(4) PY of 0.48 and 0.31 (95% CI = 0.28-0.73 and 0.12-0.53) were observed for benign meningiomas and malignant brain tumors, respectively.
  • The risk of both types of tumors was positively associated with dose.
  • The estimated ERR/Gy for malignant brain tumors decreased with increasing age at irradiation from 3.56 to 0.47 (P = 0.037), while no trend with age was seen for benign meningiomas.
  • The ERR for both types of tumor remains elevated at 30-plus years after exposure.
  • [MeSH-major] Brain / radiation effects. Brain Neoplasms / epidemiology. Neoplasms, Radiation-Induced / epidemiology. Radiotherapy / statistics & numerical data. Risk Assessment / methods. Tinea Capitis / epidemiology. Tinea Capitis / radiotherapy






Advertisement